[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20210085625A1 - Controlled release oral pharmaceutical dosage forms comprising mgbg - Google Patents

Controlled release oral pharmaceutical dosage forms comprising mgbg Download PDF

Info

Publication number
US20210085625A1
US20210085625A1 US17/111,895 US202017111895A US2021085625A1 US 20210085625 A1 US20210085625 A1 US 20210085625A1 US 202017111895 A US202017111895 A US 202017111895A US 2021085625 A1 US2021085625 A1 US 2021085625A1
Authority
US
United States
Prior art keywords
capsule
release
mgbg
ethyl
methacrylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/111,895
Inventor
John McKearn
Jeremy Blitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathologica LLC
Original Assignee
Pathologica LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathologica LLC filed Critical Pathologica LLC
Priority to US17/111,895 priority Critical patent/US20210085625A1/en
Publication of US20210085625A1 publication Critical patent/US20210085625A1/en
Assigned to PATHOLOGICA LLC reassignment PATHOLOGICA LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCKEARN, JOHN, BLITZER, JEREMY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/13—Amines containing three or more amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/12—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/78—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton

Definitions

  • MGBG methylglyoxal bis(guanylhydrazone); mitoguazone
  • ALD-I S-adenosyl methionine decarboxylase
  • the amino acid-derived polyamines have long been for cell growth and cancer, and specific oncogenes and tumor-suppressor genes regulate polyamine metabolism. Inhibition of polyamine biosynthesis has proven to be generally ineffective as an anticancer strategy in clinical trials, but it is a potent cancer chemoprevention strategy in preclinical studies.
  • MGBG has been confined to intravenous use to date.
  • Administration via IV injection or infusion must be done by a medical professional in a hospital setting. This not only presents an inconvenience and increased cost to the subject, but it also exposes him or her to hospital-based infections and illnesses, the latter both from venipuncture and the hospital or clinic visit itself.
  • immunocompromised individuals such as, for example, those with HIV or AIDS, individuals undergoing treatment with immunosuppressive agents, and the elderly, this is a relevant concern.
  • a subject with a long-term chronic condition such as an autoimmune or hyperproliferative disorder, or a doctor treating such a subject, might find the cost, inconvenience, and risks of such treatment more important than any potential therapeutic benefits the drug might offer.
  • an oral formulation of MGBG presents several benefits.
  • an oral formulation for example, a simple capsule or tablet, may be taken outside of a hospital setting, increasing the potential for ease of use and compliance. This permits a subject to avoid infection risks concomitant with IV administration and hospital visits. Where early treatment can prevent developing disease complications, this is of particular benefit. Chronic low-dose administration of MGBG is practically impossible in an IV formulation. Additionally, oral delivery typically avoids the high concentration peak and rapid clearance for an IV bolus dose. Yet another advantage of an oral drug would be the ability to formulate MGBG as a combination composition with one or more other therapeutic agents.
  • controlled-release oral pharmaceutical dosage forms comprising MGBG for treating disease.
  • FIG. 1 depicts a graph showing that as body surface area increases across species administered MGBG, T max drops while C max increases.
  • FIG. 2 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs, dosed at 10 mg/kg.
  • FIG. 3 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs, dosed at 30 mg/kg.
  • FIG. 4 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs dosed at 100 mg/kg.
  • FIG. 5 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs, at all tested doses (10, 30, and 100 mg/kg).
  • FIG. 6 depicts a bar graph that allows a visual comparison of the C max and T max of MGBG in standard and enterically-coated capsules at all tested doses (10, 30, and 100 mg/kg).
  • a controlled-release oral pharmaceutical dosage form comprising MGBG.
  • the controlled-release dosage form comprising MGBG is chosen from extended-release, sustained-release, delayed-release, and pulsed-release.
  • the controlled-release dosage form comprising MGBG is a delayed-release tablet or a delayed-release capsule.
  • delayed-release tablet or a delayed-release capsule comprising MGBG, wherein the capsule or tablet comprises an enteric coating.
  • the enteric coating comprises one or more of cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methacrylic acid/methyl methacrylate copolymer, methacrylic acid/methyl acrylate copolymers, methacrylic acid/ethyl acrylate copolymer, sodium alginate, and stearic acid.
  • CAP cellulose acetate phthalate
  • VAP polyvinyl acetate phthalate
  • methacrylic acid/methyl methacrylate copolymer methacrylic acid/methyl acrylate copolymers
  • methacrylic acid/ethyl acrylate copolymer sodium alginate, and stearic acid.
  • the enteric coating is applied to the tablet.
  • the enteric coating is applied to the capsule.
  • the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer.
  • the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55.
  • the enteric coating begins to substantially dissolve, and drug release commences in the duodenum.
  • the enteric coating begins to substantially dissolve, and drug release commences at about or more hours after ingestion.
  • the enteric coating begins to substantially dissolve, and drug release commences at about 1 ⁇ 2 or more hours after ingestion.
  • an enterically-coated capsule comprising MGBG exhibits reduced side effects in patients compared to a non-enterically-coated capsule.
  • said side effects are reduced by at least 30%, at least 40%, least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% compared to a non-enterically-coated capsule.
  • the overall incidence of said side effects is reduced.
  • the severity of said side effects is reduced.
  • both the incidence and severity of said side effects are reduced.
  • an enterically-coated capsule which does not have substantially dose-limiting side effects.
  • said side effects are gastrointestinal.
  • an enterically-coated capsule comprising MGBG, which exhibits reduced side effects in patients compared to a non-enterically-coated capsule and is orally bioavailable.
  • the percent bioavailability is between about 10 and about 50%. In certain embodiments, the percent bioavailability is between about 20 and about 40%. In certain embodiments, the percent bioavailability is between about 30 and about 40%. In certain embodiments, the percent bioavailability is about 35%.
  • said gastrointestinal side effects are chosen from nausea, emesis (vomiting), diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.
  • emesis is reduced by at least 30%, at least 40%, least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 50% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 70% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 80% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 90% compared to a reference standard that is not enterically coated.
  • said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells.
  • an enterically-coated capsule which exhibits dose-proportional increases in C max and AUC.
  • an enterically-coated capsule which exhibits a half-life comparable to a reference standard that is not enterically coated.
  • a tablet additionally comprising a seal coating between the tablet and the enteric coating.
  • a tablet additionally comprising an extended-release coating.
  • a tablet additionally comprising an immediate release coating containing MGBG atop the extended-release coating.
  • the enteric coating is applied to micropellets comprising MGBG optionally with one or more excipients, and the micropellets are enclosed in a capsule.
  • the enteric coating is applied to spheroids comprising MGBG optionally with one or more excipients, and the spheroids are enclosed in a capsule.
  • the enteric coating is applied to the capsule.
  • the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer.
  • the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55.
  • the enteric coating begins to substantially dissolve, and drug release commences in the duodenum.
  • the enteric coating begins to substantially dissolve, and drug release commences at about 1 or more hours after ingestion.
  • the oral pharmaceutical composition does not have substantially dose-limiting side effects.
  • said side effects are gastrointestinal.
  • said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, and gastrointestinal ulceration.
  • said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells.
  • the delayed-release oral pharmaceutical dosage form has a T max from about 1 hour to about 14 hours. In certain embodiments, the delayed-release oral pharmaceutical dosage form has a T max from about 1 hour to about 8 hours. In certain embodiments, the delayed-release oral pharmaceutical dosage form has a T max from about 1 hour to about 4 hours. In further embodiments, the T max is from 1 hour to 2 hours. In further embodiments, the T max is from 2 hours to 3 hours. In further embodiments, the T max is from 3 hours to 4 hours. In further embodiments, the T max is from 4 hours to 5 hours. In further embodiments, the T max is from 5 hours to 6 hours. In further embodiments, the T max is from 6 hours to 7 hours.
  • the T max is from 7 hours to 8 hours. In further embodiments, the T max is from 8 hours to 9 hours. In further embodiments, the T max is from 9 hours to 10 hours. In further embodiments, the T max is from 10 hours to 11 hours. In further embodiments, the T max is from 11 hours to 12 hours. In further embodiments, the T max is chosen from about 1, about 1.5 about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, about 11, about 11.5, and about 12 hours.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG T max is between 1 and 14 hours.
  • the enterically-coated delayed-release capsule has a T max , which is between 1 and 4 hours.
  • the enterically-coated delayed-release capsule has a T max , which is between 1 and 2 hours.
  • the enterically-coated delayed-release capsule has a T max , which is between 2 and 4 hours.
  • the enterically-coated delayed-release capsule has a T max , which is between 4 and 8 hours.
  • the enterically-coated delayed-release capsule has a T max , which is between 8 and 14 hours.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG T max is at least 1 hour later than a reference standard which is not enterically coated, etc.
  • the enterically-coated delayed-release capsule has a T max , which is at least 2 hours later than a reference standard which is not enterically coated.
  • the enterically-coated delayed-release capsule has a T max , which is at least 3 hours later than a reference standard which is not enterically coated.
  • the enterically-coated delayed-release capsule has a T max , which is at least 4 hours later than a reference standard which is not enterically coated.
  • the enterically-coated delayed-release capsule has a T max , which is at least 6 hours later than a reference standard which is not enterically coated.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG C max is less than about 500 ng/mL.
  • the enterically-coated delayed-release capsule has a C max , which is less than about 465 ng/mL.
  • the enterically-coated delayed-release capsule has a C max , which is less than about 400 ng/mL.
  • the enterically-coated delayed-release capsule has a C max , which is less than about 300 ng/mL.
  • the enterically-coated delayed-release capsule has a C max , which is less than about 200 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a C max , which is less than about 100 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a C max , which is less than about 50 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a C max , which is less than about 25 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a C max , which is less than about 12 ng/mL.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG C max is between 10 and 465 ng/mL.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG C max is 50% less than a reference standard which is not enterically coated.
  • the enterically-coated delayed-release capsule has a C max , which is at least 60% less than a reference standard which is not enterically coated.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG C max is 75% less than a reference standard which is not enterically coated.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is less than about 3,100 ng*hr/mL. In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is between about 180 and about 3,100 ng*hr/mL.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is between about 20% and about 50% less than a reference standard which is not enterically coated.
  • the enterically-coated delayed-release capsule has an MGBG AUC between about 30% and about 50% less than a reference standard, which is not enterically coated.
  • the enterically-coated delayed-release capsule has an MGBG AUC between about 30% and about 50% less than a reference standard, which is not enterically coated.
  • a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is about 40% less than a reference standard which is not enterically coated.
  • a delayed-release oral pharmaceutical dosage form comprising MGBG dihydrochloride hydrate in capsule enterically-coated for duodenal release.
  • the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer.
  • the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55.
  • the capsule comprises 25-350 mg MGBG.
  • the controlled-release dosage form is an extended-release form.
  • the delayed-release oral pharmaceutical dosage form is a capsule comprising micropellets of MGBG optionally with one or more excipients, said micropellets being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • the delayed-release oral pharmaceutical dosage form is a capsule comprising spheroids of MGBG optionally with one or more excipients, said spheroids being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • the delayed-release oral pharmaceutical dosage form is a capsule comprising MGBG optionally with one or more excipients, said capsule being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • the delayed-release oral pharmaceutical dosage form is a tablet having an enteric coating.
  • the delayed-release tablet comprises an enteric coating applied directly to the tablet.
  • a delayed-release tablet comprises a seal coating applied directly to the tablet and an enteric coating.
  • the dosage form is chosen from extended-release and sustained-release.
  • the dosage form additionally comprises a hydrogel.
  • the dosage form comprises micropellets having at least one layer comprising said MGBG and at least one layer comprising at least one cellulose ether.
  • the cellulose ethers are chosen from methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, or microcrystalline cellulose.
  • the cellulose ether layer comprises ethylcellulose and hydroxypropylcellulose.
  • the dosage form comprises micropellets having coated onto a seed a first layer comprising said MGBG and a second layer comprising ethylcellulose and hydroxypropylcellulose.
  • the second layer makes up from about 2% to about 10% by weight of the micropellet.
  • the second layer comprises 70-90% by weight of ethylcellulose and about 10-30% by weight of hydroxypropylcellulose.
  • the cellulose ether layer comprises 80-90% by weight of ethylcellulose and about 10-20% by weight of hydroxypropylcellulose.
  • the cellulose ether layer comprises about 3 parts of ethylcellulose to about 1 part of hydroxypropylcellulose.
  • the layer comprising MGBG additionally comprises a polyvinylpyrrolidone.
  • said polyvinylpyrrolidone has a molecular weight of about 30,000 to about 50,000.
  • said polyvinylpyrrolidone has a molecular weight of about 40,000.
  • the dosage form comprises spheroids comprising MGBG and cellulose ether.
  • the micropellets have diameters in the range of about 0.5 to about 0.7 mm.
  • a controlled-release oral pharmaceutical dosage form comprising MGBG together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject, which does not have substantially dose-limiting side effects.
  • said side effects are gastrointestinal.
  • said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, and gastrointestinal ulceration.
  • said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells.
  • said side effects are chosen from thrombocytopenia, leukopenia, phlebitis, laryngitis, cellulitis, dermatitis, and hypoglycemia.
  • a low-dose oral pharmaceutical composition for chronic delivery comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side effects.
  • the low-dose oral pharmaceutical composition for chronic delivery comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side effects, yields a therapeutically effective plasma level of MGBG for at least a 24-hour period in the subject with once-daily dosing.
  • the pharmaceutical composition is formulated as a tablet or capsule.
  • the pharmaceutical composition comprises:
  • the pharmaceutical composition comprises:
  • the pharmaceutical composition comprises:
  • the pharmaceutical composition comprises:
  • the pharmaceutical composition comprises
  • the pharmaceutical composition may additionally comprise
  • Also provided herein is a method of treating, or delaying the onset or development of, a condition in a subject in need thereof comprising administering a controlled-release oral pharmaceutical dosage form comprising MGBG.
  • the MGBG is delivered in a therapeutically effective amount.
  • Also provided herein is a method of treatment of a condition in a subject in need thereof comprising administering
  • the MGBG is delivered in a therapeutically effective amount. In other embodiments, the MGBG is delivered in a subtherapeutic amount. In certain embodiments, the other therapeutic agent is delivered in a therapeutically effective amount. In other embodiments, the other therapeutic agent is delivered in a subtherapeutic amount. In certain embodiments, the MGBG and the other therapeutic agent are delivered together in amounts which would individually be subtherapeutic but which together are therapeutically effective. In other embodiments, the MGBG and the other therapeutic agent are delivered together in amounts which are individually therapeutically effective.
  • Also provided herein is a method of treating a condition comprising the administration, to a patient in need thereof, a delayed-release oral pharmaceutical dosage form comprising MGBG.
  • the condition is pain. In certain embodiments, the pain is inflammatory pain.
  • said delayed-release oral pharmaceutical dosage form is an enterically-coated capsule comprising MGBG.
  • administering the enterically-coated capsule comprising MGBG results in a reduction of gastrointestinal side effects when compared to a reference standard that is not enterically coated.
  • said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.
  • said gastrointestinal side effect is emesis.
  • MGBG is administered at a dosage level, which would result in dose-limiting side effects if administered as a non-enteric coated dosage form.
  • Controlled-release oral pharmaceutical dosage forms disclosed herein are useful for targeting absorption of MGBG to a particular portion of the gastrointestinal tract, or for modulating the temporal delivery of MGBG, or both. These objectives may be achieved, for example, by formulating MGBG in an oral dosage form having a modified-release film coating, by formulating MGBG in a swelling system, by formulating MGBG in a matrix, by formulating MGBG in a controlled dissolutions system using coated particles, granules, micropellets, or spheroids of a pharmaceutical composition of MGBG or by microencapsulation, or by formulating MGBG in an osmotically active delivery system.
  • MGBG For targeting absorption of MGBG to a particular portion of the gastrointestinal tract, film coatings and swelling systems are particularly useful. Swelling systems represent a means to target the absorption of the drug in the stomach.
  • a dosage form would comprise MGBG in a matrix of material that would expand upon contact with the aqueous environment of the stomach, preventing passage into the duodenum.
  • Hydrogels are one example of such material.
  • a hydrogel comprises, for example, polyvinyl alcohol, sodium polyacrylate, acrylate polymers, and/or copolymers with an abundance of hydrophilic groups.
  • a film coating is useful.
  • One type of film coating is an enteric coating, which is designed to remain intact in the stomach but dissolves and releases the drug in the small intestine. Release in the small intestine may be desirable if, for example, the drug is inactivated or rendered less useful by reaction with gastric fluids, or if the drug causes gastric irritation or related side effects such as nausea and/or emesis.
  • enteric coatings achieve delayed-release by virtue of being resistant to dissolution at low pH, such as that found in the stomach, but which dissociate more readily in the higher pH environment of the small intestine.
  • Most effective enteric coatings are, therefore, weak acids with pKas of about 3 to about 5. Additionally, coatings which are responsive to intestinal enzymatic breakdown may be used.
  • Enteric coatings which are pH-labile, are typically formed of polymers, optionally in combination with plasticizing agents and other excipients. Shellac and gelatin may be used, but polymerization must be carefully controlled, or the contents of the dosage form will not be released.
  • Suitable polymers include cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), acrylic copolymers such as methacrylic acid/methacrylic acid ester copolymers, ethyl acrylate/methyl methacrylate/methacrylic acid copolymer, and methacrylic acid/ethyl acrylate copolymer, cellulose acetate trimellitate (CAT), carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic copolymers.
  • CAP cellulose acetate phthalate
  • PVAP polyvinyl acetate phthalate
  • HPMC hydroxypropyl methylcellulose phthalate
  • HPMCP hydroxypropyl methylcellulose phthalate
  • acrylic copolymers such as methacrylic acid/methacrylic acid
  • Prepared copolymers are commercially available in many forms, such as aqueous suspensions, organic solutions, and powders, for the release of drug to various parts of the small intestine, such as the duodenum, jejunum, or ileum.
  • aqueous suspensions such as aqueous suspensions, organic solutions, and powders
  • drug such as the duodenum, jejunum, or ileum.
  • the Eudragit® series of coatings is available from Evonik Inds.
  • Surelease® series from Colorcon.
  • a sustained-release coating may be employed. Such a coating would be useful where the rapid release of the drug causes undesirable side effects.
  • Suitable materials for creating a sustained-release coating include, in addition to the polymers above: mixtures of waxes with glyceryl monostearate, stearic acid, palmitic acid, glyceryl monopalmitate, and/or cetyl alcohol; ethylcellulose; acrylic resins; cellulose acetates; and silicone elastomers.
  • pan coating for coating dosage forms with enteric, sustained-release, or enteric/sustained-release coatings
  • electrostatic powder coating followed by heat fixation.
  • the pan coating method is useful for depositing a substantial coating onto the tablet; in certain embodiments, 3%-4% of the tablet weight is deposited as coating, but it can be significantly higher, up to about 15%. Where a thinner coating is desired, the air suspension coating technique is useful.
  • the initial seal coat can be applied on an Aeromatic StreaTM fluid bed apparatus fitted with a Wurster column and bottom spray nozzle system.
  • the electrostatic method may be useful where it is desirable to avoid the use of solvents, where dosage forms are to be partially coated, or where precision in deposition or even greater thinness of the coating is desired.
  • the MGBG oral dosing units of the invention comprise at a minimum a core containing MGBG and one or more pharmaceutically acceptable excipients.
  • the core may contain about 10 wt % to about 90 wt % MGBG.
  • the core containing the MGBG may be in a sustained-release formulation, or other suitable cores, as are described in greater detail below, may be selected.
  • a delay release coat and/or an enteric coat are provided over the core.
  • the delay release coat and/or an enteric coat can be applied to the MGBG core directly, or there may be intermediate coating layers located between the MGBG core and any overcoats.
  • a further seal or topcoat may be located outside the enteric coat.
  • the MGBG core is provided with further layers that provide a sustained-release formulation that contains rate-controlling components.
  • rate-controlling components are rate controlling polymers selected from among hydrophilic polymers and inert plasticized polymers.
  • Suitable rate-controlling hydrophilic polymers include, without limitation, polyvinyl alcohol (PVA), hypromellose, and mixtures thereof.
  • suitable insoluble or inert “plastic” polymers include, without limitation, one or more polymethacrylates (i.e., Eudragit® polymer).
  • Other suitable rate-controlling polymer materials include, e.g., hydroxyalkyl celluloses, poly(ethylene) oxides, alkyl celluloses, carboxymethyl celluloses, hydrophilic cellulose derivatives, and polyethylene glycol.
  • the formulation of the invention contains one or more coatings over the MGBG core.
  • the core can contain a non-functional seal coating (i.e., a coat which does not affect release rate) and a functional second coating.
  • the enteric coat can be applied directly to the uncoated core or may be applied over an initial seal coat.
  • an initial seal coat can be applied directly to the core.
  • the seal coat may be selected from among suitable polymers such as hydroxypropyl methylcellulose (HPMC), ethylcellulose, polyvinyl alcohol, and combinations thereof, optionally containing plasticizers and other desirable components.
  • HPMC hydroxypropyl methylcellulose
  • ethylcellulose ethylcellulose
  • polyvinyl alcohol polyvinyl alcohol
  • a particularly suitable seal coat contains HPMC.
  • a seal coat can be applied as an HPMC solution at a concentration of about 3% w/w to 25% w/w.
  • the seal coat can be applied as an HPMC solution at a concentration of about 5% w/w to about 7.5% w/w.
  • the initial seal coat is in the range of about 1% w/w to about 3% w/w, or about 2% w/w, of the uncoated core.
  • a commercially available seal coat containing HPMC, among other inert components is used.
  • One such commercially available seal coat is Opadry® Clear (Colorcon, Inc.).
  • the enteric coat contains a product which is a copolymer of methacrylic acid and methacrylates, such as the commercially available Eudragit® L 30 K55 (Röhm GmbH & Co. KG). This enteric coat may be applied such that it coats the core in an amount of about 10 wt % to 20 wt %, or about 12 wt % to about 17 wt %, or about 15.5 wt % to 16.5 wt % of the uncoated or initially-coated core.
  • the enteric coat is composed of a Eudragit® L30D-55 copolymer (Röhm GmbH & Co.
  • the enteric coating may contain about 7 wt % to about 9 wt % of a 30 wt % dispersion of Eudragit® L 30 D55 coating; about 4 wt % to about 5 wt %/w talc, about 0.7 wt % to about 1 wt % triethyl citrate; a pH adjuster such as sodium hydroxide and water.
  • the delayed-release oral pharmaceutical dosage form is a capsule comprising micropellets of MGBG optionally with one or more excipients, said micropellets being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • the delayed-release oral pharmaceutical dosage form is a capsule comprising spheroids of MGBG and one or more excipients, said spheroids being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • the delayed-release oral pharmaceutical dosage form is a tablet having an enteric coating.
  • the delayed-release tablet comprises an enteric coating applied directly to the tablet.
  • a delayed-release tablet comprises a seal coating applied directly to the tablet and an enteric coating.
  • the enteric coating comprises from about 1% to about 30% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises from 1% to 25%, or from 1% to 20%, or from 1% to 15% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises from 1% to 10%, or from 1% to 5% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 1%, about 2%, about 3%, about 4%, and about 5%. In further embodiments, the enteric coating comprises from 5% to 10% of the total weight of the delayed-release oral pharmaceutical dosage form.
  • the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 6%, about 7%, about 8%, about 9%, and about 10%. In further embodiments, the enteric coating comprises from 10% to 15% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 11%, about 12%, about 13%, about 14%, and about 15%. In further embodiments, the enteric coating comprises from 15% to 20% of the total weight of the delayed-release oral pharmaceutical dosage form.
  • the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 16%, about 17%, about 18%, about 19%, and about 20%. In further embodiments, the enteric coating comprises from 20% to 30% of the total weight of the delayed-release oral pharmaceutical dosage form. In these embodiments, the enteric coating is substantially uniform in thickness.
  • the controlled-release oral pharmaceutical dosage form may be achieved through formulation in a matrix.
  • the matrix may be a controlled release matrix, although normal release matrices having a coating that controls the release of the drug may be used. Suitable materials for inclusion in a controlled release matrix are
  • a common method of preparation is to mix drug and matrix material and then compress into a tablet.
  • the tablet may then be coated with a drug-containing layer substantially free of the matrix material.
  • An additional enteric coating may be added if a delay of release is desired.
  • the matrix comprises at least one water-soluble hydroxyalkyl cellulose, at least one C 12 -C 36 aliphatic alcohol, and, optionally, at least one polyalkylene glycol.
  • the aliphatic alcohol is a C 14 -C 22 aliphatic alcohol.
  • the hydroxyalkyl cellulose may be, for example, a hydroxy (C 1 to C 6 ) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose, or hydroxyethyl cellulose.
  • the amount of the hydroxyalkyl cellulose in the present oral dosage form will be determined, inter alia, by the precise rate of drug release required.
  • the oral dosage form contains between 5% and 25% (by wt) of the hydroxyalkyl cellulose.
  • the oral dosage form contains between 6.25% and 15% of the hydroxyalkyl cellulose.
  • the aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol, or stearyl alcohol. In certain embodiments, the aliphatic alcohol is cetyl alcohol or cetostearyl alcohol.
  • the amount of the aliphatic alcohol in the present oral dosage form will be determined, as above, by the precise rate of drug release required. It will also depend on whether polyalkylene glycol is present in or absent from the oral dosage form. In certain embodiments, in the absence of polyalkylene glycol, the oral dosage form may contain between 20% and 50% (by wt) of the aliphatic alcohol. In other embodiments, where polyalkylene glycol is present in the oral dosage form, then the combined weight of the aliphatic alcohol and the polyalkylene glycol may constitute between 20% and 50% (by wt) of the total dosage.
  • the controlled release composition comprises from about 5 to about 25% acrylic resin and from about 8 to about 40% by weight aliphatic alcohol by weight of the total dosage form.
  • acrylic resins are commercially available. Examples include the entire family of Eudragit® family of formulation copolymers-Eudragit® RS PM is one example, Eudragit® RL 30 D is another.
  • the ratio of, e.g., hydroxyalkyl cellulose or acrylic resin to aliphatic alcohol/polyalkylene glycol determines, to a considerable extent, the release rate of the drug from the formulation.
  • the ratio of hydroxyalkyl cellulose to aliphatic alcohol/polyalkylene glycol is between 1:2 and 1:4. In further embodiments, the ratio is between 1:3 and 1:4.
  • the polyalkylene glycol may be, for example, polypropylene glycol. In certain embodiments, the polyalkylene glycol is polyethylene glycol. In certain embodiments, the average molecular weight of the polyalkylene glycol is between 1,000 and 15,000. In certain embodiments, the average molecular weight of the polyalkylene glycol is between 1500 and 12000.
  • Another suitable controlled-release matrix would comprise an alkylcellulose (especially ethylcellulose), a C12 to C36 aliphatic alcohol, and, optionally, a polyalkylene glycol.
  • a controlled release matrix may also contain suitable quantities of other materials, e.g., diluents, lubricants, binders, granulating aids, colorants, flavorants, and glidants conventional in the pharmaceutical art.
  • the present matrix may be a normal release matrix having a coat that controls the release of the drug.
  • the dosage form comprises film-coated spheroids containing the active ingredient and a non-water-soluble spheronizing agent.
  • spheroid is known in the pharmaceutical art and usually refers to a spherical granule having a diameter of between 0.1 mm and 2.5 mm, especially between 0.5 mm and 2 mm.
  • the spheronizing agent may be any pharmaceutically acceptable material that, together with the active ingredient, can be spheronized to form spheroids.
  • Microcrystalline cellulose is an example of a spheronizing agent. Suitable microcrystalline cellulose is, for example, the material sold as Avicel PH 101 (Trademark, FMC Corporation).
  • the film-coated spheroids contain between 10% and 95% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 20% and 80% (by wt) of the spheronizing agent.
  • the film-coated spheroids contain between 20% and 50% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 10% and 40% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 20% and 40% (by wt) of the spheronizing agent. In further embodiments, the spheronizing agent is microcrystalline cellulose.
  • the spheroids may also contain a binder. Suitable binders, such as low viscosity, water-soluble polymers, will be well known to those skilled in the pharmaceutical art. Microcrystalline cellulose is an effective diluent and binder.
  • the binder is a water-soluble hydroxy lower alkyl cellulose, such as hydroxypropyl cellulose.
  • the spheroids may contain a water-insoluble polymer, such as an acrylic polymer, an acrylic copolymer, such as a methacrylic acid-ethyl acrylate copolymer, or ethyl cellulose.
  • the spheroids are film-coated with a material that permits the release of the drug at a controlled rate in an aqueous medium.
  • the film coat will generally include a water-insoluble material such as
  • the water-insoluble cellulose is ethyl cellulose.
  • the polymethacrylate is Eudragit®.
  • the film coat comprises a mixture of the water-insoluble material and a water-soluble material.
  • the ratio of water-insoluble to water-soluble material is determined by, amongst other factors, the release rate required and the solubility characteristics of the materials selected.
  • the water-soluble material may be, for example, polyvinylpyrrolidone or a water-soluble cellulose.
  • the water-soluble cellulose is hydroxypropylmethylcellulose.
  • Suitable combinations of water-insoluble and water-soluble materials for the film coat include shellac and polyvinylpyrrolidone, or ethylcellulose, and hydroxypropylmethylcellulose. In certain embodiments, combining water-insoluble and water-soluble materials for the film coat is ethyl cellulose and hydroxypropylmethylcellulose.
  • a process for the preparation of a solid, controlled release, oral dosage form according to the present invention comprising incorporating MGBG in a controlled release matrix.
  • Incorporation in the matrix may be effected, for example, by forming granules comprising at least one water-soluble hydroxyalkyl cellulose and MGBG, mixing the hydroxyalkyl cellulose-containing granules with at least one C12-C36 aliphatic alcohol, and optionally, compressing and shaping the granules.
  • the granules are formed by wet granulating the hydroxyalkyl cellulose/MGBG with water.
  • the amount of water added during the wet granulation step is between 1.5 and 5 times the dry weight of the MGBG. In further embodiments, the amount is between 1.75 and 3.5 times the dry weight of the MGBG.
  • the present solid, controlled release, oral dosage form may also be prepared, in the form of film-coated spheroids, by blending a mixture comprising MGBG and a non-water-soluble spheronizing agent, extruding the blended mixture to give an extrudate, spheronizing the extrudate until spheroids are formed, and coating the spheroids with a film coat.
  • the controlled-release oral pharmaceutical dosage form may be achieved through formulation in micropellets, which may then be either compressed into a tablet or put into a capsule.
  • the MGBG may be coated onto a seed, such as a sugar seed crystal of a predetermined size, by first combining it with polyvinylpyrrolidone, having a molecular weight of from about 30,000 to about 50,000 with a molecular weight of about 40,000 being preferred.
  • the sugar seeds which may be coated with a combination of MGBG and polyvinylpyrrolidone, are then, in turn, coated with an outer coating comprising two polymers.
  • the sugar seeds coated with MGBG may then be coated with from 5% to 10% by weight of the sustained-release coating, which is comprising a combination of ethylcellulose and hydroxypropylcellulose.
  • the sustained-release coating is comprising 70% to 90% by weight of ethylcellulose and 10% to 30% hydroxypropylcellulose based on the weight of the coating.
  • the outer coating is comprising 75% ethylcellulose and 25% hydroxypropylcellulose.
  • the average diameter of each of the micropellets formed is 0.5 to 0.7 mm, particularly preferably about 0.6 mm.
  • micropellets may be comprised, for example, of 5% to 10% by weight of a coating of two different polymers.
  • one polymer is ethylcellulose present in the coating in an amount of 90% to 70% by weight, based on the weight of the coating; the other polymer is hydroxypropylcellulose, which is present in an amount of 10% to 30% by weight, based on the weight of the coating.
  • hydroxypropylcellulose within the coating, along with the ethylcellulose, provides the desired sustained-release of the active ingredient MGBG. If the micropellets of the present invention were coated with a coating comprised completely of ethylcellulose (which is an ethyl ether of cellulose) containing 2.25-2.28 ethoxyl groups per anhydroglucose unit, the drug within the coating would be released very slowly or be released not at all for a long period of time. Hydroxypropylcellulose, wherein the primary hydroxyls present in cellulose have been substituted (etherified) by hydroxypropyl, is more water-soluble than ethylcellulose.
  • the presence of such hydroxypropylcellulose in the coating provides “channels” in the coating through which water can enter, and over time, leach out the MGBG contained within the non-pareil sugar seed.
  • the presence of too many “channels” will make the MGBG more quickly available than is therapeutically appropriate.
  • an optimal release rate is obtained when the outer coating contains three parts of ethylcellulose (75% by weight) to one part of hydroxypropyl cellulose (25% by weight)
  • Compounds for use in the dosage forms disclosed herein include MGBG, as well as other polyamine analogs and polyamine biosynthesis inhibitors, and their salts, prodrugs, solvates, anhydrous forms, protected derivatives, structural isomers, stereoisomers, amino acid conjugates, and porphyrin conjugates thereof. Any polyamine analog is suitable for use in the dosage forms of the present invention.
  • MGBG is 1,1′[methylethanediylidene]dinitrilodiguanidine and is also known as methylglyoxal bis(guanylhydrazone), methyl-GAG, Me-G, and mitoguazone.
  • MGBG includes the free base and salts thereof. It is commonly, but not necessarily, used as a dihydrochloride.
  • MGBG may be present as any one of the following isomers, or a tautomer and/or a syn/anti isomer thereof, mixture of one or more thereof:
  • MGBG may be present in one of the following isomers, or a tautomer and/or a syn/anti isomer thereof, mixture of one or more thereof:
  • polyamine analogs used in the methods of the invention include compounds of the structural formulas 1, 2, 3, 4, 5, 6, and 7 and the corresponding stereoisomers, salts, and protected derivatives thereof.
  • polyamine analogs are compounds of structural formulas 2 and 3, wherein
  • polyamine analogs are compounds of structural formulas 2 and 3, wherein
  • polyamine analogs are compounds of structural formulas 2 and 3, wherein
  • R 1 and R 5 are ethyl.
  • Additional polyamine analogs useful in the present invention include compounds of the formula 6, and the corresponding stereoisomers, salts, and protected derivatives thereof:
  • R 1 and R 7 are independently chosen from C 1 -C 6 alkyl and C 2 -C 6 alkenyl.
  • Additional polyamine analogs useful in the present invention include compounds of structural formula 7, and the corresponding stereoisomers, salts, and protected derivatives thereof:
  • the agent is a chemical moiety that inhibits polyamine biosynthesis by inhibiting the activity of S-adenosyl methionine decarboxylase, inhibits polyamine biosynthesis by inhibiting an enzyme distinct from S-adenosyl methionine decarboxylase, or antagonizes the end-products (i.e., polyamines, including putrescine, spermidine, and spermine) of polyamine biosynthesis.
  • moieties include, but are not limited to, those listed in Table 1. Irrespective of the form of the moiety listed in Table 1, it is understood that it includes, as applicable, a salt, protected derivative, and stereoisomer thereof.
  • the agent is a compound chosen from MGBG, MDL73811, CGP48664, Berenil, Pentamidine, SL47, and SL93, or a combination of two or more thereof.
  • the agent is MGBG, SL47, or SL93.
  • two or more agents are used in the methods of the invention to regulate the activity of osteopontin. The two or more agents can be used either sequentially or simultaneously.
  • composition “substantially” as used herein is intended to mean predominantly or having the overriding characteristic of, such that any opposing or detracting characteristics reach a level of insignificance.
  • a composition “substantially” free of water might not be absolutely free of all traces of water but would be sufficiently anhydrous that any remaining water would not influence the composition in any significant way.
  • substantially dose-limiting side effects might be side effects that limited a dose to a level which was below for therapeutic efficacy.
  • disease as used herein is intended to be generally synonymous and is used interchangeably with the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • a “proliferative disorder” may be any disorder characterized by dysregulated cellular proliferation. Examples include cancers, psoriasis, and atopic dermatitis.
  • hypoalgesia means a heightened sensitivity to pain and can be considered a type of pain or a measure of pain-related behavior.
  • treatment of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. Prevention of disease may involve complete protection from disease, for example, as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.
  • combination therapy means administering two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure.
  • administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient.
  • administration also encompasses the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • patient is generally synonymous with the term “subject” and means an animal differing from a disease, disorder, or condition treatable per the methods disclosed herein, including all mammals and humans.
  • patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses.
  • livestock such as cows, goats, sheep, pigs, and rabbits
  • companion animals such as dogs, cats, rabbits, and horses.
  • the patient is a human.
  • an “effective amount” or a “therapeutically effective amount” is a quantity of a compound (e.g., MGBG, a polyamine analog, a polyamine biosynthesis inhibitor, or an agent) that is sufficient to achieve a desired effect in a subject being treated. For instance, this can be the amount necessary to treat a disease, disorder, condition, or adverse state (such as pain or inflammation) or to otherwise measurably alter or alleviate the symptoms, markers, or mechanisms of the disease, disorder, condition, or adverse state.
  • an effective amount for treating pain is an amount sufficient to prevent, delay the onset of, or reduce pain or one or more pain-related symptoms in a subject, as measured by methods known in the art.
  • the effective amount of a compound of the present invention may vary depending upon the route of administration and dosage form.
  • specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of agents.
  • low dose in reference to a low dose formulation of a drug or a method of treatment specifically employing a “low dose” of a drug, means a dose which for at least one indication is subtherapeutic or is a fraction of the dose typically given for at least one indication.
  • a low dose formulation for treating say, chronic psoriasis might be a fraction of the dose for treating aggressive cancer.
  • the dose for one disease might be an amount that would be subtherapeutic for another disease.
  • a low dose may be simply a dose toward the low end of recognized therapeutic efficacy.
  • Chronic diseases represent an embodiment treatable by low dose formulations and methods.
  • a subtherapeutic amount of a drug might be used in combination with one or more other drugs (themselves in either therapeutic or subtherapeutic amounts) to yield a combination formulation or treatment which is potentiated, that is, more efficacious than the expected effects of the sum of the drugs given alone.
  • a low dose for treating one indication may be two-fold, three-fold, four-fold, five-fold, six-fold, seven-fold, eight-fold, nine-fold, ten-fold, fifteen-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, may be one hundred-fold less than the therapeutic dose for a different indication.
  • terapéuticaally acceptable refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of subjects without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio and are effective for their intended use.
  • drug is used herein interchangeably with “compound,” “agent,” and “active pharmaceutical ingredient” (“API”).
  • a “polyamine” is any of a group of aliphatic, straight-chain amines derived biosynthetically from amino acids; polyamines are reviewed in Marton et al. (1995) Ann. Rev. Pharm. Toxicol. 35:55-91. “Polyamine” generally means a naturally-occurring polyamine or a polyamine which is naturally produced in eukaryotic cells. Examples of polyamines include putrescine, spermidine, spermine, and cadaverine.
  • a “polyamine analog” is an organic cation structurally similar but non-identical to naturally-occurring polyamines such as spermine and/or spermidine and their precursor, diamine putrescine. Polyamine analogs can be branched or un-branched or incorporate cyclic moieties. Polyamines may comprise primary, secondary, tertiary, or quaternary amino groups. In certain embodiments, all the nitrogen atoms of the polyamine analogs are independently secondary, tertiary, or quaternary amino groups but are not so limited. Polyamine analogs may include imine, amidine, and guanidine groups in place of amine groups. The term “polyamine analog” includes stereoisomers, salts, and protected derivatives of polyamine analogs.
  • stereoisomer is an optical isomer of a compound, including enantiomers and diastereomers. Unless otherwise indicated, structural formulae of compounds are intended to embrace all possible stereoisomers.
  • prodrug refers to a compound that is made more active in vivo.
  • Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003).
  • Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound.
  • prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the compound or parent drug. They may, for instance, be bioavailable by oral administration, whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • a wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
  • An example, without limitation, of a prodrug would be a compound that is administered as an ester (the “prodrug”) but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
  • controlled release in reference to a formulation or dosage form means that the release of active drug (e.g., MGBG) from the dosage form is controlled through the use of ingredients that retard, dissolution of the dosage form, or efflux of the drug from the dosage form.
  • active drug e.g., MGBG
  • the term includes extended-release, sustained-release, delayed-release, and pulsed-release (cycled release).
  • substantially dissolve means to dissolve to the degree that is clinically relevant. For example, when an enterically coated dosage form begins to substantially dissolve, it would begin to release the drug into the GI tract to the degree that would, within the time necessary for the drug to be absorbed from the GI lumen and distributed into the plasma, yield a clinically relevant plasma concentration.
  • a clinically relevant plasma concentration might be, for example, a therapeutically effective plasma concentration.
  • a therapeutically effective plasma concentration for example, it might be between about 50% and 100% of a therapeutically effective plasma concentration, between about 80% and 100% of a therapeutically effective plasma concentration, between about 90% and 100% of a therapeutically effective plasma concentration, between about 95% and 100% of a therapeutically effective plasma concentration, or between about 99% and 100% of a therapeutically effective plasma concentration.
  • a clinically relevant plasma concentration might be a plasma concentration at which adverse effects are seen, or near such a concentration, for example, between about 50% and 100%, between about 60% and 100%, between about 70% and 100%, between about 80% and 100%, between about 90% and 100%, or between about 95% and 100% of such a concentration.
  • substantially dissolved might mean about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 800%, about 85%, about 90%, or about 95% dissolved.
  • a dosage form is not “substantially dissolved” when it dissolves only to the extent that it releases a detectable, but otherwise irrelevant, amount of drug into the GI tract.
  • the compounds disclosed herein can exist as therapeutically acceptable salts.
  • the present invention includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable.
  • Pharmaceutical Salts Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
  • terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenyl
  • basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion.
  • the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein and the like.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • compositions which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation depends on the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art, e.g., in Remington's Pharmaceutical Sciences.
  • compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
  • the optimal dose, frequency of administration, and duration of treatment with the agent in a subject may vary from subject to subject, depending on the disease to be treated or clinical endpoint to be reached (for example, decrease in the level or activity of osteopontin, inhibition of infiltration of macrophages to a tissue, or mitigation of pain) the subject's condition, the subject's age, weight, response to the treatment, and the nature of the therapeutic entity. Determination of the optimal dose and duration of treatment is within the scope of one of skill in the art. The optimal dose and duration of treatment may be best determined by monitoring the subject's response during the course of the treatment. In some instances, administering higher doses may permit less frequent administration, and lower doses may require more frequent administration to achieve a clinically significant improvement in the subject's condition.
  • the agent(s) of the invention may be administered as a single dose or in multiple doses.
  • a therapeutically effective dose of the agent per the present methods will be one or more doses of from about 10 to about 1100 mg/m 2 .
  • Lower dose regimens include doses of 10-200, 10-100, 10-50 and 20-200 mg/m 2 .
  • Higher dose regimens include 200-400, 250-500, 400-600, 500-800 600-1000 and 800-1100 mg/m 2 .
  • the dose regimens range from 200-400 mg/m 2 .
  • the dose regimens range from 250-500 mg/m 2 .
  • the dose regimens range from 600-1000 mg/m 2 .
  • the agent is administered daily, once per week, once every other week, or once per month.
  • a dosing regimen ranging from 200-400 mg/m 2 is administered once a week.
  • a dosing regimen ranging from 250-500 mg/m 2 is administered once every other week.
  • the doses may be constant over the entire treatment period, or they may increase or decrease during the course of the treatment.
  • the agent is administered once a week and starts with administering 200 mg/m 2 , and increases to 300 mg/m 2 and 400 mg/m 2 in the second and third weeks, respectively.
  • the agent is administered once every other week and is kept constant for the entire duration of treatment, with administering 250 mg/m 2 .
  • the doses of the agent may be administered for at least one week, at least two weeks, at least three weeks, at least four weeks, at least 6 weeks, or even at least 8 weeks. Adjusting the dose of the agent within these ranges for a particular subject is well within the skill of the ordinary clinician.
  • the agent may be administered via any conventional route normally used to administer a medicament including, but not limited to, oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal (including nasal), transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) routes.
  • Intravenous delivery may take place via a bolus injection or via infusion; infusion may be done over a period ranging from less than a minute to several hours to continuously.
  • a course of treatment will involve administration by a combination of routes.
  • the agent may be administered via a combination of intravenous and oral routes for treating pain or another disorder.
  • a “loading” dose may be administered IV to bring the concentration of the drug to the desired therapeutic level, followed by one or more maintenance doses via the oral route to keep it there.
  • a combination of oral and IV delivery may be used to mitigate pain in a surgery patient.
  • the agent may be delivered pre-, peri-, and post-surgically by a combination of IV and oral routes.
  • the patient may be administered or may self-administer the drug orally before surgery, be administered the drug via IV infusion during surgery and just after, and may thereafter be administered or may self-administer the drug orally or intravenously (patient-controlled analgesia pumps) after surgery.
  • the patient may be administered the drug IV before surgery, be administered the drug via IV infusion during surgery and just after, and may thereafter be administered or may self-administer the drug orally after surgery.
  • the agent may be administered as a pharmaceutical composition in a variety of forms, including, but not limited to, liquid, powder, suspensions, tablets, pills, capsules, sprays, and aerosols.
  • the pharmaceutical compositions may include various pharmaceutically acceptable additives including, but not limited to, carriers, excipients, binders, stabilizers, antimicrobial agents, antioxidants, diluents, and/or supports. Examples of suitable excipients and carriers are described, for example, in “Remington's Pharmaceutical Sciences,” Mack Pub. Co., New Jersey (1991).
  • the agent may be administered via an IV infusion in an aqueous sugar solution.
  • the agent may also be for another substance that facilitates agent delivery.
  • the agent may be associated into liposomes.
  • the liposomes may be conjugated with targeting substance(s), such as IgGFc receptors.
  • Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary, or paste.
  • Oral pharmaceutical preparations include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active, or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • Dragee cores are provided with suitable coatings.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Exemplary unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
  • Fillers to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • Examples of fillers, or diluents include, without limitation, lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugar, microcrystalline cellulose (MCC), powdered cellulose, cornstarch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers such as polyethylene oxide, and hydroxypropyl methylcellulose.
  • Fillers may have complexed solvent molecules, such as in the case where the lactose used is lactose monohydrate. Fillers may also be proprietary, such as in the case of the filler PROSOLV® (available from JRS Pharma).
  • PROSOLV is a proprietary, optionally high-density, silicified microcrystalline cellulose composed of 98% microcrystalline cellulose and 2% colloidal silicon dioxide. Silicification of the microcrystalline cellulose is achieved by a patented process, resulting in an intimate association between the colloidal silicon dioxide and microcrystalline cellulose.
  • ProSolv comes in different grades based on particle size and is a white or almost white, fine or granular powder, practically insoluble in water, acetone, ethanol, toluene, and dilute acids, and in a 50 g/l solution of sodium hydroxide.
  • Disintegrants to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • Examples of disintegrants include, without limitation, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, povidone, crospovidone (polyvinylpolypyrrolidone), methylcellulose, microcrystalline cellulose, powdered cellulose, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and sodium alginate.
  • Lubricants to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • examples of lubricants include, without limitation, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
  • Glidants to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • examples of glidants include, without limitation, silicon dioxide (SiO 2 ), talc cornstarch, and poloxamers.
  • Poloxamers or LUTROL®, available from the BASF Corporation are A-B-A block copolymers in which the A segment is a hydrophilic polyethylene glycol homopolymer, and the B segment is hydrophobic polypropylene glycol homopolymer.
  • Tablet binders to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • Examples of tablet binders include, without limitation, acacia, alginic acid, carbomer, carboxymethyl cellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose, copolyvidone, methylcellulose, liquid glucose, maltodextrin, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, sucrose, tragacanth, and zein.
  • surfactants include, without limitation, fatty acid and alkyl sulfonates; commercial surfactants such as benzethanium chloride (HYAMINE® 1622, available from Lonza, Inc., Fairlawn, N.J.); DOCUSATE SODIUM® (available from Mallinckrodt Spec. Chem., St.
  • Such materials can advantageously be employed to increase the rate of dissolution by facilitating wetting, thereby increasing the maximum dissolved concentration, and also to inhibit crystallization or precipitation of drug by interacting with the dissolved drug by mechanisms such as complexation, the formation of inclusion complexes, the formation of micelles or adsorbing to the surface of solid drug
  • Drug complexing agents and solubilizers to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • Examples of drug complexing agents or solubilizers include, without limitation, polyethylene glycols, caffeine, xanthene, gentisic acid, and cyclodextrins.
  • pH modifiers such as acids, bases, or buffers may also be beneficial, retarding or enhancing the rate of dissolution of the composition, or, alternatively, helping to improve the chemical stability of the composition.
  • Suitable pH modifiers to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • the formulations provided herein may include other agents conventional in the art having regard to the type of formulation in question. Proper formulation depends on the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art, e.g., Remington, supra.
  • the pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
  • Compounds may be generally administered orally at a dose of from 0.1 to about 500 mg/kg per day.
  • the dose range for adult humans is generally from about 5 mg to about 2 g/day.
  • Tablets, capsules, or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing about 5 mg to about 500 mg.
  • an oral dosage form will comprise about 20 to about 400 mg, about 25 to about 350 mg, about 100 to about 350 mg, about 200 to about 350 mg, or about 300 to about 350 mg.
  • the precise amount of compound administered to a subject will be the responsibility of the attendant physician.
  • the specific dose level for any particular subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity. Dosing frequency may also be selected or adjusted based on factors including those above as well as the formulation of the compound delivered.
  • Dosing may occur, for example: once daily, twice daily, three or four times daily, every other day, weekly, bi-weekly, or monthly; or in cycles comprising a sustained dosing period followed by a non-dosing period; or on an as-needed basis.
  • the compounds described herein may be administered in combination with another therapeutic agent.
  • another therapeutic agent such as a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself, the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the subject is enhanced).
  • the benefit experienced by a subject may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • another therapeutic agent which also includes a therapeutic regimen
  • increased therapeutic benefit may result by also providing the subject with another therapeutic agent for neuropathy.
  • the overall benefit experienced by the subject may simply be additive of the two therapeutic agents, or the subject may experience a synergistic benefit.
  • the other therapeutic agent is an antiviral agent.
  • the antiviral agent is an antiretroviral agent, e.g., nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, integrase inhibitors or gp41, CXCR4, or gp120 inhibitors.
  • nucleoside reverse transcriptase inhibitors for treating HIV infections include amdoxovir, elvucitabine, alovudine, racivir ( ⁇ -FTC), phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, zidovudine (AZT), didanosine (ddI), lamivudine (3TC), stavudine (d4T), zalcitabine (ddC), emtricitabine (FTC), and abacavir (ABC).
  • nucleotide reverse transcriptase inhibitors include tenofovir (TDF) and adefovir.
  • non-nucleoside reverse transcriptase inhibitors examples include capravirine, emivirine, calanolide A, etravirine, efavirenz (EFV), nevirapine (NVP), and delavirdine (DLV).
  • protease inhibitors include amprenavir (APV), tipranavir (TPV), lopinavir (LPV), fosamprenavir (FPV), atazanavir (ATV), darunavir, brecanavir, mozenavir, indinavir (IDV), nelfinavir (NFV), ritonavir (RTV), and saquinavir (SQV).
  • entry inhibitors examples include SPOIA.
  • HIV integrase inhibitor examples include curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L-25 870810, MK-0518, BMS-538158, GSK364735C,
  • a gp41 inhibitor examples include enfuvirtide (ENF).
  • Examples of a CXCR4 inhibitor examples include AMD-070, Examples of a gp120 inhibitor include BMS-488043.
  • the polyamine analog is administered concurrently with a highly active antiretroviral therapy (HAART), i.e., a combination of a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, and a nucleoside reverse transcriptase inhibitor, or a combination of two non-nucleoside reverse transcriptase inhibitors and a nucleoside reverse transcriptase inhibitor.
  • HAART highly active antiretroviral therapy
  • the polyamine analog may be administered simultaneously or sequentially (i.e., before or after) with administering antiviral or antiretroviral agents.
  • Administration of the antiviral and antiretroviral agents to subjects in need thereof can be made per regimens and dosages well known in the art.
  • the antiviral agent is an agent that is capable of reducing the HIV viral load in T-cells.
  • T-cells particularly CD4+ T-cells, also serve as a viral reservoir for immunodeficiency viruses such as HIV.
  • combination treatments of polyamine analogs with agents that reduce the viral load in T-cells are particularly desirable for flushing or destroying viral reservoirs of HIV.
  • Suitable agents that reduce the viral load in T-cells are reviewed in Pierson et al. (Annu. Rev. Immunol. (2000), 18:665-708) and include, without limitation, T-cell activating cytokines anti-CD3 antibodies, and anti-CD45RO-toxin conjugates.
  • T-cell activating cytokines such as IL-2, IL-6, TNF- ⁇ , and any two or more combinations thereof may be used in the present methods.
  • the other therapeutic agent is a TNF inhibitor.
  • the TNF inhibitor may be a monoclonal antibody such as, for example, infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), or golimumab (Simponi); a circulating receptor fusion protein such as etanercept (Enbrel); or a small molecule, such as pentoxifylline or bupropion (Zyban, Wellbutrin).
  • the other therapeutic agent is a disease-modifying anti-rheumatic drug (DMARD).
  • DMARDs include azathioprine, cyclosporin (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, leflunomide, methotrexate (MTX), minocycline, sulfasalazine (SSZ), and cyclophosphamide.
  • the other therapeutic agent is methotrexate.
  • IL-1 blockers such as anakinra (Kineret)
  • T-cell costimulation blockers such as abatacept (Orencia)
  • interleukin 6 (IL-6) blockers such as tocilizumab (an anti-IL-6 receptor antibody; RoActemra, Actemra), monoclonal antibodies against B cells such as rituximab (Rituxan), and other biologics (e.g., Ocrelizumab, Ofatumumab, Golimumab, and Certolizumab pegol).
  • the other therapeutic agent is a glucocorticoid or a non-steroidal anti-inflammatory drug (NSAID).
  • NSAIDs include propionic acid derivatives such as ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin; acetic acid derivatives such as indomethacin, sulindac, etodolac, and diclofenac; enolic acid (oxicam) derivatives such as piroxicam and meloxicam; fenamic acid derivatives such as mefenamic acid and meclofenamic acid; selective COX-2 inhibitors (Coxibs) such as celecoxib (Celebrex), rofecoxib, valdecoxib, parecoxib, lumiracoxib, and etoricoxib.
  • Coxibs selective COX-2 inhibitors
  • the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the doses of the multiple therapeutic agents may be any duration of time, ranging from a few minutes to four weeks.
  • certain embodiments provide methods for treating disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, optionally in combination with at least one additional agent for treating said disorder that is known in the art.
  • Specific diseases to be treated by the compounds, compositions, and methods disclosed herein, singly or in combination include, without limitation: pain; neuropathy; inflammation and related disorders; arthritis; metabolic inflammatory disorders; respiratory disorders; autoimmune disorders; neurological disorders; and proliferative disorders, including cancer and non-cancerous diseases.
  • Pain indications include, but are not limited to, treatment or prophylaxis of surgical or post-surgical pain for various surgical procedures including amputation, post-cardiac surgery, dental pain/dental extraction, pain resulting from cancer, muscular pain, mastalgia, pain resulting from dermal injuries, lower back pain, headaches of various etiologies, including migraine, menstrual cramps, and the like.
  • the compounds are also useful for treating pain-related disorders such as tactile allodynia and hyperalgesia.
  • the pain may be somatogenic (either nociceptive or neuropathic), acute, and/or chronic.
  • Peripheral neuropathies that can be treated with the compounds disclosed herein include mono-neuropathies, mono-multiplex neuropathies, and poly-neuropathies, including axonal and demyelinating neuropathies. Both sensory and motor neuropathies are encompassed.
  • the neuropathy or neuropathic pain may be for several peripheral neuropathies of varying etiologies, including but not limited to:
  • neuropathic pain may alternatively be manifested as allodynia, hyperalgesia pain, thermal hyperalgesia, or phantom pain.
  • neuropathy may instead lead to loss of pain sensitivity. Additional sub-categories of neuropathic pain are discussed in Dworkin, Clin J Pain (2002) vol. 18(6) pp. 343-9.
  • the compounds disclosed herein can be used in the treatment or prevention of opiate tolerance in patients needing protracted opiate analgesics, and benzodiazepine tolerance in patients taking benzodiazepines, and other addictive behavior, for example, nicotine addiction, alcoholism, and eating disorders.
  • the compounds disclosed herein are useful in the treatment or prevention of drug withdrawal symptoms, for example, treatment or prevention of symptoms of withdrawal from opiate, alcohol, or tobacco addiction.
  • the compounds disclosed herein are useful in therapeutic methods to treat or prevent respiratory disease or conditions, including therapeutic methods of use in medicine for preventing and treating a respiratory disease or condition including: asthmatic conditions including allergen-induced asthma, exercise-induced asthma, pollution-induced asthma, cold-induced asthma, and viral-induced-asthma; chronic obstructive pulmonary diseases including chronic bronchitis with normal airflow, chronic bronchitis with airway obstruction (chronic obstructive bronchitis), emphysema, asthmatic bronchitis, and bullous disease; and other pulmonary diseases involving inflammation including bronchiectasis, cystic fibrosis, hypersensitivity pneumonitis, farmer's lung, acute respiratory distress syndrome, pneumonia, aspiration or inhalation injury, fat embolism in the lung, acidosis inflammation of the lung, acute pulmonary edema, acute mountain sickness, acute pulmonary hypertension, persistent pulmonary hypertension of the newborn, perinatal aspiration syndrome, hyaline membrane disease
  • Inflammatory conditions include, without limitation: arthritis, including sub-types and related conditions such as rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis (including Still's disease), acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis, and pyogenic arthritis; osteoporosis, tendonitis, bursitis, and other related bone and joint disorders; gastrointestinal conditions such as reflux esophagitis, diarrhea, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, acute and chronic pancreatitis; pulmonary inflammation, such as that for viral infections and cystic fibrosis; skin-related conditions such as psoriasis, eczema, burns, sunburn, dermatitis, pulmonary inflammation, such as that for viral infections and cystic fibrosis; skin
  • Autoimmune disorders may be ameliorated by the treatment with compounds disclosed herein.
  • Autoimmune disorders include Crohn's disease, ulcerative colitis, dermatitis, dermatomyositis, diabetes mellitus type 1, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), autoimmune encephalomyelitis, Hashimoto's disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, mixed connective tissue disease, multiple sclerosis (MS), myasthenia gravis, narcolepsy, pemphigus vulgaris, pernicious anemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, Sjögren's syndrome, scleroderma, temporal arteritis (also known as “giant cell arteritis”), vasculitis,
  • the compounds disclosed herein may regulate TH-17 (T-helper cells producing interleukin 17) cells or IL-17 levels, as well as modulate levels of IL-10 and IL-12. They may also regulate cellular production of osteopontin (e.g., in dendritic cells, monocytes/macrophages, T cells, fibroblasts, and other immunological and non-immunological cell-types).
  • the compounds disclosed herein can be used to treat metabolic disorders typically associated with an exaggerated inflammatory signaling, such as insulin resistance, diabetes (type I or type II), metabolic syndrome, nonalcoholic fatty liver disease (including non-alcoholic steatohepatitis), atherosclerosis, cardiovascular disease, congestive heart failure, myocarditis, atherosclerosis, and aortic aneurysm.
  • metabolic disorders typically associated with an exaggerated inflammatory signaling such as insulin resistance, diabetes (type I or type II), metabolic syndrome, nonalcoholic fatty liver disease (including non-alcoholic steatohepatitis), atherosclerosis, cardiovascular disease, congestive heart failure, myocarditis, atherosclerosis, and aortic aneurysm.
  • the compounds disclosed herein are also useful in treating organ and tissue injury associated with severe burns, sepsis, trauma, wounds, and hemorrhage- or resuscitation-induced hypotension, and also in such diseases as vascular diseases, migraine headaches, periarteritis nodosa , thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephritis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, periodontitis, swelling occurring after injury, ischemias including myocardial ischemia, cardiovascular ischemia, and ischemia secondary to cardiac arrest, and the like.
  • diseases as vascular diseases, migraine headaches, periarteritis nodosa , thyroiditis, aplastic anemia, Hodg
  • the compounds of the subject invention are also useful for treating certain diseases and disorders of the nervous system.
  • Central nervous system disorders in which nitric oxide inhibition is useful include cortical dementias including Alzheimer's disease, central nervous system damage resulting from stroke, ischemias including cerebral ischemia (both focal ischemia, thrombotic stroke and global ischemia (for example, secondary to cardiac arrest), and trauma.
  • Neurodegenerative disorders in which nitric oxide inhibition is useful include nerve degeneration or necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in cases of central nervous system (CNS) trauma (such as spinal cord and head injury), hyperbaric oxygen-induced convulsions, and toxicity, dementia, e.g., pre-senile dementia, and AIDS-related dementia, cachexia, Sydenham's chorea, Huntington's disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), Korsakoffs disease, cognitive disorders relating to a cerebral vessel disorder, hypersensitivity, sleeping disorders, schizophrenia, depression, depression or other symptoms for Premenstrual Syndrome (PMS), and anxiety.
  • CNS central nervous system
  • PMS Premenstrual Syndrome
  • Still other disorders or conditions advantageously treated by the compounds of the subject invention include the prevention or treatment of (hyper)proliferative diseases, especially cancers, either alone or in combination with standards of care, especially those agents that target tumor growth by re-instating the aberrant apoptotic machinery in the malignant cells.
  • Hematological and non-hematological malignancies which may be treated or prevented include but are not limited to multiple myeloma, acute and chronic leukemias including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML), lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma (low, intermediate, and high grade), as well as solid tumors and malignancies of the brain, head, and neck, breast, lung, reproductive tract, upper digestive tract, pancreas, liver, renal, bladder, prostate and colorectal.
  • the present compounds and methods can also be used to treat fibrosis, such as that which occurs with radiation therapy.
  • the present compounds and methods can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, the present compounds and methods can be used to prevent polyps from forming in patients at risk of FAP. Non-cancerous proliferative disorders additionally include psoriasis, eczema, and dermatitis.
  • Compounds disclosed herein may also be used in the treatment of polycystic kidney disease, as well as other diseases of renal dysfunction.
  • the compounds of the subject invention can be used in the treatment of ophthalmic diseases, such as glaucoma, retinal ganglion degeneration, ocular ischemia, corneal neovascularization, optic neuritis, retinitis, retinopathies such as glaucomatous retinopathy and/or diabetic retinopathy, uveitis, ocular photophobia, dry eye, Sjogren's syndrome, seasonal and chronic allergic conjunctivitis, and of inflammation and pain for chronic ocular disorders and acute injury to the eye tissue.
  • the compounds can also be used to treat post-operative inflammation or pain from ophthalmic surgery such as cataract surgery and refractive surgery.
  • the present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-inflammatory therapies, including steroids, NSAIDs, COX-2 selective inhibitors, 5-lipoxygenase inhibitors, LTB 4 antagonists, and LTA 4 hydrolase inhibitors.
  • the compounds of the subject invention may also be used to prevent tissue damage when therapeutically combined with antibacterial or antiviral agents.
  • Multi-species allometric scaling based on pharmacokinetic parameters was employed to calculate predicted pharmacokinetic parameters in humans according to methods known in the art. See, e.g., Ings R M, “Interspecies scaling and comparisons in drug development and toxicokinetics,” Xenobiotica, 1990 November; 20(11):1201-31 and Khor, S P et al., “Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics, and toxicodynamics of 5-fluorouracil in humans,” Cancer Chemother Pharmacol (1997) 39(3): 833-38. Expected values are given below in Table 2.
  • the top efficacious dose of MGBG is 30 mg/kg PO BID (totaling 60 mg/kg/day). Based upon this dosing paradigm in mice, at least two methods to estimate the equivalent dosing in humans may be used.
  • the first method is based upon body surface area (BSA) normalization (described in Reagen-Shaw et al. (2007) FASEB J. 22, 659-661), as the authors note that BSA correlates well across species for various biological parameters, including basal metabolic rate, blood volume, caloric expenditure, plasma protein levels, and renal function. Using this method, a 60 mg/kg/day dose in mice would convert to about 4.9 mg/kg/day in humans.
  • BSA body surface area
  • the second method used to convert the efficacious 60 mg/kg/day dose in mice to an equivalent dose in humans was based more directly on allometric scaling of actual pharmacokinetic data from various animal species.
  • Data from an MGBG pharmacokinetic study consisting of a 10 mg/kg oral dose in mice was modeled in a simulation to determine the theoretical AUC INF value for a dosing regimen of 30 mg/kg PO BID, which was 9050 h*ng/mL.
  • predicted human clearance values as determined by single- and multi-species allometric scaling were used to estimate doses likely to produce exposure in humans (AUC INF ) Similar to that of the 60 mg/kg/day in mice.
  • a human equivalent dose would be in the range of 1.73 mg/kg/day to 4.51 mg/kg/day.
  • the predicted human equivalent dose is about 4.2 mg/kg/day.
  • the average body weight of a normal male human is often presumed to be 70 kg.
  • daily doses based on the predictions above could be estimated to range from about 25 mg/day to about 350 mg/day.
  • the proper dose depends, of course, on several factors.
  • the patient may weigh much more or much less or be female, elderly, or juvenile, requiring a lower or higher dose.
  • the patient may exhibit a drug metabolic profile, which might counsel for a lower or higher dose, such as a low expression level or activity of metabolizing enzymes such as cytochromes P 450 (CYPs). This low expression or activity level may be due to several factors.
  • CYPs cytochromes P 450
  • CYPs Polymorphic expression of one or more CYPs (for example, CYP2C19 and CYP2D6, though polymorphisms have been described for nearly all the CYPs) is known to be responsible for some populations to be “deficient” as compared to the population at large, leading to a “poor metabolizer” phenotype, requiring a lower dose. Additionally, exposure to an infectious agent or xenobiotic may cause repression of CYP expression or inhibition of existing CYPs. Alternatively, the patient may be physically weak, injured, or immunocompromised, all of which might counsel a lower dose.
  • the patient may be taking several other drugs that compete with metabolic systems (including CYPs as discussed above) for disposal; this well-known polypharmaceutical effect may call for a lower dose.
  • the dose also depends, as discussed above, on the condition and its severity.
  • the efficacious dose for one disease or clinical endpoint will not necessarily be the same as the dose for another, and a severe, chronic, or otherwise serious case may call for a higher dose.
  • a chronic case may also call for a lower dose administered over a longer or even indefinite period of time. All of these are discussed by way of example to illustrate the variability of ideal dosing; it is within the capacity of the skilled artisan to select an appropriate dosing range for a disease, population, or individual.
  • the daily human dose may be as low as 1 mg/day, and as high as a 1 g/day.
  • the human dose may range: from 10 mg/day to 500 mg/day, from 20 mg/day to 400 mg/day, or from 25 mg/day to 350 mg/day.
  • the human dose may range from 120 mg/day to 350 mg/day, from 150 mg/day to 350 mg/day, from 200 mg/day to 350 mg/day, or from 250 mg/day to 350 mg/day.
  • the human dose may be any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 75, 80, 85, 90, 95, 100, 110, 120, 125, 130, 140, 150, 160, 170, 175, 180, 190, 200, 210, 220, 225, 230, 240, 250, 260, 270, 275, 280, 290, 300, 310, 320, 325, 330, 240 or 350 mg/day.
  • the human dose may be any one of 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 350, 355, 360, 365, 370, or 375 mg/day.
  • the dose may be 275 mg/day.
  • the dose may be 300 mg/day.
  • the dose may be 305 mg/day.
  • the dose may be 310 mg/day.
  • the dose may be 315 mg/day.
  • the dose may be 320 mg/day.
  • the dose may be 325 mg/day.
  • the dose may be 330 mg/day.
  • the dose may be 335 mg/day.
  • the dose may be 340 mg/day.
  • the dose may be 345 mg/day.
  • the dose may be 350 mg/day.
  • the human dose may be any one of 350, 375, 400, 425, 450, 475, 500, 525, 550 or 600 mg/day. In one embodiment, the dose may be 375 mg/day. In another embodiment, the dose may be 400 mg/day. In another embodiment, the dose may be 450 mg/day. In another embodiment, the dose may be 500 mg/day.
  • the human dose may be any one of 25, 50, 75, 100, or 125 mg/day. In one embodiment, the dose may be 375 mg/day. In another embodiment, the dose may be 25 mg/day. In another embodiment, the dose may be 50 mg/day. In another embodiment, the dose may be 75 mg/day. In another embodiment, the dose may be 100 mg/day. In another embodiment, the dose may be 125 mg/day.
  • the ethylcellulose is typically a dry material of the standard type having a viscosity designation of 4 cps and an ethoxy content of 48% to 49.5%.
  • the hydroxypropylmethylcellulose is typically a dry material having a hydroxypropoxyl content of 7 to 8.6 weight percent.
  • the carrier base material concentration in the tablet formulae ranges from 21% to 26.4% (weight by weight).
  • the ethylcellulose to hydroxypropylmethylcellulose weight ratio in the tablet formulae ranges from 1 to 3.2 to 1 to 4.2.
  • Standard methods known in the art may be used to assess the efficacy of an extended-release formulation.
  • This example illustrates the preparation of a tablet with 200 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • the MGBG together with ethylcellulose, hydroxypropylmethylcellulose, lactose, talc, and the dibasic sodium phosphate, is dry blended and subsequently granulated with an alcohol, denatured 23A, and methylene chloride solvent mixture.
  • alcohol and methylene chloride instead of using alcohol and methylene chloride as the granulating liquids, other liquids such as tap water may be used instead.
  • Denatured 23A is a 100:10 blend of ethyl alcohol and acetone.
  • This example illustrates the preparation of a tablet with 300 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • the method of manufacture is the same as that of Example 1.
  • This example illustrates the preparation of a tablet with 400 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • the method of manufacture is the same as that for Example 1.
  • This example illustrates the preparation of a tablet with 600 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • the method of manufacture is the same as that for Example 1.
  • the dissolution profile of the above dosage forms may be tested according to standard USP procedures. It is expected that the tablet dosage forms will dissolve faster and release the drug more rapidly as the hydroxypropoxyl content increases.
  • the in vivo performance of the novel dosage forms of this invention may be evaluated in bioavailability studies compared to equivalent immediate release dosage forms.
  • Extended-release tablets generally prepared according to Examples 1-4 may be given once a day and evaluated in multi-day steady-state bioavailability studies compared to capsules or tablets containing an equivalent per-diem amount of conventional immediate-release drug given multiple times daily.
  • the extended-release tablets are expected to demonstrate equivalent bioavailability to the immediate-release reference dosage forms. Other pharmacokinetic parameters may be measured as well.
  • the C max and T max values are expected to be lower and later, respectively, for the extended-release dosage forms.
  • 4.0 kilograms of “MGBG pellets, Active I” are then charged into the same Wurster column under the same conditions of temperature and pressure and at the same rate.
  • the second batch having the MGBG dispersed therein is then charged into the Wurster column to further build up the coating.
  • the Wurster column is emptied, and the product is labeled “MGBG pellets, Active II.”
  • a coating mixture of 13.2 liters of chloroform and 3.3 liters of methanol is prepared, into which are dispersed 992.0 grams of ethylcellulose (Ethocel N-10 Dow) and 329.0 grams of hydroxypropyl cellulose (Hercules, Klucel LF).
  • ethylcellulose Ethocel N-10 Dow
  • 329.0 grams of hydroxypropyl cellulose Hercules, Klucel LF.
  • MGBG pellets, Active II hydroxypropyl cellulose
  • the resultant coated pellets are small micropellets which may be placed into capsules containing the desired dosage unit.
  • MGBG pellets may be outer coated with 5% by weight of a mixture containing 75% by weight ethylcellulose and 25% by weight hydroxypropylcellulose.
  • the release characteristics of the coated pellets may be measured according to the U.S.P. XX dissolution procedure (one hour in simulated gastric fluid followed by simulated intestinal fluid).
  • the plastic mass of material is extruded, spheronized, and dried to provide uncoated drug-containing spheroids.
  • the spheroids are sieved to retain the coated spheroids of a particle size between 0.85 mm to 1.76 mm diameter.
  • These selected film-coated spheroids are filled into pharmaceutically acceptable capsules conventionally, such as starch or gelatin capsules.
  • Example 7 Same as for Example 7 except that 1.11 parts of the film coating solution per part of uncoated spheroids are applied to obtain a coating level of 5%.
  • Example 7 Same as for Example 7 except that 1.33 parts of the film coating solution are applied to 1 part of uncoated spheroids to obtain a coating level of 6%.
  • Example 7 Same as for Example 7 except that 1.55 parts of the film coating solution are applied to 1 part of uncoated spheroids to obtain a coating level of 7%.
  • the required quantities of MGBG, spray-dried lactose, and Eudragit® RS PM are transferred into an appropriate-size mixer and mixed for approximately 5 minutes. While the powders are mixing, the mixture is granulated with enough water to produce a moist granular mass. The granules are then dried in a fluid bed dryer at 60° C. and then passed through an 8-mesh screen. Thereafter, the granules are redried and pushed through a 12-mesh screen. The required quantity of stearyl alcohol is melted at approximately 60°-70° C., and while the granules are mixing, the melted stearyl alcohol is added. The warm granules are returned to the mixer.
  • Example 11 The coated granules are removed from the mixer and allowed to cool. The granules are then passed through a 12-mesh screen. The granulate is then lubricated by mixing the required quantity of talc and magnesium stearate in a suitable blender. Tablets are compressed to 375 mg in weight on a suitable tableting machine.
  • the formula for the tablets of Example 11 is set forth below:
  • Example 11 The tablets of Example 11 are then tested for dissolution via the USP Basket Method, 37° C., 100 RPM, first hour 700 ml gastric fluid at pH 1.2, then changed to 900 ml at 7.5.
  • the required quantities of MGBG and spray dried lactose are transferred into an appropriately sized mixer and mix for approximately 6 minutes. Approximately 40 percent of the required Eudragit® RS PM powder is dispersed in Ethanol. While the powders are mixing, the powders are granulated with the dispersion, and the mixing continued until a moist granular mass is formed. Additional ethanol is added if needed to reach the granulation endpoint. The granulation is transferred to a fluid bed dryer and dried at 30° C., and then passed through a 12-mesh screen.
  • the remaining Eudragit® RS PM is dispersed in a solvent of 90 parts ethanol and 10 parts purified water and sprayed onto the granules in the fluid bed granulator/dryer at 30° C.
  • the granulate is passed through a 12-mesh screen.
  • the required quantity of stearyl alcohol is melted at approximately 60°-70° C.
  • the warm granules are returned to the mixer. While mixing, the melted stearyl alcohol is added.
  • the coated granules are removed from the mixer and allowed to cool. Thereafter, they are passed through a 12-mesh screen.
  • the granulate is lubricated by mixing the required quantities of talc and magnesium stearate in a suitable blender.
  • the granulate is then compressed to 125 mg tablets on a suitable tableting machine.
  • Example 12 (10 mg controlled release MGBG) is set forth below:
  • Example 12 The tablets of Example 12 are then tested for dissolution via USP Basket Method at 37° C., 100 RPM, first hour 700 ml simulated gastric (pH 1.2) then changed to 900 ml at pH 7.5.
  • Eudragit® RS 30D and Triacetin® are combined while passing through a 60 mesh screen and mixed under low shear for approximately 5 minutes or until a uniform dispersion is observed.
  • MGBG MGBG granulator/dryer
  • suitable quantities of MGBG, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed. After spraying, the granulation is passed through a #12 screen if necessary to reduce lumps. The dry granulation is placed in a mixer.
  • BFD fluid bed granulator/dryer
  • the required amount of stearyl alcohol is melted at a temperature of approximately 70° C.
  • the melted stearyl alcohol is incorporated into the granulation while mixing.
  • the waxed granulation is transferred to a fluid bed granulator/dryer or trays and allowed to cool to room temperature or below.
  • the cooled granulation is then passed through a #12 screen.
  • the waxed granulation is placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes, and then the granulate is compressed into 125 mg tablets on a suitable tableting machine.
  • Example 13 The tablets of Example 13 are then tested for dissolution via the USP Basket Method at 37° C., 100 RPM, first hour 700 ml simulated gastric fluid at pH 1.2, then changed to 900 ml at pH 7.5.
  • Example 14 The tablets of Example 14 are then tested for dissolution via the USP Basket Method at 37° C., 100 RPM, first hour 700 ml simulated gastric fluid at pH 1.2, then changed to 900 ml at pH 7.5.
  • Example 15 30 mg controlled release MGBG tablets are prepared according to the process set forth in Example 10.
  • Example 16 10 mg controlled release MGBG tablets are prepared according to the process set forth in Example 12. Thereafter, dissolution studies of the tablets of Examples 5 and 6 are conducted at different pH levels, namely, pH 1.3, 4.56, 6.88, and 7.5.
  • Example 17-22 4 mg and 10 mg MGBG tablets are prepared in a manner similar to the formulations and methods set forth in U.S. Pat. No. 4,990,341.
  • MGBG (10.00 gm) is wet granulated with lactose monohydrate (417.5 gm) and hydroxyethyl cellulose (100.00 gm), and the granules are sieved through a 12 mesh screen. The granules are then dried in a fluid bed dryer at 50° C. and sieved through a 16 mesh screen. Molten cetostearyl alcohol (300.0 gm) is added to the warmed MGBG containing granules, and the whole was mixed thoroughly.
  • the mixture is allowed to cool in the air, regranulated, and sieved through a 16 mesh screen.
  • Purified Talc (15.0 gm) and magnesium stearate (7.5 gm) are then added and mixed with the granules. The granules are then compressed into tablets.
  • Example 18 is prepared in the same manner as Example 17; however, the formulation includes 10 mg MGBG/tablet.
  • the formulas for Examples 17 and 18 are set forth below.
  • Example 19 4 mg MGBG controlled-release tablets are prepared according to the excipient formula cited in Example 2 of U.S. Pat. No. 4,990,341. The method of manufacture is the same as set forth in Examples 17 and 18 above.
  • Example 20 is prepared according to Example 19, except that 10 mg MGBG is included per tablet. The formulas for Examples 19 and 20 are set forth below.
  • Example 21 MGBG 4 mg controlled-release tablets are prepared in a manner analogous to and with the same excipient formula cited in Example 3 of U.S. Pat. No. 4,990,341.
  • MGBG (32.0 gm) is wet granulated with lactose monohydrate (240.0 gm), hydroxyethylcellulose (80.0 gm), and methacrylic acid copolymer (240.0 gm, Eudragit® L-100-55), and the granules are sieved through a 12 mesh screen. The granules are then dried in a Fluid Bed Dryer at 50° C. and passed through a 16 mesh screen.
  • molten cetostearyl alcohol 240.0 gm
  • the mixture is allowed to cool in the air, regranulated, and sieved through a 16 mesh screen. The granules are then compressed into tablets.
  • Example 22 is prepared in an identical fashion to Example 21, except that 10 mg MGBG is included per tablet.
  • the formulations for Examples 21 and 22 are set forth below.
  • Pellet Core MGBG 250 Microcrystalline cellulose 75.07 Hypromellose 65 Seal Coat: Opadry Clear 6.5 “Delay” Coat: Surelease ® ethylcellulose 27 dispersion Hypomellose 3 Water* NA
  • Tablet Dosage Unit with Delay Coat Ingredient mg/capsule (250 mg MGBG dosage) Tablet Core: MGBG 250 Microcrystalline cellulose 135 Hypromellose 60 Talc 18 Magnesium stearate 7 “Delay” Coat: Surelease ® ethylcellulose 27 dispersion Hypomellose 3 Water* NA
  • Enterically coated dosage forms may be made by the methods below. In certain embodiments, methods are chosen to ensure that the final dosage form is substantially anhydrous. The moisture content can be measured by methods known in the art. Additionally, the dosage form may be tested for isomerization of MGBG. A stable dosage form would show minimal isomerization.
  • Tablets in the examples below may be made either by direct compression or by dry granulation.
  • MGBG in the amount cited is combined with magnesium stearate in an amount equal to about 1% of the total weight of the tablet core, crospovidone in an amount equal to about 2% of the total weight of the tablet core, and sufficient anhydrous lactose to form a tablet core of a total weight of 500 mg.
  • the ingredients are de-lumped by screening or milling, then blended until the mixture is substantially uniform. Uniformity may be tested by sampling at three different points in the blend container and assessed using standard methods such as HPLC; test result of 95-105% of target potency, with an RSD of 5% would be near ideal.
  • the mixture is poured into dies, optionally with a forced-flow feeder, and compressed into tablets, which may then be enterically coated.
  • MGBG For manufacture by dry granulation, MGBG in the amount cited, a disintegrant such as crospovidone and a lubricant such as magnesium stearate, and a sufficient amount of a filler/diluent such as anhydrous lactose to form a tablet core of a total weight of 500 mg (similar quantities of other excipients used in direct compression may be used, with adjustment to allow for an additional lubricating step at the end) are de-lumped by screening or milling, then blended until the mixture is substantially uniform. The mixture is poured into dies and compressed with a flat-faced punch into slugs, typically of 3 ⁇ 4′′ to 1′′; alternatively, the powder is densified by passing through the rollers of a compacting mill.
  • a disintegrant such as crospovidone and a lubricant such as magnesium stearate
  • a filler/diluent such as anhydrous lactose
  • the slugs are then broken up gently to form granules and reduced to a substantially uniform granule size by screening or milling.
  • the granules are lubricated a second time.
  • the granules may themselves be enterically coated and then encapsulated or compressed into tablets, which may then be enterically coated.
  • MGBG is combined with a binder/filler and wet granulated using a minimum of solvent according to methods known in the art.
  • Microcrystalline cellulose is an appropriate binder. This mixture is passed through an extruder to form the cylinder's desired thickness. These cylindrical segments are collected and placed in a Marumerizer, where they are shaped into spheroids by centrifugal and frictional forces. The spheroids should be screened for uniform sizes, such as roughly 0.5-1 mm in diameter. The spheroids may then be dried, lubricated, and enterically coated before being encapsulated. Alternatively, the spheroids may be compressed into a tablet, which may then enterically coated.
  • MGBG is coated onto seed crystals of substantially uniform size, optionally after combining with a binder such as polyvinylpyrrolidone, in layers.
  • the layers may be deposited by spraying the MGBG as a solution onto sugar seeds in an air column suspension unit, repeating the process as necessary until the micropellets are of the desired size.
  • the micropellets may then be dried, lubricated, and enterically coated before being encapsulated.
  • the following Examples are enterically coated dosage forms made using a methacrylic acid/ethyl acrylate copolymer as the release-delaying agent in the enteric coat.
  • the methacrylic acid/ethyl acrylate copolymer may be any such suitable copolymer, for example, Eudragit® L 30 D-55 or Eudragit® L 100-55.
  • the MGBG core of the tablet, micropellets, or spheroids may optionally be combined with one or more excipients as disclosed herein or known in the art. It is expected that the formulations below will bypass the stomach and release MGBG in the duodenum.
  • USP or in vitro models it is expected that successful delayed-release dosage forms will dissolve between about pH 5.5 and about pH 6.
  • in vivo models it is expected that exceptionally successful delayed-release dosage forms will yield reduced gastrointestinal side effects, such as nausea, emesis, gastric irritation, ulceration, and/or bleeding, and loose stool and/or diarrhea in subjects.
  • the T max will be right-shifted (on a concentration-versus-time graph having a concentration on the vertical axis and time on the horizontal axis, i.e., delayed) by at least one hour; in certain embodiments, the T max will be right-shifted by one to six hours.
  • MGBG may be varied as needed according to methods known in the art. Different proportions of MGBG and filler may be used to achieve, for example—using the same enteric coating proportions—a 50, 75, 100, 150, 200, 225, 325, 375, 400, or 450 mg dosage form. Additional excipients such as lubricants (for example, talc), compression protectants (for example, triethyl citrate or a polyethylene glycol such as macrogol 6000), etc., may be added. Table 3 below provides additional enterically coated dosage forms.
  • lubricants for example, talc
  • compression protectants for example, triethyl citrate or a polyethylene glycol such as macrogol 6000
  • Examples 267-506 are enterically coated dosage forms which can be made in proportions analogous to each corresponding Example among those in Examples 27-266 but using amethacrylic acid/methyl methacrylate copolymer (“MA/MM-C”) as the release-delaying agent in the enteric coat instead of amethacrylic acid/ethyl acrylate copolymer.
  • the methacrylic acid/methyl methacrylate copolymer may be any such suitable copolymer, for example, Eudragit® L100 or Eudragit® L 12.5.
  • the MGBG core of the tablet, micropellets, or spheroids may optionally be combined with one or more excipients as disclosed herein or known in the art.
  • the T max will be right-shifted (on a concentration-versus-time graph having a concentration on the vertical axis and time on the horizontal axis, i.e., delayed) by at least two hours; in certain embodiments, the T max will be right-shifted by two to twelve hours.
  • MGBG may be varied as needed according to methods known in the art. Different proportions of MGBG and filler may be used to achieve, for example—using the same enteric coating proportions—a 50, 75, 100, 150, 200, 225, 325, 375, 400, or 450 mg dosage form. Additional excipients such as lubricants (for example, talc), compression protectants (for example, triethyl citrate or a polyethylene glycol such as macrogol 6000), etc., may be added. Table 4 below provides additional enterically coated dosage forms.
  • lubricants for example, talc
  • compression protectants for example, triethyl citrate or a polyethylene glycol such as macrogol 6000
  • ethyl acrylate/methyl methacrylate/methacrylic acid copolymer may be any such suitable copolymer, for example, Eudragit® S 100, Eudragit® S 12.5 or Eudragit® FS 30-D.
  • the MGBG core of the tablet, micropellets, or spheroids may optionally be combined with one or more excipients as disclosed herein or known in the art. It is expected that the formulations below will bypass the stomach and release MGBG primarily in the colon. Standard USP or in vitro assays, as well as in vivo models, which are known in the art, may be used to confirm this effect. When using USP or in vitro models, it is expected that successful delayed-release dosage forms will dissolve above about pH 7. When using in vivo models, it is expected that exceptionally successful delayed-release dosage forms will yield reduced gastrointestinal side effects, such as nausea, emesis, gastric irritation, ulceration, and/or bleeding, and loose stool and/or diarrhea in subjects.
  • the T max will be right-shifted (on a concentration-versus-time graph having a concentration on the vertical axis and time on the horizontal axis, i.e., delayed) by at least three hours; in certain embodiments, the T max will be right-shifted by three to twenty-four hours.
  • MGBG Methylglyoxal bis (guanylhydrazone) dihydrochloride hydrate (MGBG) was used; a correction factor of 1.49 (to account for the dihydrochloride salt/monohydrate) was used when calculating the required amount of test article.
  • the amount in each capsule was 10, 30, or 100 mg/kg, calculated based on subject body weight.
  • Capsules were enterically coated with Eudragit® L100-55, as required, using a Torpac Pro-Coater® according to the standard dip procedure provided by the manufacturer (see www.torpac.com, go to “Reference/ProCoater Manual.pdf” or contact Torpac, Inc. for detailed instructions).
  • Solid MGBG or a salt thereof may be passed through one or more sieve screens to produce a consistent particle size. Excipients, too, may be passed through a sieve. Appropriate weights of compounds, sufficient to achieve the target dosage per capsule, may be measured and added to a mixing container or apparatus, and the blend is then mixed until uniform. Blend uniformity testing may be done by, for example, sampling 3 points within the container (top, middle, and bottom) and testing each sample for potency. A test result of 95-105% of target, with an RSD of 5%, would be considered ideal; optionally, additional blend time may be allowed to achieve a uniform blend. Upon acceptable blend uniformity results, a measured aliquot of this stock formulation may be separated to manufacture the lower strengths.
  • Magnesium stearate may be passed through a sieve, collected, weighed, added to the blender as a lubricant, and mixed until dispersed. The final blend is weighed and reconciled. Capsules may then be opened, and blended materials flood fed into the body of the capsules using a spatula. Capsules in trays may be tamped to settle the blend in each capsule to assure uniform target fill weight, then sealed by combining the filled bodies with the caps.
  • Total fill weight of capsule is 500 mg, not including capsule weight.
  • the target compound dosage is 300 mg per capsule but may be adjusted to account for the weight of counterions and/or solvates if given as a salt or solvated polymorph thereof. In such a case, the weight of the other excipients, typically the filler, is reduced.
  • Total fill weight of capsule is 300 mg, not including capsule weight.
  • the target compound dosage is 150 mg per capsule but may be adjusted to account for the weight of counterions and/or solvates if given as a salt or solvated polymorph thereof. In such a case, the weight of the other excipients, typically the filler, is reduced.
  • the comparative immediate-release examples above will exhibit several of the following characteristics when compared to a controlled-release dosage form: shorter half-life, higher C max , shorter T max , and higher frequency and/or severity of side effects including gastrointestinal side effects.
  • the test article was administered once at each dose level during the study orally via capsule.
  • Duplicate sets of enteric-coated capsules were prepared for each animal at each dose and evaluated for dissolution.
  • the duplicate sample was placed in a 0.1 N HCl solution and stirred using a magnetic stir bar and stir plate for at least two hours.
  • Triplicate samples of the acidic dissolution media were collected for analysis of MGBG content.
  • the capsule was transferred to a phosphate buffer solution (pH 6.8) and stirred using a magnetic stir bar and stir plate for approximately one hour. The capsule was visually inspected for signs of deformation.
  • Dose levels were selected based on previous studies in dogs, which exhibited dose-limiting emesis when administered single doses of MGBG in standard capsules ⁇ 10 mg/kg.
  • the dose levels for the treated groups were 10, 30, and 100 mg/kg administered on Days 1, 8, and 33, respectively, in standard or enteric-coated gelatin capsules. Individual doses were based on the most recent body weights.
  • the animals were administered the next escalating dose of the test article after completing a 7-day (between doses 1 and 2) or 25-day (between doses 2 and 3) wash-out period.
  • Plasma samples (approximately 1 mL) were collected from all animals for determination of the plasma concentrations of the test article. Samples were collected predose and at 0.5, 1, 2, 4, 8, and 24 hours postdose on Day 1, and predose and at 0.5, 1, 2, 4, 8, 12, 18, and 24 hours postdose on Days 8 and 33. The animals were not fasted before blood collection. Samples were placed in tubes containing lithium heparin as an anticoagulant. The blood samples were collected on wet ice and centrifuged for 10 minutes at 3000 g RCF under refrigeration at 4° C. At study termination, all animals were euthanized.
  • Plasma samples were separated into two aliquots (approximately 200 ⁇ L per aliquot) following centrifugation and placed in tightly capped, pre-labeled, plastic vials and were stored frozen at ⁇ 50 to ⁇ 90° C. until analyzed.
  • the vial label included the study number, relative study day, animal number, and the date and time interval of collection.
  • FIG. 2 Mean time-versus-concentration curves for standard and enterically coated capsules are presented in FIG. 2 (10 mg/kg), FIG. 3 (30 mg/kg) and FIG. 4 (100 mg/kg) and FIG. 5 (all doses on same axes).
  • Plasma concentrations with the standard capsules generally declined rapidly during the first 4 hours and then gradually from 4 to 24 hours, while plasma concentrations with the enteric-coated capsules increased slowly from 0 to 8 (or 12) hours and then declined gradually. Measurable concentrations were observed after 24-hours in all groups and both capsule types.
  • T max ranged from 2.33 to 3.5 hours for standard capsules and from 8 to 13.3 hours for enteric-coated capsules.
  • Mean Cmax and mean AUC0-t exposure to MGBG increased with an increasing dose for both capsule types. Cmax was sometimes greater than dose-proportional with the standard capsule and dose-proportional with the enteric-coated capsules. AUC0-t was dose-proportional for both capsule types.
  • the dogs dosed with the standard capsules had higher mean exposures at all dose levels, compared to dogs dosed with the enteric-coated capsules, even at 100 mg/kg/day with the incidence of emesis/vomitus.
  • Cmax for the standard capsule ranged from 510 to 22,090 ng/mL, and 128 to 1,580 ng/mL for the enteric-coated capsules.
  • AUC0-t for the standard capsule ranged from 3,370 to 33,000 ng ⁇ hr/mL, and 2,010 to 23,700 ng ⁇ hr/mL for the enteric-coated capsules. Mean data and standard deviations are given below in Table 7; see also FIG. 6 , where Tmax and Cmax are compared across doses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Description

  • This application is a continuation of U.S. application Ser. No. 15/583,697, filed May 1, 2017, which is a continuation of U.S. application Ser. No. 14/480,847, filed Sep. 9, 2014, now U.S. Pat. No. 9,668,988, which is a continuation of U.S. application Ser. No. 13/354,076, filed Jan. 19, 2012, now U.S. Pat. No. 8,858,991, issued on Oct. 14, 2014, which claims the benefit of priority of U.S. provisional application No. 61/434,269, filed Jan. 19, 2011, the disclosures of each which are incorporated by reference as if written herein in their entireties.
  • This invention was made with government support under Grant Number U19MH081835, awarded by the National Institutes of Health. The government has certain rights in the invention.
  • Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG and their application for the improved treatment of diseases with reduced side effects.
  • MGBG (methylglyoxal bis(guanylhydrazone); mitoguazone) is a competitive inhibitor of S-adenosyl methionine decarboxylase (AMD-I), which catalyzes the synthesis of spermidine (a polyamine). The amino acid-derived polyamines have long been for cell growth and cancer, and specific oncogenes and tumor-suppressor genes regulate polyamine metabolism. Inhibition of polyamine biosynthesis has proven to be generally ineffective as an anticancer strategy in clinical trials, but it is a potent cancer chemoprevention strategy in preclinical studies. Despite its novel mechanism of action and promising preclinical data, initial clinical trials of MGBG were ceased in the middle of the 1960s due to severe toxicity, particularly to self-renewing tissues including bone marrow and intestinal tract (e.g., severe mucositis), which were both dose- and schedule-dependent.
  • Regardless, research continued with MGBG. A number of studies have examined potential uses in combination with other chemotherapeutic agents and innovative dosing regimens, designed to minimize side effects and dose where possible. Others have focused on elucidating MGBG's modes of action in the body. Yet others have investigated MGBG's activity in diseases other than cancer.
  • Perhaps due to the negative clinical findings coupled with a lack of demonstrated oral bioavailability in these early studies, MGBG has been confined to intravenous use to date. As a practical matter, this presents several problems for treating many diseases, particularly chronic or recurrent conditions. Administration via IV injection or infusion must be done by a medical professional in a hospital setting. This not only presents an inconvenience and increased cost to the subject, but it also exposes him or her to hospital-based infections and illnesses, the latter both from venipuncture and the hospital or clinic visit itself. In immunocompromised individuals such as, for example, those with HIV or AIDS, individuals undergoing treatment with immunosuppressive agents, and the elderly, this is a relevant concern. Thus, a subject with a long-term chronic condition such as an autoimmune or hyperproliferative disorder, or a doctor treating such a subject, might find the cost, inconvenience, and risks of such treatment more important than any potential therapeutic benefits the drug might offer.
  • An oral formulation of MGBG, in contrast, presents several benefits. First, an oral formulation, for example, a simple capsule or tablet, may be taken outside of a hospital setting, increasing the potential for ease of use and compliance. This permits a subject to avoid infection risks concomitant with IV administration and hospital visits. Where early treatment can prevent developing disease complications, this is of particular benefit. Chronic low-dose administration of MGBG is practically impossible in an IV formulation. Additionally, oral delivery typically avoids the high concentration peak and rapid clearance for an IV bolus dose. Yet another advantage of an oral drug would be the ability to formulate MGBG as a combination composition with one or more other therapeutic agents.
  • However, because gastrointestinal side effects have been reported during oral MGBG therapy, and because these side effects have been reported to increase in frequency and severity with dose, dose-limiting oral GI toxicity is cause for concern. Additionally, in prior studies, a correlation was observed across species whereby as body surface area increases, Tmax declines, and Cmax increases, culminating in immediate gastric irritation/emesis in dogs; see, e.g., FIG. 1. Of concern was whether humans would have a similar reaction to the drug. Dosage forms in which the location within the GI tract and the timing of the release of the drug are controlled, for example, delayed-release formulations, represent a practical solution if GI toxicity becomes a problem in the clinic.
  • Accordingly, disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG for treating disease.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts a graph showing that as body surface area increases across species administered MGBG, Tmax drops while Cmax increases.
  • FIG. 2 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs, dosed at 10 mg/kg.
  • FIG. 3 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs, dosed at 30 mg/kg.
  • FIG. 4 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs dosed at 100 mg/kg.
  • FIG. 5 depicts the time-versus-drug-concentration curves for standard and enterically-coated capsules in dogs, at all tested doses (10, 30, and 100 mg/kg).
  • FIG. 6 depicts a bar graph that allows a visual comparison of the Cmax and Tmax of MGBG in standard and enterically-coated capsules at all tested doses (10, 30, and 100 mg/kg).
    •
  • Provided herein is a controlled-release oral pharmaceutical dosage form comprising MGBG.
  • In certain embodiments, the controlled-release dosage form comprising MGBG is chosen from extended-release, sustained-release, delayed-release, and pulsed-release.
  • In certain embodiments, the controlled-release dosage form comprising MGBG is a delayed-release tablet or a delayed-release capsule.
  • Also provided a delayed-release tablet or a delayed-release capsule comprising MGBG, wherein the capsule or tablet comprises an enteric coating.
  • In certain embodiments, the enteric coating comprises one or more of cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methacrylic acid/methyl methacrylate copolymer, methacrylic acid/methyl acrylate copolymers, methacrylic acid/ethyl acrylate copolymer, sodium alginate, and stearic acid.
  • In certain embodiments, the enteric coating is applied to the tablet.
  • In certain embodiments, the enteric coating is applied to the capsule.
  • In certain embodiments, the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer.
  • In certain embodiments, the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55.
  • In certain embodiments, the enteric coating begins to substantially dissolve, and drug release commences in the duodenum.
  • In certain embodiments, the enteric coating begins to substantially dissolve, and drug release commences at about or more hours after ingestion.
  • In certain embodiments, the enteric coating begins to substantially dissolve, and drug release commences at about ½ or more hours after ingestion.
  • In certain embodiments, an enterically-coated capsule comprising MGBG exhibits reduced side effects in patients compared to a non-enterically-coated capsule. In certain embodiments, said side effects are reduced by at least 30%, at least 40%, least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% compared to a non-enterically-coated capsule. In certain embodiments, the overall incidence of said side effects is reduced. In other embodiments, the severity of said side effects is reduced. In certain embodiments, both the incidence and severity of said side effects are reduced.
  • In certain embodiments is provided an enterically-coated capsule which does not have substantially dose-limiting side effects.
  • In certain embodiments, said side effects are gastrointestinal.
  • In certain embodiments is provided an enterically-coated capsule comprising MGBG, which exhibits reduced side effects in patients compared to a non-enterically-coated capsule and is orally bioavailable. In certain embodiments, the percent bioavailability is between about 10 and about 50%. In certain embodiments, the percent bioavailability is between about 20 and about 40%. In certain embodiments, the percent bioavailability is between about 30 and about 40%. In certain embodiments, the percent bioavailability is about 35%.
  • In certain embodiments, said gastrointestinal side effects are chosen from nausea, emesis (vomiting), diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.
  • In certain embodiments, emesis is reduced by at least 30%, at least 40%, least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 50% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 70% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 80% compared to a reference standard that is not enterically coated. In certain embodiments, emesis is reduced by at least 90% compared to a reference standard that is not enterically coated.
  • In certain embodiments, said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells.
  • In certain embodiments is provided an enterically-coated capsule which exhibits dose-proportional increases in Cmax and AUC.
  • In certain embodiments is provided an enterically-coated capsule which exhibits a half-life comparable to a reference standard that is not enterically coated.
  • In certain embodiments is provided a tablet additionally comprising a seal coating between the tablet and the enteric coating.
  • In certain embodiments is provided a tablet additionally comprising an extended-release coating.
  • In certain embodiments is provided a tablet additionally comprising an immediate release coating containing MGBG atop the extended-release coating.
  • In certain embodiments, the enteric coating is applied to micropellets comprising MGBG optionally with one or more excipients, and the micropellets are enclosed in a capsule.
  • In certain embodiments, the enteric coating is applied to spheroids comprising MGBG optionally with one or more excipients, and the spheroids are enclosed in a capsule.
  • In certain embodiments, the enteric coating is applied to the capsule.
  • In certain embodiments, the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer.
  • In certain embodiments, the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55.
  • In certain embodiments, the enteric coating begins to substantially dissolve, and drug release commences in the duodenum.
  • In certain embodiments, the enteric coating begins to substantially dissolve, and drug release commences at about 1 or more hours after ingestion.
  • In certain embodiments, the oral pharmaceutical composition does not have substantially dose-limiting side effects.
  • In certain embodiments, said side effects are gastrointestinal.
  • In certain embodiments, said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, and gastrointestinal ulceration.
  • In certain embodiments, said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form has a Tmax from about 1 hour to about 14 hours. In certain embodiments, the delayed-release oral pharmaceutical dosage form has a Tmax from about 1 hour to about 8 hours. In certain embodiments, the delayed-release oral pharmaceutical dosage form has a Tmax from about 1 hour to about 4 hours. In further embodiments, the Tmax is from 1 hour to 2 hours. In further embodiments, the Tmax is from 2 hours to 3 hours. In further embodiments, the Tmax is from 3 hours to 4 hours. In further embodiments, the Tmax is from 4 hours to 5 hours. In further embodiments, the Tmax is from 5 hours to 6 hours. In further embodiments, the Tmax is from 6 hours to 7 hours. In further embodiments, the Tmax is from 7 hours to 8 hours. In further embodiments, the Tmax is from 8 hours to 9 hours. In further embodiments, the Tmax is from 9 hours to 10 hours. In further embodiments, the Tmax is from 10 hours to 11 hours. In further embodiments, the Tmax is from 11 hours to 12 hours. In further embodiments, the Tmax is chosen from about 1, about 1.5 about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, about 11, about 11.5, and about 12 hours.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG Tmax is between 1 and 14 hours. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is between 1 and 4 hours. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is between 1 and 2 hours. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is between 2 and 4 hours. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is between 4 and 8 hours. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is between 8 and 14 hours.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG Tmax is at least 1 hour later than a reference standard which is not enterically coated, etc. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is at least 2 hours later than a reference standard which is not enterically coated. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is at least 3 hours later than a reference standard which is not enterically coated. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is at least 4 hours later than a reference standard which is not enterically coated. In further embodiments, the enterically-coated delayed-release capsule has a Tmax, which is at least 6 hours later than a reference standard which is not enterically coated.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG Cmax is less than about 500 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 465 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 400 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 300 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 200 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 100 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 50 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 25 ng/mL. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is less than about 12 ng/mL.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG Cmax is between 10 and 465 ng/mL.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG Cmax is 50% less than a reference standard which is not enterically coated. In further embodiments, the enterically-coated delayed-release capsule has a Cmax, which is at least 60% less than a reference standard which is not enterically coated. In yet further embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG Cmax is 75% less than a reference standard which is not enterically coated.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is less than about 3,100 ng*hr/mL. In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is between about 180 and about 3,100 ng*hr/mL.
  • In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is between about 20% and about 50% less than a reference standard which is not enterically coated. In further embodiments, the enterically-coated delayed-release capsule has an MGBG AUC between about 30% and about 50% less than a reference standard, which is not enterically coated. In further embodiments, the enterically-coated delayed-release capsule has an MGBG AUC between about 30% and about 50% less than a reference standard, which is not enterically coated. In certain embodiments is provided a delayed-release capsule comprising between about 25 to about 350 mg/kg MGBG, wherein said capsule comprises an enteric coating, and wherein the MGBG AUC is about 40% less than a reference standard which is not enterically coated.
  • Also provided is a delayed-release oral pharmaceutical dosage form comprising MGBG dihydrochloride hydrate in capsule enterically-coated for duodenal release. In certain embodiments, wherein the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer. In certain embodiments, the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55. In certain embodiments, wherein the capsule comprises 25-350 mg MGBG. In certain embodiments, reduced gastrointestinal side effects in patients compared to a non-enterically-coated capsule.
  • In certain embodiments, the controlled-release dosage form is an extended-release form.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a capsule comprising micropellets of MGBG optionally with one or more excipients, said micropellets being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a capsule comprising spheroids of MGBG optionally with one or more excipients, said spheroids being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a capsule comprising MGBG optionally with one or more excipients, said capsule being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a tablet having an enteric coating. In further embodiments, the delayed-release tablet comprises an enteric coating applied directly to the tablet. In other embodiments, a delayed-release tablet comprises a seal coating applied directly to the tablet and an enteric coating.
  • In certain embodiments, the dosage form is chosen from extended-release and sustained-release.
  • In certain embodiments, the dosage form additionally comprises a hydrogel.
  • In certain embodiments, the dosage form comprises micropellets having at least one layer comprising said MGBG and at least one layer comprising at least one cellulose ether.
  • In certain embodiments, the cellulose ethers are chosen from methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, or microcrystalline cellulose.
  • In certain embodiments, the cellulose ether layer comprises ethylcellulose and hydroxypropylcellulose.
  • In certain embodiments, the dosage form comprises micropellets having coated onto a seed a first layer comprising said MGBG and a second layer comprising ethylcellulose and hydroxypropylcellulose.
  • In certain embodiments, the second layer makes up from about 2% to about 10% by weight of the micropellet.
  • In certain embodiments, the second layer comprises 70-90% by weight of ethylcellulose and about 10-30% by weight of hydroxypropylcellulose.
  • In certain embodiments, the cellulose ether layer comprises 80-90% by weight of ethylcellulose and about 10-20% by weight of hydroxypropylcellulose.
  • In certain embodiments, the cellulose ether layer comprises about 3 parts of ethylcellulose to about 1 part of hydroxypropylcellulose.
  • In certain embodiments, the layer comprising MGBG additionally comprises a polyvinylpyrrolidone.
  • In certain embodiments, said polyvinylpyrrolidone has a molecular weight of about 30,000 to about 50,000.
  • In certain embodiments, said polyvinylpyrrolidone has a molecular weight of about 40,000.
  • In other embodiments, the dosage form comprises spheroids comprising MGBG and cellulose ether.
  • In certain embodiments, the micropellets have diameters in the range of about 0.5 to about 0.7 mm.
  • Also provided herein is a controlled-release oral pharmaceutical dosage form comprising MGBG together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject, which does not have substantially dose-limiting side effects. In certain embodiments, said side effects are gastrointestinal. In further embodiments, said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, and gastrointestinal ulceration. In further embodiments, said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells. In certain embodiments, said side effects are chosen from thrombocytopenia, leukopenia, phlebitis, laryngitis, cellulitis, dermatitis, and hypoglycemia.
  • Also provided herein is a low-dose oral pharmaceutical composition for chronic delivery, comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side effects. In certain embodiments, the low-dose oral pharmaceutical composition for chronic delivery, comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side effects, yields a therapeutically effective plasma level of MGBG for at least a 24-hour period in the subject with once-daily dosing.
  • In certain embodiments, the pharmaceutical composition is formulated as a tablet or capsule. For example, in certain embodiments, the pharmaceutical composition comprises:
      • 0.1-50% of a polyamine analog or a polyamine biosynthesis inhibitor;
      • 0.1-99.9% of a filler;
      • 0-10% of a disintegrant;
      • 0-5% of a lubricant; and
      • 0-5% of a glidant.
  • In certain embodiments, the pharmaceutical composition comprises:
      • 0.1-50% of MGBG;
      • 0.1-99.9% of a filler;
      • 0-10% of a disintegrant;
      • 0-5% of a lubricant; and
      • 0-5% of a glidant.
  • In further embodiments,
      • said filler is chosen from a sugar, a starch, a cellulose, and a poloxamer;
      • said disintegrant is chosen from povidone and crospovidone;
      • said lubricant is magnesium stearate; and
      • said glidant is silicon dioxide.
  • In further embodiments,
      • said filler is chosen from lactose and microcrystalline cellulose;
      • said disintegrant is chosen from povidone and crospovidone;
      • said lubricant is magnesium stearate; and
      • said glidant is silicon dioxide.
  • In certain embodiments, the pharmaceutical composition comprises:
      • 10-300 mg of a polyamine analog or a polyamine biosynthesis inhibitor, making up 2-50% of the tablet content or capsule fill content;
      • 0-10% of a disintegrant;
      • 0-5% of a lubricant;
      • 0-5% of a glidant; and
      • 30-98% of a filler.
  • In certain embodiments, the pharmaceutical composition comprises:
      • 10-300 mg of MGBG, making up 2-50% of the tablet content or capsule fill content;
      • 0-10% of a disintegrant;
      • 0-5% of a lubricant;
      • 0-5% of a glidant; and
      • 30-98% of a filler.
  • In further embodiments, the pharmaceutical composition comprises
      • 0.1-10% of a binder;
      • 0-5% of a surfactant;
      • 0-10% of an intergranular disintegrant; and
      • 0-10% of an extragranular disintegrant.
  • In further embodiments, the pharmaceutical composition may additionally comprise
      • 0-10% of a binder;
      • 0-5% of a surfactant;
      • 0-10% of an intergranular disintegrant; and
      • 0-10% of an extragranular disintegrant.
  • In further embodiments,
      • said binder is chosen from copolyvidone, hydroxypropyl-cellulose, hydroxypropylmethylcellulose, and povidone;
      • said surfactant is chosen from polyoxyethylene (20) sorbitan monooleate, a poloxamer, and sodium lauryl sulfate;
      • said intergranular disintegrant is chosen from croscarmellose sodium, sodium starch glyconate, and crospovidone; and
      • said extragranular disintegrant is chosen from croscarmellose sodium, sodium starch glyconate, and crospovidone.
  • Also provided herein is a method of treating, or delaying the onset or development of, a condition in a subject in need thereof comprising administering a controlled-release oral pharmaceutical dosage form comprising MGBG. In certain embodiments, the MGBG is delivered in a therapeutically effective amount.
  • Also provided herein is a method of treatment of a condition in a subject in need thereof comprising administering
      • an oral pharmaceutical composition comprising MGBG and at least one pharmaceutically acceptable excipient; and
      • another therapeutic agent.
  • In certain embodiments, the MGBG is delivered in a therapeutically effective amount. In other embodiments, the MGBG is delivered in a subtherapeutic amount. In certain embodiments, the other therapeutic agent is delivered in a therapeutically effective amount. In other embodiments, the other therapeutic agent is delivered in a subtherapeutic amount. In certain embodiments, the MGBG and the other therapeutic agent are delivered together in amounts which would individually be subtherapeutic but which together are therapeutically effective. In other embodiments, the MGBG and the other therapeutic agent are delivered together in amounts which are individually therapeutically effective.
  • Also provided herein is a method of treating a condition comprising the administration, to a patient in need thereof, a delayed-release oral pharmaceutical dosage form comprising MGBG.
  • In certain embodiments, the condition is pain. In certain embodiments, the pain is inflammatory pain.
  • In certain embodiments, said delayed-release oral pharmaceutical dosage form is an enterically-coated capsule comprising MGBG.
  • In certain embodiments, administering the enterically-coated capsule comprising MGBG results in a reduction of gastrointestinal side effects when compared to a reference standard that is not enterically coated.
  • In certain embodiments, said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.
  • In certain embodiments, said gastrointestinal side effect is emesis.
  • In certain embodiments, MGBG is administered at a dosage level, which would result in dose-limiting side effects if administered as a non-enteric coated dosage form.
  • Controlled-release oral pharmaceutical dosage forms disclosed herein are useful for targeting absorption of MGBG to a particular portion of the gastrointestinal tract, or for modulating the temporal delivery of MGBG, or both. These objectives may be achieved, for example, by formulating MGBG in an oral dosage form having a modified-release film coating, by formulating MGBG in a swelling system, by formulating MGBG in a matrix, by formulating MGBG in a controlled dissolutions system using coated particles, granules, micropellets, or spheroids of a pharmaceutical composition of MGBG or by microencapsulation, or by formulating MGBG in an osmotically active delivery system.
  • For targeting absorption of MGBG to a particular portion of the gastrointestinal tract, film coatings and swelling systems are particularly useful. Swelling systems represent a means to target the absorption of the drug in the stomach. Such a dosage form would comprise MGBG in a matrix of material that would expand upon contact with the aqueous environment of the stomach, preventing passage into the duodenum. Hydrogels are one example of such material. Typically a hydrogel comprises, for example, polyvinyl alcohol, sodium polyacrylate, acrylate polymers, and/or copolymers with an abundance of hydrophilic groups.
  • When targeting the small intestine is desired, a film coating is useful. One type of film coating is an enteric coating, which is designed to remain intact in the stomach but dissolves and releases the drug in the small intestine. Release in the small intestine may be desirable if, for example, the drug is inactivated or rendered less useful by reaction with gastric fluids, or if the drug causes gastric irritation or related side effects such as nausea and/or emesis.
  • Most enteric coatings achieve delayed-release by virtue of being resistant to dissolution at low pH, such as that found in the stomach, but which dissociate more readily in the higher pH environment of the small intestine. Most effective enteric coatings are, therefore, weak acids with pKas of about 3 to about 5. Additionally, coatings which are responsive to intestinal enzymatic breakdown may be used.
  • Enteric coatings, which are pH-labile, are typically formed of polymers, optionally in combination with plasticizing agents and other excipients. Shellac and gelatin may be used, but polymerization must be carefully controlled, or the contents of the dosage form will not be released. Suitable polymers include cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose phthalate (HPMCP), acrylic copolymers such as methacrylic acid/methacrylic acid ester copolymers, ethyl acrylate/methyl methacrylate/methacrylic acid copolymer, and methacrylic acid/ethyl acrylate copolymer, cellulose acetate trimellitate (CAT), carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic copolymers. Prepared copolymers are commercially available in many forms, such as aqueous suspensions, organic solutions, and powders, for the release of drug to various parts of the small intestine, such as the duodenum, jejunum, or ileum. For example, the Eudragit® series of coatings is available from Evonik Inds., and the Surelease® series from Colorcon.
  • Alternatively, or in addition to an enteric coating, a sustained-release coating may be employed. Such a coating would be useful where the rapid release of the drug causes undesirable side effects. Suitable materials for creating a sustained-release coating include, in addition to the polymers above: mixtures of waxes with glyceryl monostearate, stearic acid, palmitic acid, glyceryl monopalmitate, and/or cetyl alcohol; ethylcellulose; acrylic resins; cellulose acetates; and silicone elastomers.
  • Methods for coating dosage forms with enteric, sustained-release, or enteric/sustained-release coatings include spray-drying (pan coating), air suspension column coating, and electrostatic powder coating followed by heat fixation. The pan coating method is useful for depositing a substantial coating onto the tablet; in certain embodiments, 3%-4% of the tablet weight is deposited as coating, but it can be significantly higher, up to about 15%. Where a thinner coating is desired, the air suspension coating technique is useful. The initial seal coat can be applied on an Aeromatic Strea™ fluid bed apparatus fitted with a Wurster column and bottom spray nozzle system. The electrostatic method may be useful where it is desirable to avoid the use of solvents, where dosage forms are to be partially coated, or where precision in deposition or even greater thinness of the coating is desired.
  • In certain embodiments, the MGBG oral dosing units of the invention comprise at a minimum a core containing MGBG and one or more pharmaceutically acceptable excipients. In certain embodiments, the core may contain about 10 wt % to about 90 wt % MGBG. The core containing the MGBG may be in a sustained-release formulation, or other suitable cores, as are described in greater detail below, may be selected. In certain embodiments, a delay release coat and/or an enteric coat are provided over the core.
  • The delay release coat and/or an enteric coat (rate-controlling film) can be applied to the MGBG core directly, or there may be intermediate coating layers located between the MGBG core and any overcoats. Optionally, a further seal or topcoat may be located outside the enteric coat.
  • In certain embodiments, the MGBG core is provided with further layers that provide a sustained-release formulation that contains rate-controlling components. Typically, such rate-controlling components are rate controlling polymers selected from among hydrophilic polymers and inert plasticized polymers. Suitable rate-controlling hydrophilic polymers include, without limitation, polyvinyl alcohol (PVA), hypromellose, and mixtures thereof. Examples of suitable insoluble or inert “plastic” polymers include, without limitation, one or more polymethacrylates (i.e., Eudragit® polymer). Other suitable rate-controlling polymer materials include, e.g., hydroxyalkyl celluloses, poly(ethylene) oxides, alkyl celluloses, carboxymethyl celluloses, hydrophilic cellulose derivatives, and polyethylene glycol.
  • Thus, in certain embodiments, the formulation of the invention contains one or more coatings over the MGBG core. In still other embodiments, the core can contain a non-functional seal coating (i.e., a coat which does not affect release rate) and a functional second coating. The enteric coat can be applied directly to the uncoated core or may be applied over an initial seal coat.
  • In certain embodiments, an initial seal coat can be applied directly to the core. Although the components of this seal coat can be modified by one of skill in the art, the seal coat may be selected from among suitable polymers such as hydroxypropyl methylcellulose (HPMC), ethylcellulose, polyvinyl alcohol, and combinations thereof, optionally containing plasticizers and other desirable components. A particularly suitable seal coat contains HPMC. For example, a seal coat can be applied as an HPMC solution at a concentration of about 3% w/w to 25% w/w. In certain embodiments, the seal coat can be applied as an HPMC solution at a concentration of about 5% w/w to about 7.5% w/w. In certain embodiments, the initial seal coat is in the range of about 1% w/w to about 3% w/w, or about 2% w/w, of the uncoated core. In another embodiment, a commercially available seal coat containing HPMC, among other inert components, is used. One such commercially available seal coat is Opadry® Clear (Colorcon, Inc.).
  • In certain embodiments, the enteric coat contains a product which is a copolymer of methacrylic acid and methacrylates, such as the commercially available Eudragit® L 30 K55 (Röhm GmbH & Co. KG). This enteric coat may be applied such that it coats the core in an amount of about 10 wt % to 20 wt %, or about 12 wt % to about 17 wt %, or about 15.5 wt % to 16.5 wt % of the uncoated or initially-coated core. In certain embodiments, the enteric coat is composed of a Eudragit® L30D-55 copolymer (Röhm GmbH & Co. KG), talc, triethyl citrate, and water. In certain embodiments, the enteric coating may contain about 7 wt % to about 9 wt % of a 30 wt % dispersion of Eudragit® L 30 D55 coating; about 4 wt % to about 5 wt %/w talc, about 0.7 wt % to about 1 wt % triethyl citrate; a pH adjuster such as sodium hydroxide and water.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a capsule comprising micropellets of MGBG optionally with one or more excipients, said micropellets being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a capsule comprising spheroids of MGBG and one or more excipients, said spheroids being coated with an enteric coating, and optionally with a seal coating beneath the enteric coating.
  • In certain embodiments, the delayed-release oral pharmaceutical dosage form is a tablet having an enteric coating. In further embodiments, the delayed-release tablet comprises an enteric coating applied directly to the tablet. In other embodiments, a delayed-release tablet comprises a seal coating applied directly to the tablet and an enteric coating.
  • In certain embodiments, the enteric coating comprises from about 1% to about 30% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises from 1% to 25%, or from 1% to 20%, or from 1% to 15% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises from 1% to 10%, or from 1% to 5% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 1%, about 2%, about 3%, about 4%, and about 5%. In further embodiments, the enteric coating comprises from 5% to 10% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 6%, about 7%, about 8%, about 9%, and about 10%. In further embodiments, the enteric coating comprises from 10% to 15% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 11%, about 12%, about 13%, about 14%, and about 15%. In further embodiments, the enteric coating comprises from 15% to 20% of the total weight of the delayed-release oral pharmaceutical dosage form. In further embodiments, the enteric coating comprises a percentage of the total weight of the delayed-release oral pharmaceutical dosage form chosen from about 16%, about 17%, about 18%, about 19%, and about 20%. In further embodiments, the enteric coating comprises from 20% to 30% of the total weight of the delayed-release oral pharmaceutical dosage form. In these embodiments, the enteric coating is substantially uniform in thickness.
  • In certain embodiments, the controlled-release oral pharmaceutical dosage form may be achieved through formulation in a matrix. The matrix may be a controlled release matrix, although normal release matrices having a coating that controls the release of the drug may be used. Suitable materials for inclusion in a controlled release matrix are
      • a) Hydrophilic polymers, such as gums, cellulose ethers, acrylic resins, and protein-derived materials. In certain embodiments, the polymers are cellulose ethers. In further embodiments, the cellulose ethers are hydroxyalkylcelluloses (e.g., methylcellulose, hydroxypropyl methylcellulose) and carboxyalkylcelluloses (e.g., carboxymethylcellulose, carbopol 934). The oral dosage form may contain between 1% and 80% (by weight) of at least one hydrophilic or hydrophobic polymer.
      • b) Insoluble plastics, including methyl-acrylate, methyl-methacrylate, polyvinyl chloride, and polyethylene.
      • c) Digestible, long-chain (C8-C50, especially C12-C40), substituted or unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty acids, mineral and vegetable oils, and waxes. In certain embodiments, the hydrocarbons have a melting point of between 25° and 90° C. In further embodiments, the long-chain hydrocarbon materials are fatty (aliphatic) alcohols. The oral dosage form may contain up to 60% (by weight) of at least one digestible, long-chain hydrocarbon.
      • d) Polyalkylene glycols. The oral dosage form may contain up to 60% (by weight) of at least one polyalkylene glycol.
  • A common method of preparation is to mix drug and matrix material and then compress into a tablet. When a priming dose is desirable, the tablet may then be coated with a drug-containing layer substantially free of the matrix material. An additional enteric coating may be added if a delay of release is desired.
  • In certain embodiments, the matrix comprises at least one water-soluble hydroxyalkyl cellulose, at least one C12-C36 aliphatic alcohol, and, optionally, at least one polyalkylene glycol. In further embodiments, the aliphatic alcohol is a C14-C22 aliphatic alcohol.
  • The hydroxyalkyl cellulose may be, for example, a hydroxy (C1 to C6) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose, or hydroxyethyl cellulose. The amount of the hydroxyalkyl cellulose in the present oral dosage form will be determined, inter alia, by the precise rate of drug release required. In certain embodiments, the oral dosage form contains between 5% and 25% (by wt) of the hydroxyalkyl cellulose. In further embodiments, the oral dosage form contains between 6.25% and 15% of the hydroxyalkyl cellulose.
  • The aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol, or stearyl alcohol. In certain embodiments, the aliphatic alcohol is cetyl alcohol or cetostearyl alcohol. The amount of the aliphatic alcohol in the present oral dosage form will be determined, as above, by the precise rate of drug release required. It will also depend on whether polyalkylene glycol is present in or absent from the oral dosage form. In certain embodiments, in the absence of polyalkylene glycol, the oral dosage form may contain between 20% and 50% (by wt) of the aliphatic alcohol. In other embodiments, where polyalkylene glycol is present in the oral dosage form, then the combined weight of the aliphatic alcohol and the polyalkylene glycol may constitute between 20% and 50% (by wt) of the total dosage.
  • In certain embodiments, the controlled release composition comprises from about 5 to about 25% acrylic resin and from about 8 to about 40% by weight aliphatic alcohol by weight of the total dosage form. Many acrylic resins are commercially available. Examples include the entire family of Eudragit® family of formulation copolymers-Eudragit® RS PM is one example, Eudragit® RL 30 D is another.
  • In general, the ratio of, e.g., hydroxyalkyl cellulose or acrylic resin to aliphatic alcohol/polyalkylene glycol determines, to a considerable extent, the release rate of the drug from the formulation. In certain embodiments, the ratio of hydroxyalkyl cellulose to aliphatic alcohol/polyalkylene glycol is between 1:2 and 1:4. In further embodiments, the ratio is between 1:3 and 1:4.
  • The polyalkylene glycol may be, for example, polypropylene glycol. In certain embodiments, the polyalkylene glycol is polyethylene glycol. In certain embodiments, the average molecular weight of the polyalkylene glycol is between 1,000 and 15,000. In certain embodiments, the average molecular weight of the polyalkylene glycol is between 1500 and 12000.
  • Another suitable controlled-release matrix would comprise an alkylcellulose (especially ethylcellulose), a C12 to C36 aliphatic alcohol, and, optionally, a polyalkylene glycol.
  • In addition to the above ingredients, a controlled release matrix may also contain suitable quantities of other materials, e.g., diluents, lubricants, binders, granulating aids, colorants, flavorants, and glidants conventional in the pharmaceutical art.
  • As an alternative to a controlled release matrix, the present matrix may be a normal release matrix having a coat that controls the release of the drug. In certain embodiments, the dosage form comprises film-coated spheroids containing the active ingredient and a non-water-soluble spheronizing agent. The term spheroid is known in the pharmaceutical art and usually refers to a spherical granule having a diameter of between 0.1 mm and 2.5 mm, especially between 0.5 mm and 2 mm.
  • The spheronizing agent may be any pharmaceutically acceptable material that, together with the active ingredient, can be spheronized to form spheroids. Microcrystalline cellulose is an example of a spheronizing agent. Suitable microcrystalline cellulose is, for example, the material sold as Avicel PH 101 (Trademark, FMC Corporation). In certain embodiments, the film-coated spheroids contain between 10% and 95% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 20% and 80% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 20% and 50% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 10% and 40% (by wt) of the spheronizing agent. In further embodiments, the film-coated spheroids contain between 20% and 40% (by wt) of the spheronizing agent. In further embodiments, the spheronizing agent is microcrystalline cellulose.
  • In addition to the active ingredient and spheronizing agent, the spheroids may also contain a binder. Suitable binders, such as low viscosity, water-soluble polymers, will be well known to those skilled in the pharmaceutical art. Microcrystalline cellulose is an effective diluent and binder. In certain embodiments, the binder is a water-soluble hydroxy lower alkyl cellulose, such as hydroxypropyl cellulose. Additionally (or alternatively), the spheroids may contain a water-insoluble polymer, such as an acrylic polymer, an acrylic copolymer, such as a methacrylic acid-ethyl acrylate copolymer, or ethyl cellulose.
  • In certain embodiments, the spheroids are film-coated with a material that permits the release of the drug at a controlled rate in an aqueous medium.
  • The film coat will generally include a water-insoluble material such as
      • a wax, either alone or in admixture with a fatty alcohol,
      • shellac or zein,
      • a water-insoluble cellulose, or
      • a polymethacrylate.
  • In certain embodiments, the water-insoluble cellulose is ethyl cellulose.
  • In certain embodiments, the polymethacrylate is Eudragit®.
  • In further embodiments, the film coat comprises a mixture of the water-insoluble material and a water-soluble material. The ratio of water-insoluble to water-soluble material is determined by, amongst other factors, the release rate required and the solubility characteristics of the materials selected.
  • The water-soluble material may be, for example, polyvinylpyrrolidone or a water-soluble cellulose. In certain embodiments, the water-soluble cellulose is hydroxypropylmethylcellulose.
  • Suitable combinations of water-insoluble and water-soluble materials for the film coat include shellac and polyvinylpyrrolidone, or ethylcellulose, and hydroxypropylmethylcellulose. In certain embodiments, combining water-insoluble and water-soluble materials for the film coat is ethyl cellulose and hydroxypropylmethylcellulose.
  • Additionally, a process for the preparation of a solid, controlled release, oral dosage form according to the present invention comprising incorporating MGBG in a controlled release matrix is provided. Incorporation in the matrix may be effected, for example, by forming granules comprising at least one water-soluble hydroxyalkyl cellulose and MGBG, mixing the hydroxyalkyl cellulose-containing granules with at least one C12-C36 aliphatic alcohol, and optionally, compressing and shaping the granules. In certain embodiments, the granules are formed by wet granulating the hydroxyalkyl cellulose/MGBG with water. In further embodiments of this process, the amount of water added during the wet granulation step is between 1.5 and 5 times the dry weight of the MGBG. In further embodiments, the amount is between 1.75 and 3.5 times the dry weight of the MGBG.
  • The present solid, controlled release, oral dosage form may also be prepared, in the form of film-coated spheroids, by blending a mixture comprising MGBG and a non-water-soluble spheronizing agent, extruding the blended mixture to give an extrudate, spheronizing the extrudate until spheroids are formed, and coating the spheroids with a film coat.
  • In certain embodiments, the controlled-release oral pharmaceutical dosage form may be achieved through formulation in micropellets, which may then be either compressed into a tablet or put into a capsule.
  • In certain embodiments, the MGBG may be coated onto a seed, such as a sugar seed crystal of a predetermined size, by first combining it with polyvinylpyrrolidone, having a molecular weight of from about 30,000 to about 50,000 with a molecular weight of about 40,000 being preferred. The sugar seeds, which may be coated with a combination of MGBG and polyvinylpyrrolidone, are then, in turn, coated with an outer coating comprising two polymers. The sugar seeds coated with MGBG may then be coated with from 5% to 10% by weight of the sustained-release coating, which is comprising a combination of ethylcellulose and hydroxypropylcellulose. In certain embodiments, the sustained-release coating is comprising 70% to 90% by weight of ethylcellulose and 10% to 30% hydroxypropylcellulose based on the weight of the coating. In certain embodiments, the outer coating is comprising 75% ethylcellulose and 25% hydroxypropylcellulose. In further embodiments, the average diameter of each of the micropellets formed is 0.5 to 0.7 mm, particularly preferably about 0.6 mm.
  • These micropellets may be comprised, for example, of 5% to 10% by weight of a coating of two different polymers. In certain embodiments, one polymer is ethylcellulose present in the coating in an amount of 90% to 70% by weight, based on the weight of the coating; the other polymer is hydroxypropylcellulose, which is present in an amount of 10% to 30% by weight, based on the weight of the coating. When a coating is comprised in this manner and placed on a micropellet as described in detail below, the oral formulation of the invention will provide zero-order release of MGBG.
  • The inclusion of hydroxypropylcellulose within the coating, along with the ethylcellulose, provides the desired sustained-release of the active ingredient MGBG. If the micropellets of the present invention were coated with a coating comprised completely of ethylcellulose (which is an ethyl ether of cellulose) containing 2.25-2.28 ethoxyl groups per anhydroglucose unit, the drug within the coating would be released very slowly or be released not at all for a long period of time. Hydroxypropylcellulose, wherein the primary hydroxyls present in cellulose have been substituted (etherified) by hydroxypropyl, is more water-soluble than ethylcellulose. Accordingly, the presence of such hydroxypropylcellulose in the coating provides “channels” in the coating through which water can enter, and over time, leach out the MGBG contained within the non-pareil sugar seed. The presence of too many “channels” will make the MGBG more quickly available than is therapeutically appropriate. Within the stated range, an optimal release rate is obtained when the outer coating contains three parts of ethylcellulose (75% by weight) to one part of hydroxypropyl cellulose (25% by weight)
  • Compounds for use in the dosage forms disclosed herein include MGBG, as well as other polyamine analogs and polyamine biosynthesis inhibitors, and their salts, prodrugs, solvates, anhydrous forms, protected derivatives, structural isomers, stereoisomers, amino acid conjugates, and porphyrin conjugates thereof. Any polyamine analog is suitable for use in the dosage forms of the present invention.
  • MGBG is 1,1′[methylethanediylidene]dinitrilodiguanidine and is also known as methylglyoxal bis(guanylhydrazone), methyl-GAG, Me-G, and mitoguazone. As used herein, MGBG includes the free base and salts thereof. It is commonly, but not necessarily, used as a dihydrochloride. MGBG may be present as any one of the following isomers, or a tautomer and/or a syn/anti isomer thereof, mixture of one or more thereof:
  • Figure US20210085625A1-20210325-C00001
    Figure US20210085625A1-20210325-C00002
  • In certain embodiments, MGBG may be present in one of the following isomers, or a tautomer and/or a syn/anti isomer thereof, mixture of one or more thereof:
  • Figure US20210085625A1-20210325-C00003
  • Other polyamine analogs used in the methods of the invention include compounds of the structural formulas 1, 2, 3, 4, 5, 6, and 7 and the corresponding stereoisomers, salts, and protected derivatives thereof.
  • Formula 1 has the Structure
  • Figure US20210085625A1-20210325-C00004
  • wherein
      • R1, R2, R4, R6, and R7 are independently chosen from hydrogen, alkyl, and aryl; and
      • R3 and R5 are alkyl groups.
  • Formula 2 has the Structure
  • Figure US20210085625A1-20210325-C00005
  • wherein
      • R1, R2, R4, R6, R8, and R9 are independently chosen from hydrogen, alkyl, and aryl; and
      • R3, R5, and R7 are alkyl groups.
  • Formula 3 has the Structure
  • Figure US20210085625A1-20210325-C00006
  • wherein
      • R1, R2, R4, R6, R10, and R11 are independently chosen from hydrogen, alkyl and aryl; and
      • R3, R5, R7, and R9 are alkyl groups.
  • Formula 4 has the Structure
  • Figure US20210085625A1-20210325-C00007
  • wherein
      • R1 and R5 are independently chosen from methyl, ethyl, n-propyl, and isopropyl;
      • R2, R3, and R4 are independently chosen from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkyl-C3-C6 cycloalkyl-C1-C6 alkyl, C3-C10 aryl, and C1-C6 alkyl-C3-C10 aryl-C1-C6 alkyl; and
      • R6, R7, R8, and R9 are independently chosen from hydrogen, methyl, and ethyl;
  • Formula 5 has the Structure
  • Figure US20210085625A1-20210325-C00008
  • wherein
      • R1 and R6 are independently chosen from methyl, ethyl, n-propyl, and isopropyl;
      • R2, R3, R4, and R5 are independently chosen from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkyl-C3-C6 cycloalkyl-C1-C6 alkyl, C3-C10 aryl, and C3-C10 aryl-C1-C6 alkyl; and
      • R7, R8, R9, R10, and R11 are independently chosen from hydrogen, methyl, and ethyl.
  • In another embodiment, the polyamine analogs are compounds of structural formulas 2 and 3, wherein
      • R3, R5, R7, and R9 are independently (CH2)x groups;
      • x is an integer from 2 to 6; and
      • R4, R6, and R8 are hydrogen atoms.
  • In yet another embodiment, the polyamine analogs are compounds of structural formulas 2 and 3, wherein
      • R3, R5, R7, and R9 are independently (CH2)x groups;
      • x is an integer from 2 to 6;
      • R4, R6, and R8 are hydrogen atoms;
      • R1 and R10 are alkyl groups; and
      • R2 and R11 are hydrogen atoms.
  • In yet another embodiment, the polyamine analogs are compounds of structural formulas 2 and 3, wherein
      • R3, R5, R7, and R9 are independently (CH2)x groups;
      • x is an integer from 2 to 6;
      • R4, R6, and R8 are hydrogen atoms;
      • R1 and R10 are alkyl groups;
      • R2 and R11 are hydrogen atoms; and
      • the polyamine analogs have a molecular weight of less than 500.
  • Further embodiments of compounds of structural formula 4 include those wherein R6, R7, R8, and R9 are hydrogen.
  • In other embodiments, R1 and R5 are ethyl.
  • In yet further embodiments,
      • R6, R7, R8, and R9 are hydrogen; and
      • R1 and R5 are ethyl.
  • In yet further embodiments,
      • R2 and R4 are independently chosen from C1-C6 alkyl; and
      • R3 is chosen from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkyl-C3-C6 cycloalkyl-C1-C6 alkyl, C3-C10 aryl, and C1-C6 alkyl-C3-C1 aryl-C1-C6 alkyl.
  • Additional polyamine analogs useful in the present invention include compounds of the formula 6, and the corresponding stereoisomers, salts, and protected derivatives thereof:
  • Figure US20210085625A1-20210325-C00009
  • wherein
      • R4 is chosen from C2-C6 n-alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, and C3-C6 aryl;
      • R3 and R5 are independently chosen from a single bond, C1-C6 alkyl, and C1-C6 alkenyl;
      • R2 and R6 are independently chosen from C1-C6 alkyl, C1-C6 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, and C3-C6 aryl;
      • R1 and R7 are independently chosen from hydrogen, C1-C6 alkyl, and C2-C6 alkenyl; and
      • R8, R9, R10, and R11 are hydrogen.
  • In certain embodiments of the compounds of formula 6, R1 and R7 are independently chosen from C1-C6 alkyl and C2-C6 alkenyl.
  • Additional polyamine analogs useful in the present invention include compounds of structural formula 7, and the corresponding stereoisomers, salts, and protected derivatives thereof:
  • Figure US20210085625A1-20210325-C00010
  • wherein
      • R4 is chosen from C1-C6 n-alkyl and C1-C6 branched alkyl;
      • R3 and R5 are independently chosen from a single bond or C1-C6 alkyl;
      • R2 and R6 are independently chosen from C1-C6 alkyl, C1-C6 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, or C3-C6 aryl;
      • R1 and R7 are independently chosen from H, C1-C6 alkyl, or C2-C6 alkenyl; and
      • R8, R9, R10, and R11 are hydrogen.
  • In certain embodiments of the compounds of formula 7
      • R2 and R7 are independently chosen from C1-C6 alkyl or C2-C6 alkenyl;
      • R4 is chosen from C1-C6 saturated n-alkyl and C1-C6 saturated branched alkyl; and
      • R3 and R5 are independently chosen from a single bond and C1-C6 saturated n-alkyl.
  • According to another embodiment of the present invention, the agent is a chemical moiety that inhibits polyamine biosynthesis by inhibiting the activity of S-adenosyl methionine decarboxylase, inhibits polyamine biosynthesis by inhibiting an enzyme distinct from S-adenosyl methionine decarboxylase, or antagonizes the end-products (i.e., polyamines, including putrescine, spermidine, and spermine) of polyamine biosynthesis.
  • Examples of such moieties include, but are not limited to, those listed in Table 1. Irrespective of the form of the moiety listed in Table 1, it is understood that it includes, as applicable, a salt, protected derivative, and stereoisomer thereof.
  • TABLE 1
    Pub
    Chem
    Compound Official Name (Not IUPAC) ID
    Decarboxylated s-adenosyl-3-methylthiopropylamine 5351154
    SAM
    Mitoguazone or Methylglyoxal bis(guanylhydrazone) 9561662
    “MGBG”
    EGBG Ethylglyoxal bis(guanylhydrazone) 2354
    Berenil Diminazene or Diminazene aceturate 4735
    Pentamidine 4-[5-(4-carbamimidoylphenoxy)pentoxy]
    benzenecarboximidamide
    5′-(Dimethylsulfino)-5′-deoxyadenosine
    S-adneosy1-4-methylthiobutyrate
    S-adenosyl-S-methyl-L-cysteine
    AMA S-(5′-Deoxy-5′-adenosyl)
    methylthioethylhydroxylamine
    EMGBG Ethylmethylglyoxal bis(guanylhydrazone)
    DEGBG Diethylglyoxal bis(guanylhydrazone) 9574151
    CGP-33′829 6-((2-carbamimidoylhydrazono)methyl) 5479208
    picolinimidamide
    CGP-36′958
    CGP-39′937 2,2′-bipyridine-6,6′-bis(carboximidamide)
    CGP-48664 or 4-amidinoindan-1-one 5486811
    CGP48664Aor 2′-amidinohydrazone
    SAM 364A
    AbeAdo 5′-[[(Z)-4-amino-2-butenyl]methyl- 6436013
    orMDL-73811 amino]-5′-deoxyadenosine
    MAOEA 5′-deoxy-5′-[N-methyl-N-[2- 3081018
    (aminooxy)ethyl]amino]adenosine
    MHZPA 5′-deoxy-5′-[N-methyl-N-(3- 122092
    hydrazinopropyl)amino]adenosine
    MHZEA 5′-deoxy-5′-[(2-hydrazinoethyl)-
    methylamino]adenosine
    AdoMac S-(5′-deoxy-5′-adenosyl)-1-ammonio-4- 3083364
    (methylsulfonio)-2cyclopentene
    AdoMao S-(5′-deoxy-5′-adenosyl)-1-aminoxy-4-
    (methylsulfonio)-2-cyclopentene
    APA 1-Aminooxy-3-aminopropane 65020
    AOE-PU N-[2-aminooxyethyl]-1,4-diaminobutane
    AP-APA 1-aminooxy-3-N-[3-aminopropyl]-
    aminopropane
    1,11-bis(ethyl)norspermine
    BES 1,8-bis(ethyl)spermidine
    BES 1,12-bis(ethyl)spermine
    DESPM N1,N12-diethylspermine
    BE-3-3-3 1,11-bis(ethylamino)-4,8-diazaundecan
    BE-4-4-4 1,14-bis(ethylamino)-5,10-diazatetradecane
    DEHOP or Diethylhomospermine, N1,N14-
    DEHSPM diethylhomospermine
    DENOP diethyl-norspermine
    BE-4-4-4-4 1,19-bis(ethylamino)-5,10,15-triaza-
    nonadecane
    SL11037 N-ethyl-N′-(2-(3′-ethylamino-propylamino
    methyl)-cis-cyclopropylmethyl)-propane
    1,3-diamine tetrahydrochloride
    SL11038 N-ethyl-N′-(2-(3′-ethylamino-propylamino
    methyl)-trans-cyclobutylmethyl)-propane
    1,3-diamine tetrahydrochloride
    SL11044 N-ethyl-N′-(2-(3′-ethylamino-propylamino
    methyl)-transcyclopropylmethyl)-propane
    1,3-diamine tetrahydrochloride
    SL11047 or N,N′-bis(3-ethylaminopropyl)-cis-but-
    SL47 2-ene-1,4-diaminetetrahydrochloride
    SL11093 or N,N′-(cyclopropane-1,2-
    SL93 diylbis(methylene))bis(N4-ethylbutane-
    1,4-diamine)
  • In yet another embodiment, the agent is a compound chosen from MGBG, MDL73811, CGP48664, Berenil, Pentamidine, SL47, and SL93, or a combination of two or more thereof. In yet another embodiment, the agent is MGBG, SL47, or SL93. In still another embodiment, two or more agents are used in the methods of the invention to regulate the activity of osteopontin. The two or more agents can be used either sequentially or simultaneously.
  • As used herein, the terms below have the meanings indicated.
  • When ranges of values are disclosed, and the notation “from n1 . . . to n2” or “between n1 . . . and n2” is used, where n1 and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 μM (micromolar),” which is intended to include 1 μM, 3 μM, and everything in between to any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).
  • The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures.
  • The term “substantially” as used herein is intended to mean predominantly or having the overriding characteristic of, such that any opposing or detracting characteristics reach a level of insignificance. By way of example, a composition “substantially” free of water might not be absolutely free of all traces of water but would be sufficiently anhydrous that any remaining water would not influence the composition in any significant way. By way of further example, “substantially dose-limiting side effects” might be side effects that limited a dose to a level which was below for therapeutic efficacy.
  • The following standard abbreviations are used to represent the associated pharmacokinetic parameters.
      • AUC Area under the curve up to the last measurable concentration plus the AUC extrapolated from the last measurable concentration (Clast at tlast) to infinity: AUCINFobs=AUC0-tlast+Clast/Lambda z (where λz is the first-order rate constant for the terminal (log-linear) portion of the curve)
      • AUC0-12 Area under the curve between the time of dose and the 12 h time point
      • AUC0-24 Area under the curve between the time of dose and the 24 h time point
      • F Fraction available (bioavailability):

  • F=[AUC oral]·doseiv/[AUC iv]·doseoral
      • Clobs Observed clearance
      • Vssobs Steady-state volume of distribution
      • Vd Volume of distribution (often used with oral)
      • Cl/Fobs Apparent total body clearance as a function of bioavailability
      • t1/2 Terminal half-life (HLλz)
      • Cmax The maximum observed concentration
      • Tmax The time at which Cmax occurred
  • The term “disease” as used herein is intended to be generally synonymous and is used interchangeably with the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • A “proliferative disorder” may be any disorder characterized by dysregulated cellular proliferation. Examples include cancers, psoriasis, and atopic dermatitis.
  • As used herein, “hyperalgesia” means a heightened sensitivity to pain and can be considered a type of pain or a measure of pain-related behavior.
  • As used herein, reference to “treatment” of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. Prevention of disease may involve complete protection from disease, for example, as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.
  • The term “combination therapy” means administering two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • The term “patient” is generally synonymous with the term “subject” and means an animal differing from a disease, disorder, or condition treatable per the methods disclosed herein, including all mammals and humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
  • An “effective amount” or a “therapeutically effective amount” is a quantity of a compound (e.g., MGBG, a polyamine analog, a polyamine biosynthesis inhibitor, or an agent) that is sufficient to achieve a desired effect in a subject being treated. For instance, this can be the amount necessary to treat a disease, disorder, condition, or adverse state (such as pain or inflammation) or to otherwise measurably alter or alleviate the symptoms, markers, or mechanisms of the disease, disorder, condition, or adverse state. As just one example, an effective amount for treating pain is an amount sufficient to prevent, delay the onset of, or reduce pain or one or more pain-related symptoms in a subject, as measured by methods known in the art. Similar methods of assessing response to treatment of several diseases are well-known in the art. The effective amount of a compound of the present invention may vary depending upon the route of administration and dosage form. In addition, specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of agents.
  • The term “low dose,” in reference to a low dose formulation of a drug or a method of treatment specifically employing a “low dose” of a drug, means a dose which for at least one indication is subtherapeutic or is a fraction of the dose typically given for at least one indication. Take, for example, the case of a drug for treating proliferative disorders—a low dose formulation for treating, say, chronic psoriasis might be a fraction of the dose for treating aggressive cancer. In this way, the dose for one disease might be an amount that would be subtherapeutic for another disease. Alternatively, for a drug that is therapeutic in different individuals or populations at different doses and is available in a range of doses, a low dose may be simply a dose toward the low end of recognized therapeutic efficacy. Chronic diseases represent an embodiment treatable by low dose formulations and methods. Additionally, a subtherapeutic amount of a drug might be used in combination with one or more other drugs (themselves in either therapeutic or subtherapeutic amounts) to yield a combination formulation or treatment which is potentiated, that is, more efficacious than the expected effects of the sum of the drugs given alone. A low dose for treating one indication may be two-fold, three-fold, four-fold, five-fold, six-fold, seven-fold, eight-fold, nine-fold, ten-fold, fifteen-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, may be one hundred-fold less than the therapeutic dose for a different indication.
  • The term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of subjects without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio and are effective for their intended use.
  • The term “drug” is used herein interchangeably with “compound,” “agent,” and “active pharmaceutical ingredient” (“API”).
  • As used herein, a “polyamine” is any of a group of aliphatic, straight-chain amines derived biosynthetically from amino acids; polyamines are reviewed in Marton et al. (1995) Ann. Rev. Pharm. Toxicol. 35:55-91. “Polyamine” generally means a naturally-occurring polyamine or a polyamine which is naturally produced in eukaryotic cells. Examples of polyamines include putrescine, spermidine, spermine, and cadaverine.
  • As used herein, a “polyamine analog” is an organic cation structurally similar but non-identical to naturally-occurring polyamines such as spermine and/or spermidine and their precursor, diamine putrescine. Polyamine analogs can be branched or un-branched or incorporate cyclic moieties. Polyamines may comprise primary, secondary, tertiary, or quaternary amino groups. In certain embodiments, all the nitrogen atoms of the polyamine analogs are independently secondary, tertiary, or quaternary amino groups but are not so limited. Polyamine analogs may include imine, amidine, and guanidine groups in place of amine groups. The term “polyamine analog” includes stereoisomers, salts, and protected derivatives of polyamine analogs.
  • A “stereoisomer” is an optical isomer of a compound, including enantiomers and diastereomers. Unless otherwise indicated, structural formulae of compounds are intended to embrace all possible stereoisomers.
  • The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound or parent drug. They may, for instance, be bioavailable by oral administration, whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound that is administered as an ester (the “prodrug”) but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
  • The term “controlled release” in reference to a formulation or dosage form means that the release of active drug (e.g., MGBG) from the dosage form is controlled through the use of ingredients that retard, dissolution of the dosage form, or efflux of the drug from the dosage form. The term includes extended-release, sustained-release, delayed-release, and pulsed-release (cycled release).
  • The term “substantially dissolve,” as used herein in reference to a dosage form, means to dissolve to the degree that is clinically relevant. For example, when an enterically coated dosage form begins to substantially dissolve, it would begin to release the drug into the GI tract to the degree that would, within the time necessary for the drug to be absorbed from the GI lumen and distributed into the plasma, yield a clinically relevant plasma concentration. A clinically relevant plasma concentration might be, for example, a therapeutically effective plasma concentration. Alternatively, it might be near a therapeutically effective plasma concentration; for example, it might be between about 50% and 100% of a therapeutically effective plasma concentration, between about 80% and 100% of a therapeutically effective plasma concentration, between about 90% and 100% of a therapeutically effective plasma concentration, between about 95% and 100% of a therapeutically effective plasma concentration, or between about 99% and 100% of a therapeutically effective plasma concentration. Alternatively, a clinically relevant plasma concentration might be a plasma concentration at which adverse effects are seen, or near such a concentration, for example, between about 50% and 100%, between about 60% and 100%, between about 70% and 100%, between about 80% and 100%, between about 90% and 100%, or between about 95% and 100% of such a concentration. Alternatively, substantially dissolved might mean about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 800%, about 85%, about 90%, or about 95% dissolved. A dosage form is not “substantially dissolved” when it dissolves only to the extent that it releases a detectable, but otherwise irrelevant, amount of drug into the GI tract.
  • The compounds disclosed herein can exist as therapeutically acceptable salts. The present invention includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
  • The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein and the like.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • Provided herein are pharmaceutical formulations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation depends on the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art, e.g., in Remington's Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
  • The optimal dose, frequency of administration, and duration of treatment with the agent in a subject may vary from subject to subject, depending on the disease to be treated or clinical endpoint to be reached (for example, decrease in the level or activity of osteopontin, inhibition of infiltration of macrophages to a tissue, or mitigation of pain) the subject's condition, the subject's age, weight, response to the treatment, and the nature of the therapeutic entity. Determination of the optimal dose and duration of treatment is within the scope of one of skill in the art. The optimal dose and duration of treatment may be best determined by monitoring the subject's response during the course of the treatment. In some instances, administering higher doses may permit less frequent administration, and lower doses may require more frequent administration to achieve a clinically significant improvement in the subject's condition. The agent(s) of the invention may be administered as a single dose or in multiple doses.
  • Generally, a therapeutically effective dose of the agent per the present methods will be one or more doses of from about 10 to about 1100 mg/m2. Lower dose regimens include doses of 10-200, 10-100, 10-50 and 20-200 mg/m2. Higher dose regimens include 200-400, 250-500, 400-600, 500-800 600-1000 and 800-1100 mg/m2. In certain embodiments, the dose regimens range from 200-400 mg/m2. In another embodiment, the dose regimens range from 250-500 mg/m2. In yet another embodiment, the dose regimens range from 600-1000 mg/m2. In some embodiments, the agent is administered daily, once per week, once every other week, or once per month. In certain embodiments, a dosing regimen ranging from 200-400 mg/m2 is administered once a week. In another embodiment, a dosing regimen ranging from 250-500 mg/m2 is administered once every other week.
  • The doses may be constant over the entire treatment period, or they may increase or decrease during the course of the treatment. In certain embodiments, the agent is administered once a week and starts with administering 200 mg/m2, and increases to 300 mg/m2 and 400 mg/m2 in the second and third weeks, respectively. In another embodiment, the agent is administered once every other week and is kept constant for the entire duration of treatment, with administering 250 mg/m2. The doses of the agent may be administered for at least one week, at least two weeks, at least three weeks, at least four weeks, at least 6 weeks, or even at least 8 weeks. Adjusting the dose of the agent within these ranges for a particular subject is well within the skill of the ordinary clinician.
  • The agent may be administered via any conventional route normally used to administer a medicament including, but not limited to, oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal (including nasal), transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) routes. Intravenous delivery may take place via a bolus injection or via infusion; infusion may be done over a period ranging from less than a minute to several hours to continuously. In certain embodiments, a course of treatment will involve administration by a combination of routes.
  • For example, the agent may be administered via a combination of intravenous and oral routes for treating pain or another disorder. In one embodiment, a “loading” dose may be administered IV to bring the concentration of the drug to the desired therapeutic level, followed by one or more maintenance doses via the oral route to keep it there. In a further embodiment, a combination of oral and IV delivery may be used to mitigate pain in a surgery patient. The agent may be delivered pre-, peri-, and post-surgically by a combination of IV and oral routes. In one embodiment, the patient may be administered or may self-administer the drug orally before surgery, be administered the drug via IV infusion during surgery and just after, and may thereafter be administered or may self-administer the drug orally or intravenously (patient-controlled analgesia pumps) after surgery. In another embodiment, the patient may be administered the drug IV before surgery, be administered the drug via IV infusion during surgery and just after, and may thereafter be administered or may self-administer the drug orally after surgery.
  • The agent may be administered as a pharmaceutical composition in a variety of forms, including, but not limited to, liquid, powder, suspensions, tablets, pills, capsules, sprays, and aerosols. The pharmaceutical compositions may include various pharmaceutically acceptable additives including, but not limited to, carriers, excipients, binders, stabilizers, antimicrobial agents, antioxidants, diluents, and/or supports. Examples of suitable excipients and carriers are described, for example, in “Remington's Pharmaceutical Sciences,” Mack Pub. Co., New Jersey (1991). In some embodiments, the agent may be administered via an IV infusion in an aqueous sugar solution. The agent may also be for another substance that facilitates agent delivery. For example, the agent may be associated into liposomes. The liposomes, in turn, may be conjugated with targeting substance(s), such as IgGFc receptors.
  • Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary, or paste.
  • Oral pharmaceutical preparations include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active, or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Exemplary unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
  • Fillers to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of fillers, or diluents, include, without limitation, lactose, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugar, microcrystalline cellulose (MCC), powdered cellulose, cornstarch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers such as polyethylene oxide, and hydroxypropyl methylcellulose. Fillers may have complexed solvent molecules, such as in the case where the lactose used is lactose monohydrate. Fillers may also be proprietary, such as in the case of the filler PROSOLV® (available from JRS Pharma). PROSOLV is a proprietary, optionally high-density, silicified microcrystalline cellulose composed of 98% microcrystalline cellulose and 2% colloidal silicon dioxide. Silicification of the microcrystalline cellulose is achieved by a patented process, resulting in an intimate association between the colloidal silicon dioxide and microcrystalline cellulose. ProSolv comes in different grades based on particle size and is a white or almost white, fine or granular powder, practically insoluble in water, acetone, ethanol, toluene, and dilute acids, and in a 50 g/l solution of sodium hydroxide.
  • Disintegrants to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of disintegrants include, without limitation, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, povidone, crospovidone (polyvinylpolypyrrolidone), methylcellulose, microcrystalline cellulose, powdered cellulose, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and sodium alginate.
  • Lubricants to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of lubricants include, without limitation, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
  • Glidants to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of glidants include, without limitation, silicon dioxide (SiO2), talc cornstarch, and poloxamers. Poloxamers (or LUTROL®, available from the BASF Corporation) are A-B-A block copolymers in which the A segment is a hydrophilic polyethylene glycol homopolymer, and the B segment is hydrophobic polypropylene glycol homopolymer.
  • Tablet binders to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of tablet binders include, without limitation, acacia, alginic acid, carbomer, carboxymethyl cellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropylmethylcellulose, copolyvidone, methylcellulose, liquid glucose, maltodextrin, polymethacrylates, povidone, pregelatinized starch, sodium alginate, starch, sucrose, tragacanth, and zein.
  • Examples of surfactants include, without limitation, fatty acid and alkyl sulfonates; commercial surfactants such as benzethanium chloride (HYAMINE® 1622, available from Lonza, Inc., Fairlawn, N.J.); DOCUSATE SODIUM® (available from Mallinckrodt Spec. Chem., St. Louis, Mo.); polyoxyethylene sorbitan fatty acid esters (TWEEN®, available from ICI Americas Inc., Wilmington, Del.; LIPOSORB® P-20, available from Lipochem Inc., Patterson N.J.; CAPMUL® POE-0, available from Abitec Corp., Janesville, Wis.), polyoxyethylene (20) sorbitan monooleate (TWEEN 80@, available from ICI Americas Inc., Wilmington, Del.); and natural surfactants such as sodium taurocholic acid, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, lecithin, and other phospholipids and mono- and diglycerides. Such materials can advantageously be employed to increase the rate of dissolution by facilitating wetting, thereby increasing the maximum dissolved concentration, and also to inhibit crystallization or precipitation of drug by interacting with the dissolved drug by mechanisms such as complexation, the formation of inclusion complexes, the formation of micelles or adsorbing to the surface of solid drug
  • Drug complexing agents and solubilizers to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of drug complexing agents or solubilizers include, without limitation, polyethylene glycols, caffeine, xanthene, gentisic acid, and cyclodextrins.
  • The addition of pH modifiers such as acids, bases, or buffers may also be beneficial, retarding or enhancing the rate of dissolution of the composition, or, alternatively, helping to improve the chemical stability of the composition. Suitable pH modifiers to be used in the compositions herein include all those now known and in use, as well as those developed in the future.
  • It should be understood that in addition to the ingredients particularly mentioned above, the formulations provided herein may include other agents conventional in the art having regard to the type of formulation in question. Proper formulation depends on the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art, e.g., Remington, supra. The pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or compression processes.
  • Compounds may be generally administered orally at a dose of from 0.1 to about 500 mg/kg per day. The dose range for adult humans is generally from about 5 mg to about 2 g/day. Tablets, capsules, or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing about 5 mg to about 500 mg. In certain embodiments, an oral dosage form will comprise about 20 to about 400 mg, about 25 to about 350 mg, about 100 to about 350 mg, about 200 to about 350 mg, or about 300 to about 350 mg.
  • The precise amount of compound administered to a subject will be the responsibility of the attendant physician. The specific dose level for any particular subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity. Dosing frequency may also be selected or adjusted based on factors including those above as well as the formulation of the compound delivered. Dosing may occur, for example: once daily, twice daily, three or four times daily, every other day, weekly, bi-weekly, or monthly; or in cycles comprising a sustained dosing period followed by a non-dosing period; or on an as-needed basis.
  • In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt, ester, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a subject upon receiving one of the compounds herein is hypertension, then it may be appropriate to administer an anti-hypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself, the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the subject is enhanced). Or, by way of example only, the benefit experienced by a subject may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. By way of example only, in treatment for neuropathy involving administration of one of the compounds described herein, increased therapeutic benefit may result by also providing the subject with another therapeutic agent for neuropathy. In any case, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the subject may simply be additive of the two therapeutic agents, or the subject may experience a synergistic benefit.
  • In certain embodiments, the other therapeutic agent is an antiviral agent. In one embodiment, the antiviral agent is an antiretroviral agent, e.g., nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, integrase inhibitors or gp41, CXCR4, or gp120 inhibitors. Examples of nucleoside reverse transcriptase inhibitors for treating HIV infections include amdoxovir, elvucitabine, alovudine, racivir (±-FTC), phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, zidovudine (AZT), didanosine (ddI), lamivudine (3TC), stavudine (d4T), zalcitabine (ddC), emtricitabine (FTC), and abacavir (ABC). Examples of nucleotide reverse transcriptase inhibitors include tenofovir (TDF) and adefovir. Examples of non-nucleoside reverse transcriptase inhibitors include capravirine, emivirine, calanolide A, etravirine, efavirenz (EFV), nevirapine (NVP), and delavirdine (DLV). Examples of protease inhibitors include amprenavir (APV), tipranavir (TPV), lopinavir (LPV), fosamprenavir (FPV), atazanavir (ATV), darunavir, brecanavir, mozenavir, indinavir (IDV), nelfinavir (NFV), ritonavir (RTV), and saquinavir (SQV). Examples of entry inhibitors include SPOIA. Examples of an HIV integrase inhibitor include curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, and L-25 870810, MK-0518, BMS-538158, GSK364735C, Examples of a gp41 inhibitor include enfuvirtide (ENF). Examples of a CXCR4 inhibitor include AMD-070, Examples of a gp120 inhibitor include BMS-488043.
  • In another embodiment, the polyamine analog is administered concurrently with a highly active antiretroviral therapy (HAART), i.e., a combination of a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, and a nucleoside reverse transcriptase inhibitor, or a combination of two non-nucleoside reverse transcriptase inhibitors and a nucleoside reverse transcriptase inhibitor. In general, the polyamine analog may be administered simultaneously or sequentially (i.e., before or after) with administering antiviral or antiretroviral agents. Administration of the antiviral and antiretroviral agents to subjects in need thereof can be made per regimens and dosages well known in the art.
  • In yet other embodiments, the antiviral agent is an agent that is capable of reducing the HIV viral load in T-cells. T-cells, particularly CD4+ T-cells, also serve as a viral reservoir for immunodeficiency viruses such as HIV. Thus, combination treatments of polyamine analogs with agents that reduce the viral load in T-cells are particularly desirable for flushing or destroying viral reservoirs of HIV. Suitable agents that reduce the viral load in T-cells are reviewed in Pierson et al. (Annu. Rev. Immunol. (2000), 18:665-708) and include, without limitation, T-cell activating cytokines anti-CD3 antibodies, and anti-CD45RO-toxin conjugates. For example, T-cell activating cytokines such as IL-2, IL-6, TNF-α, and any two or more combinations thereof may be used in the present methods.
  • In other embodiments, the other therapeutic agent is a TNF inhibitor. The TNF inhibitor may be a monoclonal antibody such as, for example, infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), or golimumab (Simponi); a circulating receptor fusion protein such as etanercept (Enbrel); or a small molecule, such as pentoxifylline or bupropion (Zyban, Wellbutrin).
  • In other embodiments, the other therapeutic agent is a disease-modifying anti-rheumatic drug (DMARD). Examples of DMARDs include azathioprine, cyclosporin (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, leflunomide, methotrexate (MTX), minocycline, sulfasalazine (SSZ), and cyclophosphamide.
  • In further embodiments, the other therapeutic agent is methotrexate.
  • Other agents for use in combination include interleukin 1 (IL-1) blockers such as anakinra (Kineret), T-cell costimulation blockers such as abatacept (Orencia), interleukin 6 (IL-6) blockers such as tocilizumab (an anti-IL-6 receptor antibody; RoActemra, Actemra), monoclonal antibodies against B cells such as rituximab (Rituxan), and other biologics (e.g., Ocrelizumab, Ofatumumab, Golimumab, and Certolizumab pegol).
  • In other embodiments, the other therapeutic agent is a glucocorticoid or a non-steroidal anti-inflammatory drug (NSAID). NSAIDs include propionic acid derivatives such as ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin; acetic acid derivatives such as indomethacin, sulindac, etodolac, and diclofenac; enolic acid (oxicam) derivatives such as piroxicam and meloxicam; fenamic acid derivatives such as mefenamic acid and meclofenamic acid; selective COX-2 inhibitors (Coxibs) such as celecoxib (Celebrex), rofecoxib, valdecoxib, parecoxib, lumiracoxib, and etoricoxib.
  • In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the doses of the multiple therapeutic agents may be any duration of time, ranging from a few minutes to four weeks.
  • Thus, in another aspect, certain embodiments provide methods for treating disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, optionally in combination with at least one additional agent for treating said disorder that is known in the art. Specific diseases to be treated by the compounds, compositions, and methods disclosed herein, singly or in combination, include, without limitation: pain; neuropathy; inflammation and related disorders; arthritis; metabolic inflammatory disorders; respiratory disorders; autoimmune disorders; neurological disorders; and proliferative disorders, including cancer and non-cancerous diseases.
  • The compounds disclosed herein are useful to treat patients with pain, including neuropathy and/or neuropathic pain and inflammatory pain. Pain indications include, but are not limited to, treatment or prophylaxis of surgical or post-surgical pain for various surgical procedures including amputation, post-cardiac surgery, dental pain/dental extraction, pain resulting from cancer, muscular pain, mastalgia, pain resulting from dermal injuries, lower back pain, headaches of various etiologies, including migraine, menstrual cramps, and the like. The compounds are also useful for treating pain-related disorders such as tactile allodynia and hyperalgesia. The pain may be somatogenic (either nociceptive or neuropathic), acute, and/or chronic.
  • Peripheral neuropathies that can be treated with the compounds disclosed herein include mono-neuropathies, mono-multiplex neuropathies, and poly-neuropathies, including axonal and demyelinating neuropathies. Both sensory and motor neuropathies are encompassed. The neuropathy or neuropathic pain may be for several peripheral neuropathies of varying etiologies, including but not limited to:
      • trauma-induced neuropathies, including those caused by physical injury (such as blunt trauma, abrasion, or burns) or disease state, physical damage to the brain, physical damage to the spinal cord, or stroke for brain damage; neurological disorders related to neurodegeneration; and post-surgical neuropathies and neuropathic pain (such as from tumor resection, mastectomy, and the like)
      • infectious and viral neuropathies, including those caused by leprosy, Lyme disease, a herpes virus (and more particularly by a herpes zoster virus, which may lead to post-herpetic neuralgia), human immunodeficiency virus (HIV, which may lead to HIV neuropathy), or papillomavirus, or any other pathogen-induced nerve damage;
      • toxin-induced neuropathies (including but not limited to neuropathies induced by alcoholism, vitamin B6 intoxication, hexacarbonyl intoxication, amiodarone, chloramphenicol, disulfiram, isoniazide, gold, lithium, metronidazole, misonidazole, nitrofurantoin);
      • drug-induced neuropathies, including therapeutic-drug-induced neuropathy, particularly a) chemotherapy-induced neuropathies caused by anti-cancer agents such as taxol, taxotere, cisplatin, nocodazole, vincristine, vindesine and vinblastine, and b) anti-viral neuropathies caused by anti-viral agents such as ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid);
      • vitamin-deficiency-induced neuropathies including those resulting from vitamin B12 deficiency, vitamin B6 deficiency, and vitamin E deficiency);
      • hereditary neuropathy (including but not limited to Friedreich ataxia, familial amyloid polyneuropathy, Tangier disease, Fabry disease;
      • diabetic neuropathy and neuropathy caused by metabolic disorders such as renal insufficiency and hypothyroidism;
      • neuropathy secondary to tumor infiltration;
      • auto-immune neuropathies, including those resulting from Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, monoclonal gammopathy of undetermined significance and polyneuropathy, and multiple sclerosis;
      • other neuropathies and neuropathic pain syndromes including inflammation-induced nerve damage, neurodegeneration, post-traumatic neuralgia, central neuropathic pain syndromes such as phantom limb pain, pain, complex regional pain syndromes (including but not limited to reflex sympathetic dystrophy, causalgia), neoplasia-associated pain, vasculitic/angiopathic neuropathy, and sciatica; and
      • idiopathic neuropathies,
  • In certain embodiments, neuropathic pain may alternatively be manifested as allodynia, hyperalgesia pain, thermal hyperalgesia, or phantom pain. In another embodiment, neuropathy may instead lead to loss of pain sensitivity. Additional sub-categories of neuropathic pain are discussed in Dworkin, Clin J Pain (2002) vol. 18(6) pp. 343-9.
  • Furthermore, the compounds disclosed herein can be used in the treatment or prevention of opiate tolerance in patients needing protracted opiate analgesics, and benzodiazepine tolerance in patients taking benzodiazepines, and other addictive behavior, for example, nicotine addiction, alcoholism, and eating disorders. Moreover, the compounds disclosed herein are useful in the treatment or prevention of drug withdrawal symptoms, for example, treatment or prevention of symptoms of withdrawal from opiate, alcohol, or tobacco addiction.
  • The compounds disclosed herein are useful in therapeutic methods to treat or prevent respiratory disease or conditions, including therapeutic methods of use in medicine for preventing and treating a respiratory disease or condition including: asthmatic conditions including allergen-induced asthma, exercise-induced asthma, pollution-induced asthma, cold-induced asthma, and viral-induced-asthma; chronic obstructive pulmonary diseases including chronic bronchitis with normal airflow, chronic bronchitis with airway obstruction (chronic obstructive bronchitis), emphysema, asthmatic bronchitis, and bullous disease; and other pulmonary diseases involving inflammation including bronchiectasis, cystic fibrosis, hypersensitivity pneumonitis, farmer's lung, acute respiratory distress syndrome, pneumonia, aspiration or inhalation injury, fat embolism in the lung, acidosis inflammation of the lung, acute pulmonary edema, acute mountain sickness, acute pulmonary hypertension, persistent pulmonary hypertension of the newborn, perinatal aspiration syndrome, hyaline membrane disease, acute pulmonary thromboembolism, heparin-protamine reactions, sepsis, status asthmaticus, hypoxia, hyperoxic lung injuries, and injury-induced by inhalation of certain injurious agents including cigarette smoking, leading up to complications thereof such as lung carcinoma.
  • Other disorders or conditions which can be advantageously treated by the compounds disclosed herein include inflammation and inflammatory conditions. Inflammatory conditions include, without limitation: arthritis, including sub-types and related conditions such as rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis (including Still's disease), acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis, and pyogenic arthritis; osteoporosis, tendonitis, bursitis, and other related bone and joint disorders; gastrointestinal conditions such as reflux esophagitis, diarrhea, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, acute and chronic pancreatitis; pulmonary inflammation, such as that for viral infections and cystic fibrosis; skin-related conditions such as psoriasis, eczema, burns, sunburn, dermatitis (such as contact dermatitis, atopic dermatitis, and allergic dermatitis), and hives; pancreatitis, hepatitis, pruritis, and vitiligo. In addition, compounds of the invention are also useful in organ transplant patients either alone or in combination with conventional immunomodulators.
  • Autoimmune disorders may be ameliorated by the treatment with compounds disclosed herein. Autoimmune disorders include Crohn's disease, ulcerative colitis, dermatitis, dermatomyositis, diabetes mellitus type 1, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), autoimmune encephalomyelitis, Hashimoto's disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, mixed connective tissue disease, multiple sclerosis (MS), myasthenia gravis, narcolepsy, pemphigus vulgaris, pernicious anemia, psoriasis, psoriatic arthritis, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, Sjögren's syndrome, scleroderma, temporal arteritis (also known as “giant cell arteritis”), vasculitis, and Wegener's granulomatosis. The compounds disclosed herein may regulate TH-17 (T-helper cells producing interleukin 17) cells or IL-17 levels, as well as modulate levels of IL-10 and IL-12. They may also regulate cellular production of osteopontin (e.g., in dendritic cells, monocytes/macrophages, T cells, fibroblasts, and other immunological and non-immunological cell-types).
  • In addition, the compounds disclosed herein can be used to treat metabolic disorders typically associated with an exaggerated inflammatory signaling, such as insulin resistance, diabetes (type I or type II), metabolic syndrome, nonalcoholic fatty liver disease (including non-alcoholic steatohepatitis), atherosclerosis, cardiovascular disease, congestive heart failure, myocarditis, atherosclerosis, and aortic aneurysm.
  • The compounds disclosed herein are also useful in treating organ and tissue injury associated with severe burns, sepsis, trauma, wounds, and hemorrhage- or resuscitation-induced hypotension, and also in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephritis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, periodontitis, swelling occurring after injury, ischemias including myocardial ischemia, cardiovascular ischemia, and ischemia secondary to cardiac arrest, and the like.
  • The compounds of the subject invention are also useful for treating certain diseases and disorders of the nervous system. Central nervous system disorders in which nitric oxide inhibition is useful include cortical dementias including Alzheimer's disease, central nervous system damage resulting from stroke, ischemias including cerebral ischemia (both focal ischemia, thrombotic stroke and global ischemia (for example, secondary to cardiac arrest), and trauma. Neurodegenerative disorders in which nitric oxide inhibition is useful include nerve degeneration or necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in cases of central nervous system (CNS) trauma (such as spinal cord and head injury), hyperbaric oxygen-induced convulsions, and toxicity, dementia, e.g., pre-senile dementia, and AIDS-related dementia, cachexia, Sydenham's chorea, Huntington's disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), Korsakoffs disease, cognitive disorders relating to a cerebral vessel disorder, hypersensitivity, sleeping disorders, schizophrenia, depression, depression or other symptoms for Premenstrual Syndrome (PMS), and anxiety.
  • Still other disorders or conditions advantageously treated by the compounds of the subject invention include the prevention or treatment of (hyper)proliferative diseases, especially cancers, either alone or in combination with standards of care, especially those agents that target tumor growth by re-instating the aberrant apoptotic machinery in the malignant cells. Hematological and non-hematological malignancies which may be treated or prevented include but are not limited to multiple myeloma, acute and chronic leukemias including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML), lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma (low, intermediate, and high grade), as well as solid tumors and malignancies of the brain, head, and neck, breast, lung, reproductive tract, upper digestive tract, pancreas, liver, renal, bladder, prostate and colorectal. The present compounds and methods can also be used to treat fibrosis, such as that which occurs with radiation therapy. The present compounds and methods can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, the present compounds and methods can be used to prevent polyps from forming in patients at risk of FAP. Non-cancerous proliferative disorders additionally include psoriasis, eczema, and dermatitis.
  • Compounds disclosed herein may also be used in the treatment of polycystic kidney disease, as well as other diseases of renal dysfunction.
  • The compounds of the subject invention can be used in the treatment of ophthalmic diseases, such as glaucoma, retinal ganglion degeneration, ocular ischemia, corneal neovascularization, optic neuritis, retinitis, retinopathies such as glaucomatous retinopathy and/or diabetic retinopathy, uveitis, ocular photophobia, dry eye, Sjogren's syndrome, seasonal and chronic allergic conjunctivitis, and of inflammation and pain for chronic ocular disorders and acute injury to the eye tissue. The compounds can also be used to treat post-operative inflammation or pain from ophthalmic surgery such as cataract surgery and refractive surgery.
  • The present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-inflammatory therapies, including steroids, NSAIDs, COX-2 selective inhibitors, 5-lipoxygenase inhibitors, LTB4 antagonists, and LTA4 hydrolase inhibitors. The compounds of the subject invention may also be used to prevent tissue damage when therapeutically combined with antibacterial or antiviral agents.
    • Predicted Human Efficacy
  • Multi-species allometric scaling based on pharmacokinetic parameters was employed to calculate predicted pharmacokinetic parameters in humans according to methods known in the art. See, e.g., Ings R M, “Interspecies scaling and comparisons in drug development and toxicokinetics,” Xenobiotica, 1990 November; 20(11):1201-31 and Khor, S P et al., “Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics, and toxicodynamics of 5-fluorouracil in humans,” Cancer Chemother Pharmacol (1997) 39(3): 833-38. Expected values are given below in Table 2.
  • TABLE 2
    t1/2 CL/F V/F
    ORAL (h) (mL/min/kg) (L/kg)
    Based on 23.3 21.0 42.4
    Mouse, Rat, Dog, Rhesus
    Based on 23.0 20.9 41.6
    Mouse, Dog, Rhesus
  • In both the murine carrageenan-induced paw edema and hyperalgesia models, the top efficacious dose of MGBG is 30 mg/kg PO BID (totaling 60 mg/kg/day). Based upon this dosing paradigm in mice, at least two methods to estimate the equivalent dosing in humans may be used.
  • The first method is based upon body surface area (BSA) normalization (described in Reagen-Shaw et al. (2007) FASEB J. 22, 659-661), as the authors note that BSA correlates well across species for various biological parameters, including basal metabolic rate, blood volume, caloric expenditure, plasma protein levels, and renal function. Using this method, a 60 mg/kg/day dose in mice would convert to about 4.9 mg/kg/day in humans.
  • The second method used to convert the efficacious 60 mg/kg/day dose in mice to an equivalent dose in humans was based more directly on allometric scaling of actual pharmacokinetic data from various animal species. Data from an MGBG pharmacokinetic study consisting of a 10 mg/kg oral dose in mice was modeled in a simulation to determine the theoretical AUCINF value for a dosing regimen of 30 mg/kg PO BID, which was 9050 h*ng/mL. Next, predicted human clearance values as determined by single- and multi-species allometric scaling were used to estimate doses likely to produce exposure in humans (AUCINF) Similar to that of the 60 mg/kg/day in mice. Using single-species allometric scaling and a range of predicted human clearance values, a human equivalent dose would be in the range of 1.73 mg/kg/day to 4.51 mg/kg/day. Using multi-species allometric scaling, the predicted human equivalent dose is about 4.2 mg/kg/day.
  • In the murine carrageenan models, we also observed the efficacy of MGBG at lower doses, including 3 mg/kg PO BID and 10 mg/kg PO BID, which would proportionally convert to human doses of ˜0.42 mg/kg/day and ˜1.2 mg/kg/day.
  • The average body weight of a normal male human is often presumed to be 70 kg. Thus, daily doses based on the predictions above could be estimated to range from about 25 mg/day to about 350 mg/day.
  • The proper dose depends, of course, on several factors. The patient may weigh much more or much less or be female, elderly, or juvenile, requiring a lower or higher dose. The patient may exhibit a drug metabolic profile, which might counsel for a lower or higher dose, such as a low expression level or activity of metabolizing enzymes such as cytochromes P450 (CYPs). This low expression or activity level may be due to several factors. Polymorphic expression of one or more CYPs (for example, CYP2C19 and CYP2D6, though polymorphisms have been described for nearly all the CYPs) is known to be responsible for some populations to be “deficient” as compared to the population at large, leading to a “poor metabolizer” phenotype, requiring a lower dose. Additionally, exposure to an infectious agent or xenobiotic may cause repression of CYP expression or inhibition of existing CYPs. Alternatively, the patient may be physically weak, injured, or immunocompromised, all of which might counsel a lower dose. The patient may be taking several other drugs that compete with metabolic systems (including CYPs as discussed above) for disposal; this well-known polypharmaceutical effect may call for a lower dose. The dose also depends, as discussed above, on the condition and its severity. The efficacious dose for one disease or clinical endpoint will not necessarily be the same as the dose for another, and a severe, chronic, or otherwise serious case may call for a higher dose. However, a chronic case may also call for a lower dose administered over a longer or even indefinite period of time. All of these are discussed by way of example to illustrate the variability of ideal dosing; it is within the capacity of the skilled artisan to select an appropriate dosing range for a disease, population, or individual.
  • With these factors in mind, it should be clear that it is possible that the daily human dose may be as low as 1 mg/day, and as high as a 1 g/day. In certain embodiments, the human dose may range: from 10 mg/day to 500 mg/day, from 20 mg/day to 400 mg/day, or from 25 mg/day to 350 mg/day. In further embodiments, the human dose may range from 120 mg/day to 350 mg/day, from 150 mg/day to 350 mg/day, from 200 mg/day to 350 mg/day, or from 250 mg/day to 350 mg/day. In certain embodiments, the human dose may be any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 75, 80, 85, 90, 95, 100, 110, 120, 125, 130, 140, 150, 160, 170, 175, 180, 190, 200, 210, 220, 225, 230, 240, 250, 260, 270, 275, 280, 290, 300, 310, 320, 325, 330, 240 or 350 mg/day.
  • In certain embodiments, the human dose may be any one of 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 350, 355, 360, 365, 370, or 375 mg/day. In one embodiment, the dose may be 275 mg/day. In another embodiment, the dose may be 300 mg/day. In another embodiment, the dose may be 305 mg/day. In another embodiment, the dose may be 310 mg/day. In another embodiment, the dose may be 315 mg/day. In another embodiment, the dose may be 320 mg/day. In another embodiment, the dose may be 325 mg/day. In another embodiment, the dose may be 330 mg/day. In another embodiment, the dose may be 335 mg/day. In another embodiment, the dose may be 340 mg/day. In another embodiment, the dose may be 345 mg/day. In another embodiment, the dose may be 350 mg/day.
  • In certain embodiments, the human dose may be any one of 350, 375, 400, 425, 450, 475, 500, 525, 550 or 600 mg/day. In one embodiment, the dose may be 375 mg/day. In another embodiment, the dose may be 400 mg/day. In another embodiment, the dose may be 450 mg/day. In another embodiment, the dose may be 500 mg/day.
  • In certain embodiments, the human dose may be any one of 25, 50, 75, 100, or 125 mg/day. In one embodiment, the dose may be 375 mg/day. In another embodiment, the dose may be 25 mg/day. In another embodiment, the dose may be 50 mg/day. In another embodiment, the dose may be 75 mg/day. In another embodiment, the dose may be 100 mg/day. In another embodiment, the dose may be 125 mg/day.
    • Exemplary Oral Pharmaceutical Formulations
  • The following are examples of dosage forms that may be used to orally deliver compounds disclosed herein.
    • Extended-Release Examples
  • The following examples illustrate the formulation of several therapeutic tablet dosage forms. In these examples, the ethylcellulose is typically a dry material of the standard type having a viscosity designation of 4 cps and an ethoxy content of 48% to 49.5%. The hydroxypropylmethylcellulose is typically a dry material having a hydroxypropoxyl content of 7 to 8.6 weight percent.
  • The carrier base material concentration in the tablet formulae (hydroxypropylmethylcellulose and ethylcellulose) ranges from 21% to 26.4% (weight by weight). The ethylcellulose to hydroxypropylmethylcellulose weight ratio in the tablet formulae ranges from 1 to 3.2 to 1 to 4.2.
  • Standard methods known in the art may be used to assess the efficacy of an extended-release formulation.
    • EXAMPLE 1
  • This example illustrates the preparation of a tablet with 200 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • Ingredient mg/tablet
    MGBG, micronized  200 mg
    Hydroxypropyl Methylcellulose, USP  5.0 mg
    Dibasic Sodium Phosphate, USP 35.0 mg
    Lactose, NF 18.0 mg
    Ethylcellulose, NF 17.5 mg
    Magnesium Stearate, NF 3.50 mg
    Talc 1.00 mg
    Theoretical Tablet Weight = 350 mg
  • The MGBG, together with ethylcellulose, hydroxypropylmethylcellulose, lactose, talc, and the dibasic sodium phosphate, is dry blended and subsequently granulated with an alcohol, denatured 23A, and methylene chloride solvent mixture. Instead of using alcohol and methylene chloride as the granulating liquids, other liquids such as tap water may be used instead. Following wet sizing, drying, and dry sizing of the granulate, it is blended with magnesium stearate. The final blend is compressed into tablets of the correct weight. Subsequently, an aqueous film coat color suspension and a gloss solution are applied to the tablets. Denatured 23A is a 100:10 blend of ethyl alcohol and acetone.
    • EXAMPLE 2
  • This example illustrates the preparation of a tablet with 300 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • Ingredient mg/tablet
    MGBG, micronized 300.0 mg
    Hydroxypropyl Methylcellulose, USP 112.5 mg
    Dibasic Sodium Phosphate, USP  52.5 mg
    Lactose, NF  27.0 mg
    Ethylcellulose, NF 26.25 mg
    Magnesium Stearate, NF  5.25 mg
    Talc  1.5 mg
    Theoretical Tablet Weight = 525 mg
  • The method of manufacture is the same as that of Example 1.
    • EXAMPLE 3
  • This example illustrates the preparation of a tablet with 400 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • Ingredient mg/tablet
    MGBG, micronized 400.0 mg
    Hydroxypropyl Methylcellulose, USP 150.0 mg
    Dibasic Sodium Phosphate, USP  70.0 mg
    Lactose, NF  36.0 mg
    Ethylcellulose, NF  35.0 mg
    Magnesium Stearate, NF  7.0 mg
    Talc  2.0 mg
    Theoretical Tablet Weight = 700 mg
  • The method of manufacture is the same as that for Example 1.
    • EXAMPLE 4
  • This example illustrates the preparation of a tablet with 600 milligrams of MGBG and containing the following ingredients in the listed amounts per tablet.
  • Ingredient mg/tablet
    MGBG, micronized 600.0 mg
    Hydroxypropyl Methylcellulose, USP 168.0 mg
    Lactose, NF 105.8 mg
    Dibasic Sodium Phosphate, USP 105.0 mg
    Ethylcellulose, NF  52.5 mg
    Magnesium Stearate, NF 15.75 mg
    Talc  3.0 mg
    Theoretical Tablet Weight = 1050 mg
  • The method of manufacture is the same as that for Example 1.
  • The dissolution profile of the above dosage forms may be tested according to standard USP procedures. It is expected that the tablet dosage forms will dissolve faster and release the drug more rapidly as the hydroxypropoxyl content increases.
  • The in vivo performance of the novel dosage forms of this invention may be evaluated in bioavailability studies compared to equivalent immediate release dosage forms. Extended-release tablets generally prepared according to Examples 1-4 may be given once a day and evaluated in multi-day steady-state bioavailability studies compared to capsules or tablets containing an equivalent per-diem amount of conventional immediate-release drug given multiple times daily. The extended-release tablets are expected to demonstrate equivalent bioavailability to the immediate-release reference dosage forms. Other pharmacokinetic parameters may be measured as well. The Cmax and Tmax values are expected to be lower and later, respectively, for the extended-release dosage forms.
    • Encapsulated Micropellet Sustained-Release Examples EXAMPLE 5
  • 3.2 Kilograms polyvinylpyrrolidone, molecular weight 40,000 (Kollidon 30) is dissolved in 32 liters of isopropanol, and 12.8 kilograms of micronized MGBG is dispersed therein. 4.0 kilograms of sugar, 60/80 mesh is placed in the Wurster air suspension coating column. After the air suspension system is in operation with the sugar, the dispersed MGBG is sprayed into the column with the inlet air having a temperature of 60° C., the spray pressure at 4 bars, and the spray rate being 100 ml/min. After completion of the above procedure, operation of the Wurster column is stopped, and the product is reserved as “MGBG pellets, Active I.”
  • A second 3.2 kilogram batch of polyvinylpyrrolidone, molecular weight 40,000 (Kollidon 30), is dissolved in 32.0 liters of isopropanol and dispersed into the resultant mixture is 12.8 kilograms of micronized MGBG. 4.0 kilograms of “MGBG pellets, Active I” are then charged into the same Wurster column under the same conditions of temperature and pressure and at the same rate. The second batch having the MGBG dispersed therein is then charged into the Wurster column to further build up the coating. The Wurster column is emptied, and the product is labeled “MGBG pellets, Active II.”
  • A coating mixture of 13.2 liters of chloroform and 3.3 liters of methanol is prepared, into which are dispersed 992.0 grams of ethylcellulose (Ethocel N-10 Dow) and 329.0 grams of hydroxypropyl cellulose (Hercules, Klucel LF). Into the Wurster column is charged 19.0 kilograms of “MGBG pellets, Active II,” which are then coated with the coating mixture under conditions of 30° C., spray pressure 3 bars, and spray rate 100 ml/min. The resultant coated pellets are small micropellets which may be placed into capsules containing the desired dosage unit.
  • The above protocol may be scaled appropriately according to methods known in the art.
    • EXAMPLE 6
  • Using a procedure similar to that described in Example 5, MGBG pellets may be outer coated with 5% by weight of a mixture containing 75% by weight ethylcellulose and 25% by weight hydroxypropylcellulose. The release characteristics of the coated pellets may be measured according to the U.S.P. XX dissolution procedure (one hour in simulated gastric fluid followed by simulated intestinal fluid).
    • Spheronized Extended-Release Examples EXAMPLE 7
  • A mixture of 44.8 parts of MGBG, 74.6 parts of the microcrystalline cellulose, NF, and 0.60 parts of hydroxypropylmethylcellulose 2208, USP, are blended with the addition of 41.0 parts water. The plastic mass of material is extruded, spheronized, and dried to provide uncoated drug-containing spheroids.
  • Stir 38.25 parts of ethylcellulose, NF, HG2834, and 6.75 parts of hydroxypropylmethylcellulose 2910, USP in a 1:1 v/v mixture of methylene chloride and anhydrous methanol until the solution of the film coating material is complete.
  • To a fluidized bed of the uncoated spheroids is applied 0.667 parts of coating solution per part of uncoated spheroids to obtain extended-release, film-coated spheroids having a coating level of 3%.
  • The spheroids are sieved to retain the coated spheroids of a particle size between 0.85 mm to 1.76 mm diameter. These selected film-coated spheroids are filled into pharmaceutically acceptable capsules conventionally, such as starch or gelatin capsules.
    • EXAMPLE 8
  • Same as for Example 7 except that 1.11 parts of the film coating solution per part of uncoated spheroids are applied to obtain a coating level of 5%.
    • EXAMPLE 9
  • Same as for Example 7 except that 1.33 parts of the film coating solution are applied to 1 part of uncoated spheroids to obtain a coating level of 6%.
    • EXAMPLE 10
  • Same as for Example 7 except that 1.55 parts of the film coating solution are applied to 1 part of uncoated spheroids to obtain a coating level of 7%.
    • EXAMPLE 11 MGBG 100-mg Tablets
  • The required quantities of MGBG, spray-dried lactose, and Eudragit® RS PM are transferred into an appropriate-size mixer and mixed for approximately 5 minutes. While the powders are mixing, the mixture is granulated with enough water to produce a moist granular mass. The granules are then dried in a fluid bed dryer at 60° C. and then passed through an 8-mesh screen. Thereafter, the granules are redried and pushed through a 12-mesh screen. The required quantity of stearyl alcohol is melted at approximately 60°-70° C., and while the granules are mixing, the melted stearyl alcohol is added. The warm granules are returned to the mixer.
  • The coated granules are removed from the mixer and allowed to cool. The granules are then passed through a 12-mesh screen. The granulate is then lubricated by mixing the required quantity of talc and magnesium stearate in a suitable blender. Tablets are compressed to 375 mg in weight on a suitable tableting machine. The formula for the tablets of Example 11 is set forth below:
  • Component mg/Tablet % (by wt)
    MGBG 100.0 27
    Lactose (spray-dried) 143.75 38
    Eudragit ® RS PM 45.0 12
    Purified Water q.s* --
    Stearyl Alcohol 75.0 20
    Talc 7.5 2
    Magnesium Stearate 3.75 1
    Total: 375.0 100%
    *Used in manufacture and remains in final product as residual quantity only.
  • The tablets of Example 11 are then tested for dissolution via the USP Basket Method, 37° C., 100 RPM, first hour 700 ml gastric fluid at pH 1.2, then changed to 900 ml at 7.5.
    • EXAMPLE 12 MGBG 50 mg Controlled-Release Tablets
  • The required quantities of MGBG and spray dried lactose are transferred into an appropriately sized mixer and mix for approximately 6 minutes. Approximately 40 percent of the required Eudragit® RS PM powder is dispersed in Ethanol. While the powders are mixing, the powders are granulated with the dispersion, and the mixing continued until a moist granular mass is formed. Additional ethanol is added if needed to reach the granulation endpoint. The granulation is transferred to a fluid bed dryer and dried at 30° C., and then passed through a 12-mesh screen. The remaining Eudragit® RS PM is dispersed in a solvent of 90 parts ethanol and 10 parts purified water and sprayed onto the granules in the fluid bed granulator/dryer at 30° C. Next the granulate is passed through a 12-mesh screen. The required quantity of stearyl alcohol is melted at approximately 60°-70° C. The warm granules are returned to the mixer. While mixing, the melted stearyl alcohol is added. The coated granules are removed from the mixer and allowed to cool. Thereafter, they are passed through a 12-mesh screen.
  • Next, the granulate is lubricated by mixing the required quantities of talc and magnesium stearate in a suitable blender. The granulate is then compressed to 125 mg tablets on a suitable tableting machine.
  • The formula for the tablets of Example 12 (10 mg controlled release MGBG) is set forth below:
  • Component mg/Tablet % (by wt)
    MGBG 50.00 40
    Lactose (spray-dried) 31.25 25
    Eudragit ® RS PM 15.00 12
    Ethanol q.s.* --
    Purified Water q.s.* --
    Stearyl Alcohol 25.00 20
    Talc 2.50 2
    Magnesium stearate 1.25 1
    Total: 125.00 mg 100%
    *Used only in the manufacture and remains in final product as residual quantity only.
  • The tablets of Example 12 are then tested for dissolution via USP Basket Method at 37° C., 100 RPM, first hour 700 ml simulated gastric (pH 1.2) then changed to 900 ml at pH 7.5.
    • EXAMPLES 13-14
  • Controlled Release MGBG 50 and 25 mg Tablets (Aqueous Manufacture)
  • Eudragit® RS 30D and Triacetin® are combined while passing through a 60 mesh screen and mixed under low shear for approximately 5 minutes or until a uniform dispersion is observed.
  • Next, suitable quantities of MGBG, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed. After spraying, the granulation is passed through a #12 screen if necessary to reduce lumps. The dry granulation is placed in a mixer.
  • In the meantime, the required amount of stearyl alcohol is melted at a temperature of approximately 70° C. The melted stearyl alcohol is incorporated into the granulation while mixing. The waxed granulation is transferred to a fluid bed granulator/dryer or trays and allowed to cool to room temperature or below. The cooled granulation is then passed through a #12 screen. Thereafter, the waxed granulation is placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes, and then the granulate is compressed into 125 mg tablets on a suitable tableting machine.
  • The formula for the tablets of Example 13 is set forth below:
    • Formula of Controlled Release MGBG 10 mg Tablets
  • Component mg/Tablet % (by wt)
    MGBG 50.0 40.0
    Lactose (spray dried) 29.25 23.4
    Povidone 5.0 4.0
    Eudragit ® RS 30D (solids) 10.0* 8.0
    Triacetin ® 2.0 1.6
    Stearyl Alcohol 25.0 20.0
    Talc 2.5 2.0
    Magnesium Stearate 1.25 1.0
    Total: 125.0 100%
    *Approximately 33.33 mg Eudragit ® RS 30D Aqueous dispersion is equivalent to 10 mg of Eudragit ® RS 30D dry substance.
  • The tablets of Example 13 are then tested for dissolution via the USP Basket Method at 37° C., 100 RPM, first hour 700 ml simulated gastric fluid at pH 1.2, then changed to 900 ml at pH 7.5.
  • The formula for the tablets of Example 14 is set forth below:
    • Formula of Controlled Release MGBG 20 mg Tablets
  • Component mg/Tablet
    MGBG 25.0
    Lactose (spray dried) 54.25
    Povidone 5.0
    Eudragit ® RS 30D (solids) 10.0*
    Triacetin ® 2.0
    Stearyl Alcohol 25.0
    Talc 2.5
    Magnesium Stearate 1.25
    Total: 125.0
  • The tablets of Example 14 are then tested for dissolution via the USP Basket Method at 37° C., 100 RPM, first hour 700 ml simulated gastric fluid at pH 1.2, then changed to 900 ml at pH 7.5.
    • EXAMPLES 15-16
  • In Example 15, 30 mg controlled release MGBG tablets are prepared according to the process set forth in Example 10. In Example 16, 10 mg controlled release MGBG tablets are prepared according to the process set forth in Example 12. Thereafter, dissolution studies of the tablets of Examples 5 and 6 are conducted at different pH levels, namely, pH 1.3, 4.56, 6.88, and 7.5.
    • EXAMPLES 17-22
  • In Examples 17-22, 4 mg and 10 mg MGBG tablets are prepared in a manner similar to the formulations and methods set forth in U.S. Pat. No. 4,990,341. In Example 17, MGBG (10.00 gm) is wet granulated with lactose monohydrate (417.5 gm) and hydroxyethyl cellulose (100.00 gm), and the granules are sieved through a 12 mesh screen. The granules are then dried in a fluid bed dryer at 50° C. and sieved through a 16 mesh screen. Molten cetostearyl alcohol (300.0 gm) is added to the warmed MGBG containing granules, and the whole was mixed thoroughly. The mixture is allowed to cool in the air, regranulated, and sieved through a 16 mesh screen. Purified Talc (15.0 gm) and magnesium stearate (7.5 gm) are then added and mixed with the granules. The granules are then compressed into tablets.
  • Example 18 is prepared in the same manner as Example 17; however, the formulation includes 10 mg MGBG/tablet. The formulas for Examples 17 and 18 are set forth below.
    • Formulation of Example 17
  • Ingredient mg/tablet g/batch
    MGBG 4.0 10.0
    Lactose monohydrate 167.0 417.5
    Hydroxyethylcellulose 40.0 100.0
    Cetostearyl alcohol 120.0 300.0
    Purified talc 6.0 15.0
    Magnesium stearate 3.0 7.5
    • Formulation of Example 18
  • Ingredient mg/tablet g/batch
    MGBG 10.0 25.0
    Lactose monohydrate 167.0 417.5
    Hydroxyethylcellulose 40.0 100.0
    Cetostearyl alcohol 120.0 300.0
    Talc 6.0 15.0
    Magnesium stearate 3.0 7.5
  • In Example 19, 4 mg MGBG controlled-release tablets are prepared according to the excipient formula cited in Example 2 of U.S. Pat. No. 4,990,341. The method of manufacture is the same as set forth in Examples 17 and 18 above. Example 20 is prepared according to Example 19, except that 10 mg MGBG is included per tablet. The formulas for Examples 19 and 20 are set forth below.
    • Formulation of Example 19
  • Ingredient mg/tablet g/batch
    MGBG 4.0 10.0
    Anhydrous Lactose 167.0 417.5
    Hydroxyethylcellulose 30.0 75.0
    Cetostearyl alcohol 90.0 225.0
    Talc 6.0 15.0
    Magnesium stearate 3.0 7.5
    • Formulation of Example 20
  • Ingredient mg/tablet g/batch
    MGBG 10.0 25.0
    Hydrous lactose 167.0 417.5
    Hydroxyethylcellulose 30.0 75.0
    Cetostearyl alcohol 90.0 225.0
    Talc 6.0 15.0
    Magnesium stearate 3.0 7.5
  • In Example 21, MGBG 4 mg controlled-release tablets are prepared in a manner analogous to and with the same excipient formula cited in Example 3 of U.S. Pat. No. 4,990,341.
  • MGBG (32.0 gm) is wet granulated with lactose monohydrate (240.0 gm), hydroxyethylcellulose (80.0 gm), and methacrylic acid copolymer (240.0 gm, Eudragit® L-100-55), and the granules are sieved through a 12 mesh screen. The granules are then dried in a Fluid Bed Dryer at 50° C. and passed through a 16 mesh screen.
  • To the warmed MGBG containing granules is added molten cetostearyl alcohol (240.0 gm), and the whole is mixed thoroughly. The mixture is allowed to cool in the air, regranulated, and sieved through a 16 mesh screen. The granules are then compressed into tablets.
  • Example 22 is prepared in an identical fashion to Example 21, except that 10 mg MGBG is included per tablet. The formulations for Examples 21 and 22 are set forth below.
    • Formulation of Example 21
  • Ingredient mg/tablet g/batch
    MGBG 4.0 32.0
    Lactose monohydrate 30.0 240.5
    Hydroxyethylcellulose 10.0 80.0
    Methacrylic acid copolymer 30.0 240.0
    Cetostearyl alcohol 30.0 240.0
    • Formulation of Example 22
  • Ingredient mg/tablet g/batch
    MGBG 10.0 80.0
    Lactose monohydrate 30.0 240.5
    Hydroxyethylcellulose 10.0 80.0
    Methacrylic acid copolymer 30.0 240.0
    Cetostearyl alcohol 30.0 240.0
    • Delayed-Release Enteric-Coated Dosage Forms EXAMPLE 23
  • Enteric Coated Capsule With Hypromellose/Microcrystalline
    Cellulose Pellet Core
    Ingredient mg/capsule (250 mg MGBG dosage)
    Pellet Core:
    MBGB 250
    Microcrystalline cellulose 75.07
    Hypromellose 65
    Seal Coat:
    Opadry Clear 6.5
    Enteric Coat:
    Eudragit L30-D55 71.77
    Triethyl Citrate 2.15
    Sodium Hydroxide 3.23
    Talc 10.64
    Water* NA
    • EXAMPLE 24
  • Capsule Dosage Unit with Pellet Core and Delay Coat
    Ingredient mg/capsule (250 mg MGBG dosage)
    Pellet Core:
    MGBG 250
    Microcrystalline cellulose 75.07
    Hypromellose 65
    Seal Coat:
    Opadry Clear 6.5
    “Delay” Coat:
    Surelease ® ethylcellulose 27
    dispersion
    Hypomellose 3
    Water* NA
    • EXAMPLE 25
  • Tablet Dosage Unit with Delay Coat
    Ingredient mg/capsule (250 mg MGBG dosage)
    Tablet Core:
    MGBG 250
    Microcrystalline cellulose 135
    Hypromellose 60
    Talc 18
    Magnesium stearate 7
    “Delay” Coat:
    Surelease ® ethylcellulose 27
    dispersion
    Hypomellose 3
    Water* NA
    • EXAMPLE 26
  • Tablet Core with Enteric Coat
    Tablet Core:
    MGBG 250
    Microcrystalline cellulose 135
    Hypromellose 60
    Talc 18
    Magnesium stearate 7
    Enteric (“delay”) Coat:
    Eudragit L30-D55 71.77
    Triethyl Citrate 2.15
    Sodium Hydroxide 3.23
    Talc 10.64
    • EXAMPLES 27-506 Additional Enterically Coated Dosage Forms
  • Enterically coated dosage forms may be made by the methods below. In certain embodiments, methods are chosen to ensure that the final dosage form is substantially anhydrous. The moisture content can be measured by methods known in the art. Additionally, the dosage form may be tested for isomerization of MGBG. A stable dosage form would show minimal isomerization.
  • Tablets in the examples below may be made either by direct compression or by dry granulation. For manufacture by direct compression, MGBG in the amount cited is combined with magnesium stearate in an amount equal to about 1% of the total weight of the tablet core, crospovidone in an amount equal to about 2% of the total weight of the tablet core, and sufficient anhydrous lactose to form a tablet core of a total weight of 500 mg. The ingredients are de-lumped by screening or milling, then blended until the mixture is substantially uniform. Uniformity may be tested by sampling at three different points in the blend container and assessed using standard methods such as HPLC; test result of 95-105% of target potency, with an RSD of 5% would be near ideal. The mixture is poured into dies, optionally with a forced-flow feeder, and compressed into tablets, which may then be enterically coated.
  • For manufacture by dry granulation, MGBG in the amount cited, a disintegrant such as crospovidone and a lubricant such as magnesium stearate, and a sufficient amount of a filler/diluent such as anhydrous lactose to form a tablet core of a total weight of 500 mg (similar quantities of other excipients used in direct compression may be used, with adjustment to allow for an additional lubricating step at the end) are de-lumped by screening or milling, then blended until the mixture is substantially uniform. The mixture is poured into dies and compressed with a flat-faced punch into slugs, typically of ¾″ to 1″; alternatively, the powder is densified by passing through the rollers of a compacting mill. The slugs are then broken up gently to form granules and reduced to a substantially uniform granule size by screening or milling. The granules are lubricated a second time. At this stage, the granules may themselves be enterically coated and then encapsulated or compressed into tablets, which may then be enterically coated.
  • For manufacture by spheronization, MGBG is combined with a binder/filler and wet granulated using a minimum of solvent according to methods known in the art. Microcrystalline cellulose is an appropriate binder. This mixture is passed through an extruder to form the cylinder's desired thickness. These cylindrical segments are collected and placed in a Marumerizer, where they are shaped into spheroids by centrifugal and frictional forces. The spheroids should be screened for uniform sizes, such as roughly 0.5-1 mm in diameter. The spheroids may then be dried, lubricated, and enterically coated before being encapsulated. Alternatively, the spheroids may be compressed into a tablet, which may then enterically coated. For manufacture by micropeletization, MGBG is coated onto seed crystals of substantially uniform size, optionally after combining with a binder such as polyvinylpyrrolidone, in layers. The layers may be deposited by spraying the MGBG as a solution onto sugar seeds in an air column suspension unit, repeating the process as necessary until the micropellets are of the desired size. The micropellets may then be dried, lubricated, and enterically coated before being encapsulated.
    • EXAMPLES 27-212 Additional Enterically Coated Dosage Forms for Duodenal Release
  • The following Examples are enterically coated dosage forms made using a methacrylic acid/ethyl acrylate copolymer as the release-delaying agent in the enteric coat. The methacrylic acid/ethyl acrylate copolymer may be any such suitable copolymer, for example, Eudragit® L 30 D-55 or Eudragit® L 100-55. As formulated, the MGBG core of the tablet, micropellets, or spheroids may optionally be combined with one or more excipients as disclosed herein or known in the art. It is expected that the formulations below will bypass the stomach and release MGBG in the duodenum. Standard USP or in vitro assays, as well as in vivo models, which are known in the art, may be used to confirm this effect. When using USP or in vitro models, it is expected that successful delayed-release dosage forms will dissolve between about pH 5.5 and about pH 6. When using in vivo models, it is expected that exceptionally successful delayed-release dosage forms will yield reduced gastrointestinal side effects, such as nausea, emesis, gastric irritation, ulceration, and/or bleeding, and loose stool and/or diarrhea in subjects. It is also expected that the Tmax will be right-shifted (on a concentration-versus-time graph having a concentration on the vertical axis and time on the horizontal axis, i.e., delayed) by at least one hour; in certain embodiments, the Tmax will be right-shifted by one to six hours.
  • Additionally, the amounts of MGBG may be varied as needed according to methods known in the art. Different proportions of MGBG and filler may be used to achieve, for example—using the same enteric coating proportions—a 50, 75, 100, 150, 200, 225, 325, 375, 400, or 450 mg dosage form. Additional excipients such as lubricants (for example, talc), compression protectants (for example, triethyl citrate or a polyethylene glycol such as macrogol 6000), etc., may be added. Table 3 below provides additional enterically coated dosage forms.
  • TABLE 3
    Enteric Enteric
    Coating as Coating
    MGBG % of Total Applied To
    Dose, Weight of (Dosage
    Ex. mg Enteric Coating Formulation Form)
    27 250 Methacrylic acid/ethyl 1%-5% tablet
    acrylate copolymer
    28 250 Methacrylic acid/ethyl 1%-2% tablet
    acrylate copolymer
    29 250 Methacrylic acid/ethyl 2%-3% tablet
    acrylate copolymer
    30 250 Methacrylic acid/ethyl 3%-4% tablet
    acrylate copolymer
    31 250 Methacrylic acid/ethyl 4%-5% tablet
    acrylate copolymer
    32 250 Methacrylic acid/ethyl  5%-10% tablet
    acrylate copolymer
    33 250 Methacrylic acid/ethyl 5%-6% tablet
    acrylate copolymer
    34 250 Methacrylic acid/ethyl 6%-7% tablet
    acrylate copolymer
    35 250 Methacrylic acid/ethyl 7%-8% tablet
    acrylate copolymer
    36 250 Methacrylic acid/ethyl 8%-9% tablet
    acrylate copolymer
    37 250 Methacrylic acid/ethyl  9%-10% tablet
    acrylate copolymer
    38 250 Methacrylic acid/ethyl 10%-15% tablet
    acrylate copolymer
    39 250 Methacrylic acid/ethyl 10%-11% tablet
    acrylate copolymer
    40 250 Methacrylic acid/ethyl 11%-12% tablet
    acrylate copolymer
    41 250 Methacrylic acid/ethyl 12%-13% tablet
    acrylate copolymer
    42 250 Methacrylic acid/ethyl 13%-14% tablet
    acrylate copolymer
    43 250 Methacrylic acid/ethyl 14%-15% tablet
    acrylate copolymer
    44 250 Methacrylic acid/ethyl 15%-20% tablet
    acrylate copolymer
    45 250 Methacrylic acid/ethyl 20%-25% tablet
    acrylate copolymer
    46 250 Methacrylic acid/ethyl 25%-30% tablet
    acrylate copolymer
    47 250 Methacrylic acid/ethyl 1%-5% capsule
    acrylate copolymer
    48 250 Methacrylic acid/ethyl 1%-2% capsule
    acrylate copolymer
    49 250 Methacrylic acid/ethyl 2%-3% capsule
    acrylate copolymer
    50 250 Methacrylic acid/ethyl 3%-4% capsule
    acrylate copolymer
    51 250 Methacrylic acid/ethyl 4%-5% capsule
    acrylate copolymer
    52 250 Methacrylic acid/ethyl  5%-10% capsule
    acrylate copolymer
    53 250 Methacrylic acid/ethyl 5%-6% capsule
    acrylate copolymer
    54 250 Methacrylic acid/ethyl 6%-7% capsule
    acrylate copolymer
    55 250 Methacrylic acid/ethyl 7%-8% capsule
    acrylate copolymer
    56 250 Methacrylic acid/ethyl 8%-9% capsule
    acrylate copolymer
    57 250 Methacrylic acid/ethyl  9%-10% capsule
    acrylate copolymer
    58 250 Methacrylic acid/ethyl 10%-15% capsule
    acrylate copolymer
    59 250 Methacrylic acid/ethyl 10%-11% capsule
    acrylate copolymer
    60 250 Methacrylic acid/ethyl 11%-12% capsule
    acrylate copolymer
    61 250 Methacrylic acid/ethyl 12%-13% capsule
    acrylate copolymer
    62 250 Methacrylic acid/ethyl 13%-14% capsule
    acrylate copolymer
    63 250 Methacrylic acid/ethyl 14%-15% capsule
    acrylate copolymer
    64 250 Methacrylic acid/ethyl 15%-20% capsule
    acrylate copolymer
    65 250 Methacrylic acid/ethyl 20%-25% capsule
    acrylate copolymer
    66 250 Methacrylic acid/ethyl 25%-30% capsule
    acrylate copolymer
    67 250 Methacrylic acid/ethyl 1%-5% micropellets
    acrylate copolymer (capsule)
    68 250 Methacrylic acid/ethyl 1%-2% micropellets
    acrylate copolymer (capsule)
    69 250 Methacrylic acid/ethyl 2%-3% micropellets
    acrylate copolymer (capsule)
    70 250 Methacrylic acid/ethyl 3%-4% micropellets
    acrylate copolymer (capsule)
    71 250 Methacrylic acid/ethyl 4%-5% micropellets
    acrylate copolymer (capsule)
    72 250 Methacrylic acid/ethyl  5%-10% micropellets
    acrylate copolymer (capsule)
    73 250 Methacrylic acid/ethyl 5%-6% micropellets
    acrylate copolymer (capsule)
    74 250 Methacrylic acid/ethyl 6%-7% micropellets
    acrylate copolymer (capsule)
    75 250 Methacrylic acid/ethyl 7%-8% micropellets
    acrylate copolymer (capsule)
    76 250 Methacrylic acid/ethyl 8%-9% micropellets
    acrylate copolymer (capsule)
    77 250 Methacrylic acid/ethyl  9%-10% micropellets
    acrylate copolymer (capsule)
    78 250 Methacrylic acid/ethyl 10%-15% micropellets
    acrylate copolymer (capsule)
    79 250 Methacrylic acid/ethyl 10%-11% micropellets
    acrylate copolymer (capsule)
    80 250 Methacrylic acid/ethyl 11%-12% micropellets
    acrylate copolymer (capsule)
    81 250 Methacrylic acid/ethyl 12%-13% micropellets
    acrylate copolymer (capsule)
    82 250 Methacrylic acid/ethyl 13%-14% micropellets
    acrylate copolymer (capsule)
    83 250 Methacrylic acid/ethyl 14%-15% micropellets
    acrylate copolymer (capsule)
    84 250 Methacrylic acid/ethyl 15%-20% micropellets
    acrylate copolymer (capsule)
    85 250 Methacrylic acid/ethyl 20%-25% micropellets
    acrylate copolymer (capsule)
    86 250 Methacrylic acid/ethyl 25%-30% micropellets
    acrylate copolymer (capsule)
    87 250 Methacrylic acid/ethyl 1%-5% spheroids
    acrylate copolymer (capsule)
    88 250 Methacrylic acid/ethyl 1%-2% spheroids
    acrylate copolymer (capsule)
    89 250 Methacrylic acid/ethyl 2%-3% spheroids
    acrylate copolymer (capsule)
    90 250 Methacrylic acid/ethyl 3%-4% spheroids
    acrylate copolymer (capsule)
    91 250 Methacrylic acid/ethyl 4%-5% spheroids
    acrylate copolymer (capsule)
    92 250 Methacrylic acid/ethyl  5%-10% spheroids
    acrylate copolymer (capsule)
    93 250 Methacrylic acid/ethyl 5%-6% spheroids
    acrylate copolymer (capsule)
    94 250 Methacrylic acid/ethyl 6%-7% spheroids
    acrylate copolymer (capsule)
    95 250 Methacrylic acid/ethyl 7%-8% spheroids
    acrylate copolymer (capsule)
    96 250 Methacrylic acid/ethyl 8%-9% spheroids
    acrylate copolymer (capsule)
    97 250 Methacrylic acid/ethyl  9%-10% spheroids
    acrylate copolymer (capsule)
    98 250 Methacrylic acid/ethyl 10%-15% spheroids
    acrylate copolymer (capsule)
    99 250 Methacrylic acid/ethyl 10%-11% spheroids
    acrylate copolymer (capsule)
    100 250 Methacrylic acid/ethyl 11%-12% spheroids
    acrylate copolymer (capsule)
    101 250 Methacrylic acid/ethyl 12%-13% spheroids
    acrylate copolymer (capsule)
    102 250 Methacrylic acid/ethyl 13%-14% spheroids
    acrylate copolymer (capsule)
    103 250 Methacrylic acid/ethyl 14%-15% spheroids
    acrylate copolymer (capsule)
    104 250 Methacrylic acid/ethyl 15%-20% spheroids
    acrylate copolymer (capsule)
    105 250 Methacrylic acid/ethyl 20%-25% spheroids
    acrylate copolymer (capsule)
    106 250 Methacrylic acid/ethyl 25%-30% spheroids
    acrylate copolymer (capsule)
    107 300 Methacrylic acid/ethyl 1%-5% tablet
    acrylate copolymer
    108 300 Methacrylic acid/ethyl 1%-2% tablet
    acrylate copolymer
    109 300 Methacrylic acid/ethyl 2%-3% tablet
    acrylate copolymer
    110 300 Methacrylic acid/ethyl 3%-4% tablet
    acrylate copolymer
    111 300 Methacrylic acid/ethyl 4%-5% tablet
    acrylate copolymer
    112 300 Methacrylic acid/ethyl  5%-10% tablet
    acrylate copolymer
    113 300 Methacrylic acid/ethyl 5%-6% tablet
    acrylate copolymer
    114 300 Methacrylic acid/ethyl 6%-7% tablet
    acrylate copolymer
    115 300 Methacrylic acid/ethyl 7%-8% tablet
    acrylate copolymer
    116 300 Methacrylic acid/ethyl 8%-9% tablet
    acrylate copolymer
    117 300 Methacrylic acid/ethyl  9%-10% tablet
    acrylate copolymer
    118 300 Methacrylic acid/ethyl 10%-15% tablet
    acrylate copolymer
    119 300 Methacrylic acid/ethyl 10%-11% tablet
    acrylate copolymer
    120 300 Methacrylic acid/ethyl 11%-12% tablet
    acrylate copolymer
    121 300 Methacrylic acid/ethyl 12%-13% tablet
    acrylate copolymer
    122 300 Methacrylic acid/ethyl 13%-14% tablet
    acrylate copolymer
    123 300 Methacrylic acid/ethyl 14%-15% tablet
    acrylate copolymer
    124 300 Methacrylic acid/ethyl 15%-20% tablet
    acrylate copolymer
    125 300 Methacrylic acid/ethyl 20%-25% tablet
    acrylate copolymer
    126 300 Methacrylic acid/ethyl 25%-30% tablet
    acrylate copolymer
    127 300 Methacrylic acid/ethyl 1%-5% capsule
    acrylate copolymer
    128 300 Methacrylic acid/ethyl 1%-2% capsule
    acrylate copolymer
    129 300 Methacrylic acid/ethyl 2%-3% capsule
    acrylate copolymer
    130 300 Methacrylic acid/ethyl 3%-4% capsule
    acrylate copolymer
    131 300 Methacrylic acid/ethyl 4%-5% capsule
    acrylate copolymer
    132 300 Methacrylic acid/ethyl  5%-10% capsule
    acrylate copolymer
    133 300 Methacrylic acid/ethyl 5%-6% capsule
    acrylate copolymer
    134 300 Methacrylic acid/ethyl 6%-7% capsule
    acrylate copolymer
    135 300 Methacrylic acid/ethyl 7%-8% capsule
    acrylate copolymer
    136 300 Methacrylic acid/ethyl 8%-9% capsule
    acrylate copolymer
    137 300 Methacrylic acid/ethyl  9%-10% capsule
    acrylate copolymer
    138 300 Methacrylic acid/ethyl 10%-15% capsule
    acrylate copolymer
    139 300 Methacrylic acid/ethyl 10%-11% capsule
    acrylate copolymer
    140 300 Methacrylic acid/ethyl 11%-12% capsule
    acrylate copolymer
    141 300 Methacrylic acid/ethyl 12%-13% capsule
    acrylate copolymer
    142 300 Methacrylic acid/ethyl 13%-14% capsule
    acrylate copolymer
    143 300 Methacrylic acid/ethyl 14%-15% capsule
    acrylate copolymer
    144 300 Methacrylic acid/ethyl 15%-20% capsule
    acrylate copolymer
    145 300 Methacrylic acid/ethyl 20%-25% capsule
    acrylate copolymer
    146 300 Methacrylic acid/ethyl 25%-30% capsule
    acrylate copolymer
    147 300 Methacrylic acid/ethyl 1%-5% micropellets
    acrylate copolymer (capsule)
    148 300 Methacrylic acid/ethyl 1%-2% micropellets
    acrylate copolymer (capsule)
    149 300 Methacrylic acid/ethyl 2%-3% micropellets
    acrylate copolymer (capsule)
    150 300 Methacrylic acid/ethyl 3%-4% micropellets
    acrylate copolymer (capsule)
    151 300 Methacrylic acid/ethyl 4%-5% micropellets
    acrylate copolymer (capsule)
    152 300 Methacrylic acid/ethyl  5%-10% micropellets
    acrylate copolymer (capsule)
    153 300 Methacrylic acid/ethyl 5%-6% micropellets
    acrylate copolymer (capsule)
    154 300 Methacrylic acid/ethyl 6%-7% micropellets
    acrylate copolymer (capsule)
    155 300 Methacrylic acid/ethyl 7%-8% micropellets
    acrylate copolymer (capsule)
    156 300 Methacrylic acid/ethyl 8%-9% micropellets
    acrylate copolymer (capsule)
    157 300 Methacrylic acid/ethyl  9%-10% micropellets
    acrylate copolymer (capsule)
    158 300 Methacrylic acid/ethyl 10%-15% micropellets
    acrylate copolymer (capsule)
    159 300 Methacrylic acid/ethyl 10%-11% micropellets
    acrylate copolymer (capsule)
    160 300 Methacrylic acid/ethyl 11%-12% micropellets
    acrylate copolymer (capsule)
    161 300 Methacrylic acid/ethyl 12%-13% micropellets
    acrylate copolymer (capsule)
    162 300 Methacrylic acid/ethyl 13%-14% micropellets
    acrylate copolymer (capsule)
    163 300 Methacrylic acid/ethyl 14%-15% micropellets
    acrylate copolymer (capsule)
    164 300 Methacrylic acid/ethyl 15%-20% micropellets
    acrylate copolymer (capsule)
    165 300 Methacrylic acid/ethyl 20%-25% micropellets
    acrylate copolymer (capsule)
    166 300 Methacrylic acid/ethyl 25%-30% micropellets
    acrylate copolymer (capsule)
    167 300 Methacrylic acid/ethyl 1%-5% spheroids
    acrylate copolymer (capsule)
    168 300 Methacrylic acid/ethyl 1%-2% spheroids
    acrylate copolymer (capsule)
    169 300 Methacrylic acid/ethyl 2%-3% spheroids
    acrylate copolymer (capsule)
    170 300 Methacrylic acid/ethyl 3%-4% spheroids
    acrylate copolymer (capsule)
    171 300 Methacrylic acid/ethyl 4%-5% spheroids
    acrylate copolymer (capsule)
    172 300 Methacrylic acid/ethyl  5%-10% spheroids
    acrylate copolymer (capsule)
    173 300 Methacrylic acid/ethyl 5%-6% spheroids
    acrylate copolymer (capsule)
    174 300 Methacrylic acid/ethyl 6%-7% spheroids
    acrylate copolymer (capsule)
    175 300 Methacrylic acid/ethyl 7%-8% spheroids
    acrylate copolymer (capsule)
    176 300 Methacrylic acid/ethyl 8%-9% spheroids
    acrylate copolymer (capsule)
    177 300 Methacrylic acid/ethyl  9%-10% spheroids
    acrylate copolymer (capsule)
    178 300 Methacrylic acid/ethyl 10%-15% spheroids
    acrylate copolymer (capsule)
    179 300 Methacrylic acid/ethyl 10%-11% spheroids
    acrylate copolymer (capsule)
    180 300 Methacrylic acid/ethyl 11%-12% spheroids
    acrylate copolymer (capsule)
    181 300 Methacrylic acid/ethyl 12%-13% spheroids
    acrylate copolymer (capsule)
    182 300 Methacrylic acid/ethyl 13%-14% spheroids
    acrylate copolymer (capsule)
    183 300 Methacrylic acid/ethyl 14%-15% spheroids
    acrylate copolymer (capsule)
    184 300 Methacrylic acid/ethyl 15%-20% spheroids
    acrylate copolymer (capsule)
    185 300 Methacrylic acid/ethyl 20%-25% spheroids
    acrylate copolymer (capsule)
    186 300 Methacrylic acid/ethyl 25%-30% spheroids
    acrylate copolymer (capsule)
    187 350 Methacrylic acid/ethyl 1%-5% tablet
    acrylate copolymer
    188 350 Methacrylic acid/ethyl 1%-2% tablet
    acrylate copolymer
    189 350 Methacrylic acid/ethyl 2%-3% tablet
    acrylate copolymer
    190 350 Methacrylic acid/ethyl 3%-4% tablet
    acrylate copolymer
    191 350 Methacrylic acid/ethyl 4%-5% tablet
    acrylate copolymer
    192 350 Methacrylic acid/ethyl  5%-10% tablet
    acrylate copolymer
    193 350 Methacrylic acid/ethyl 5%-6% tablet
    acrylate copolymer
    194 350 Methacrylic acid/ethyl 6%-7% tablet
    acrylate copolymer
    195 350 Methacrylic acid/ethyl 7%-8% tablet
    acrylate copolymer
    196 350 Methacrylic acid/ethyl 8%-9% tablet
    acrylate copolymer
    197 350 Methacrylic acid/ethyl  9%-10% tablet
    acrylate copolymer
    198 350 Methacrylic acid/ethyl 10%-15% tablet
    acrylate copolymer
    199 350 Methacrylic acid/ethyl 10%-11% tablet
    acrylate copolymer
    200 350 Methacrylic acid/ethyl 11%-12% tablet
    acrylate copolymer
    201 350 Methacrylic acid/ethyl 12%-13% tablet
    acrylate copolymer
    202 350 Methacrylic acid/ethyl 13%-14% tablet
    acrylate copolymer
    203 350 Methacrylic acid/ethyl 14%-15% tablet
    acrylate copolymer
    204 350 Methacrylic acid/ethyl 15%-20% tablet
    acrylate copolymer
    205 350 Methacrylic acid/ethyl 20%-25% tablet
    acrylate copolymer
    206 350 Methacrylic acid/ethyl 25%-30% tablet
    acrylate copolymer
    207 350 Methacrylic acid/ethyl 1%-5% capsule
    acrylate copolymer
    208 350 Methacrylic acid/ethyl 1%-2% capsule
    acrylate copolymer
    209 350 Methacrylic acid/ethyl 2%-3% capsule
    acrylate copolymer
    210 350 Methacrylic acid/ethyl 3%-4% capsule
    acrylate copolymer
    211 350 Methacrylic acid/ethyl 4%-5% capsule
    acrylate copolymer
    212 350 Methacrylic acid/ethyl  5%-10% capsule
    acrylate copolymer
    213 350 Methacrylic acid/ethyl 5%-6% capsule
    acrylate copolymer
    214 350 Methacrylic acid/ethyl 6%-7% capsule
    acrylate copolymer
    215 350 Methacrylic acid/ethyl 7%-8% capsule
    acrylate copolymer
    216 350 Methacrylic acid/ethyl 8%-9% capsule
    acrylate copolymer
    217 350 Methacrylic acid/ethyl  9%-10% capsule
    acrylate copolymer
    218 350 Methacrylic acid/ethyl 10%-15% capsule
    acrylate copolymer
    219 350 Methacrylic acid/ethyl 10%-11% capsule
    acrylate copolymer
    220 350 Methacrylic acid/ethyl 11%-12% capsule
    acrylate copolymer
    221 350 Methacrylic acid/ethyl 12%-13% capsule
    acrylate copolymer
    222 350 Methacrylic acid/ethyl 13%-14% capsule
    acrylate copolymer
    223 350 Methacrylic acid/ethyl 14%-15% capsule
    acrylate copolymer
    224 350 Methacrylic acid/ethyl 15%-20% capsule
    acrylate copolymer
    225 350 Methacrylic acid/ethyl 20%-25% capsule
    acrylate copolymer
    226 350 Methacrylic acid/ethyl 25%-30% capsule
    acrylate copolymer
    227 350 Methacrylic acid/ethyl 1%-5% micropellets
    acrylate copolymer (capsule)
    228 350 Methacrylic acid/ethyl 1%-2% micropellets
    acrylate copolymer (capsule)
    229 350 Methacrylic acid/ethyl 2%-3% micropellets
    acrylate copolymer (capsule)
    230 350 Methacrylic acid/ethyl 3%-4% micropellets
    acrylate copolymer (capsule)
    231 350 Methacrylic acid/ethyl 4%-5% micropellets
    acrylate copolymer (capsule)
    232 350 Methacrylic acid/ethyl  5%-10% micropellets
    acrylate copolymer (capsule)
    233 350 Methacrylic acid/ethyl 5%-6% micropellets
    acrylate copolymer (capsule)
    234 350 Methacrylic acid/ethyl 6%-7% micropellets
    acrylate copolymer (capsule)
    235 350 Methacrylic acid/ethyl 7%-8% micropellets
    acrylate copolymer (capsule)
    236 350 Methacrylic acid/ethyl 8%-9% micropellets
    acrylate copolymer (capsule)
    237 350 Methacrylic acid/ethyl  9%-10% micropellets
    acrylate copolymer (capsule)
    238 350 Methacrylic acid/ethyl 10%-15% micropellets
    acrylate copolymer (capsule)
    239 350 Methacrylic acid/ethyl 10%-11% micropellets
    acrylate copolymer (capsule)
    240 350 Methacrylic acid/ethyl 11%-12% micropellets
    acrylate copolymer (capsule)
    241 350 Methacrylic acid/ethyl 12%-13% micropellets
    acrylate copolymer (capsule)
    242 350 Methacrylic acid/ethyl 13%-14% micropellets
    acrylate copolymer (capsule)
    243 350 Methacrylic acid/ethyl 14%-15% micropellets
    acrylate copolymer (capsule)
    244 350 Methacrylic acid/ethyl 15%-20% micropellets
    acrylate copolymer (capsule)
    245 350 Methacrylic acid/ethyl 20%-25% micropellets
    acrylate copolymer (capsule)
    246 350 Methacrylic acid/ethyl 25%-30% micropellets
    acrylate copolymer (capsule)
    247 350 Methacrylic acid/ethyl 1%-5% spheroids
    acrylate copolymer (capsule)
    248 350 Methacrylic acid/ethyl 1%-2% spheroids
    acrylate copolymer (capsule)
    249 350 Methacrylic acid/ethyl 2%-3% spheroids
    acrylate copolymer (capsule)
    250 350 Methacrylic acid/ethyl 3%-4% spheroids
    acrylate copolymer (capsule)
    251 350 Methacrylic acid/ethyl 4%-5% spheroids
    acrylate copolymer (capsule)
    252 350 Methacrylic acid/ethyl  5%-10% spheroids
    acrylate copolymer (capsule)
    253 350 Methacrylic acid/ethyl 5%-6% spheroids
    acrylate copolymer (capsule)
    254 350 Methacrylic acid/ethyl 6%-7% spheroids
    acrylate copolymer (capsule)
    255 350 Methacrylic acid/ethyl 7%-8% spheroids
    acrylate copolymer (capsule)
    256 350 Methacrylic acid/ethyl 8%-9% spheroids
    acrylate copolymer (capsule)
    257 350 Methacrylic acid/ethyl  9%-10% spheroids
    acrylate copolymer (capsule)
    258 350 Methacrylic acid/ethyl 10%-15% spheroids
    acrylate copolymer (capsule)
    259 350 Methacrylic acid/ethyl 10%-11% spheroids
    acrylate copolymer (capsule)
    260 350 Methacrylic acid/ethyl 11%-12% spheroids
    acrylate copolymer (capsule)
    261 350 Methacrylic acid/ethyl 12%-13% spheroids
    acrylate copolymer (capsule)
    262 350 Methacrylic acid/ethyl 13%-14% spheroids
    acrylate copolymer (capsule)
    263 350 Methacrylic acid/ethyl 14%-15% spheroids
    acrylate copolymer (capsule)
    264 350 Methacrylic acid/ethyl 15%-20% spheroids
    acrylate copolymer (capsule)
    265 350 Methacrylic acid/ethyl 20%-25% spheroids
    acrylate copolymer (capsule)
    266 350 Methacrylic acid/ethyl 25%-30% spheroids
    acrylate copolymer (capsule)
    • EXAMPLES 267-506 Additional Enterically Coated Dosage Forms for Jejunal Release
  • Examples 267-506 are enterically coated dosage forms which can be made in proportions analogous to each corresponding Example among those in Examples 27-266 but using amethacrylic acid/methyl methacrylate copolymer (“MA/MM-C”) as the release-delaying agent in the enteric coat instead of amethacrylic acid/ethyl acrylate copolymer. The methacrylic acid/methyl methacrylate copolymer may be any such suitable copolymer, for example, Eudragit® L100 or Eudragit® L 12.5. As formulated, the MGBG core of the tablet, micropellets, or spheroids may optionally be combined with one or more excipients as disclosed herein or known in the art. Itis expected that the formulations below will bypass the stomach and release MGBG primarily in the jejunum. Standard USP or in vitro assays, as well as in vivo models, which are known in the art, may be used to confirm this effect. When using USP or in vitro models, it is expected that successful delayed-release dosage forms will dissolve between about pH 6 and about pH7. When using in vivo models, it is expected that exceptionally successful delayed-release dosage forms will yield reduced gastrointestinal side effects, such as nausea, emesis, gastric irritation, ulceration, and/or bleeding, and looses tool and/or diarrhea in subjects. It is also expected that the Tmax will be right-shifted (on a concentration-versus-time graph having a concentration on the vertical axis and time on the horizontal axis, i.e., delayed) by at least two hours; in certain embodiments, the Tmax will be right-shifted by two to twelve hours.
  • Additionally, the amounts of MGBG may be varied as needed according to methods known in the art. Different proportions of MGBG and filler may be used to achieve, for example—using the same enteric coating proportions—a 50, 75, 100, 150, 200, 225, 325, 375, 400, or 450 mg dosage form. Additional excipients such as lubricants (for example, talc), compression protectants (for example, triethyl citrate or a polyethylene glycol such as macrogol 6000), etc., may be added. Table 4 below provides additional enterically coated dosage forms.
  • TABLE 4
    MA/MM-C
    Enteric Enteric
    Coating as Coating
    MGBG % of Total on
    Dose, Weight of Dosage
    Ex. mg Formulation Form:
    267 250 1%-5% tablet
    268 250 1%-2% tablet
    269 250 2%-3% tablet
    270 250 3%-4% tablet
    271 250 4%-5% tablet
    272 250  5%-10% tablet
    273 250 5%-6% tablet
    274 250 6%-7% tablet
    275 250 7%-8% tablet
    276 250 8%-9% tablet
    277 250  9%-10% tablet
    278 250 10%-15% tablet
    279 250 10%-11% tablet
    280 250 11%-12% tablet
    281 250 12%-13% tablet
    282 250 13%-14% tablet
    283 250 14%-15% tablet
    284 250 15%-20% tablet
    285 250 20%-25% tablet
    286 250 25%-30% tablet
    287 250 1%-5% capsule
    288 250 1%-2% capsule
    289 250 2%-3% capsule
    290 250 3%-4% capsule
    291 250 4%-5% capsule
    292 250  5%-10% capsule
    293 250 5%-6% capsule
    294 250 6%-7% capsule
    295 250 7%-8% capsule
    296 250 8%-9% capsule
    297 250  9%-10% capsule
    298 250 10%-15% capsule
    299 250 10%-11% capsule
    300 250 11%-12% capsule
    301 250 12%-13% capsule
    302 250 13%-14% capsule
    303 250 14%-15% capsule
    304 250 15%-20% capsule
    305 250 20%-25% capsule
    306 250 25%-30% capsule
    307 250 1%-5% micropellets (capsule)
    308 250 1%-2% micropellets (capsule)
    309 250 2%-3% micropellets (capsule)
    310 250 3%-4% micropellets (capsule)
    311 250 4%-5% micropellets (capsule)
    312 250  5%-10% micropellets (capsule)
    313 250 5%-6% micropellets (capsule)
    314 250 6%-7% micropellets (capsule)
    315 250 7%-8% micropellets (capsule)
    316 250 8%-9% micropellets (capsule)
    317 250  9%-10% micropellets (capsule)
    318 250 10%-15% micropellets (capsule)
    319 250 10%-11% micropellets (capsule)
    320 250 11%-12% micropellets (capsule)
    321 250 12%-13% micropellets (capsule)
    322 250 13%-14% micropellets (capsule)
    323 250 14%-15% micropellets (capsule)
    324 250 15%-20% micropellets (capsule)
    325 250 20%-25% micropellets (capsule)
    326 250 25%-30% micropellets (capsule)
    327 250 1%-5% spheroids (capsule)
    328 250 1%-2% spheroids (capsule)
    329 250 2%-3% spheroids (capsule)
    330 250 3%-4% spheroids (capsule)
    331 250 4%-5% spheroids (capsule)
    332 250  5%-10% spheroids (capsule)
    333 250 5%-6% spheroids (capsule)
    334 250 6%-7% spheroids (capsule)
    335 250 7%-8% spheroids (capsule)
    336 250 8%-9% spheroids (capsule)
    337 250  9%-10% spheroids (capsule)
    338 250 10%-15% spheroids (capsule)
    339 250 10%-11% spheroids (capsule)
    340 250 11%-12% spheroids (capsule)
    341 250 12%-13% spheroids (capsule)
    342 250 13%-14% spheroids (capsule)
    343 250 14%-15% spheroids (capsule)
    344 250 15%-20% spheroids (capsule)
    345 250 20%-25% spheroids (capsule)
    346 250 25%-30% spheroids (capsule)
    347 300 1%-5% tablet
    348 300 1%-2% tablet
    349 300 2%-3% tablet
    350 300 3%-4% tablet
    351 300 4%-5% tablet
    352 300  5%-10% tablet
    353 300 5%-6% tablet
    354 300 6%-7% tablet
    355 300 7%-8% tablet
    356 300 8%-9% tablet
    357 300  9%-10% tablet
    358 300 10%-15% tablet
    359 300 10%-11% tablet
    360 300 11%-12% tablet
    361 300 12%-13% tablet
    362 300 13%-14% tablet
    363 300 14%-15% tablet
    364 300 15%-20% tablet
    365 300 20%-25% tablet
    366 300 25%-30% tablet
    367 300 1%-5% capsule
    368 300 1%-2% capsule
    369 300 2%-3% capsule
    370 300 3%-4% capsule
    371 300 4%-5% capsule
    372 300  5%-10% capsule
    373 300 5%-6% capsule
    374 300 6%-7% capsule
    375 300 7%-8% capsule
    376 300 8%-9% capsule
    377 300  9%-10% capsule
    378 300 10%-15% capsule
    379 300 10%-11% capsule
    380 300 11%-12% capsule
    381 300 12%-13% capsule
    382 300 13%-14% capsule
    383 300 14%-15% capsule
    384 300 15%-20% capsule
    385 300 20%-25% capsule
    386 300 25%-30% capsule
    387 300 1%-5% micropellets (capsule)
    388 300 1%-2% micropellets (capsule)
    389 300 2%-3% micropellets (capsule)
    390 300 3%-4% micropellets (capsule)
    391 300 4%-5% micropellets (capsule)
    392 300  5%-10% micropellets (capsule)
    393 300 5%-6% micropellets (capsule)
    394 300 6%-7% micropellets (capsule)
    395 300 7%-8% micropellets (capsule)
    396 300 8%-9% micropellets (capsule)
    397 300  9%-10% micropellets (capsule)
    398 300 10%-15% micropellets (capsule)
    399 300 10%-11% micropellets (capsule)
    400 300 11%-12% micropellets (capsule)
    401 300 12%-13% micropellets (capsule)
    402 300 13%-14% micropellets (capsule)
    403 300 14%-15% micropellets (capsule)
    404 300 15%-20% micropellets (capsule)
    405 300 20%-25% micropellets (capsule)
    406 300 25%-30% micropellets (capsule)
    407 300 1%-5% spheroids (capsule)
    408 300 1%-2% spheroids (capsule)
    409 300 2%-3% spheroids (capsule)
    410 300 3%-4% spheroids (capsule)
    411 300 4%-5% spheroids (capsule)
    412 300  5%-10% spheroids (capsule)
    413 300 5%-6% spheroids (capsule)
    414 300 6%-7% spheroids (capsule)
    415 300 7%-8% spheroids (capsule)
    416 300 8%-9% spheroids (capsule)
    417 300  9%-10% spheroids (capsule)
    418 300 10%-15% spheroids (capsule)
    419 300 10%-11% spheroids (capsule)
    420 300 11%-12% spheroids (capsule)
    421 300 12%-13% spheroids (capsule)
    422 300 13%-14% spheroids (capsule)
    423 300 14%-15% spheroids (capsule)
    424 300 15%-20% spheroids (capsule)
    425 300 20%-25% spheroids (capsule)
    426 300 25%-30% spheroids (capsule)
    427 350 1%-5% tablet
    428 350 1%-2% tablet
    429 350 2%-3% tablet
    430 350 3%-4% tablet
    431 350 4%-5% tablet
    432 350  5%-10% tablet
    433 350 5%-6% tablet
    434 350 6%-7% tablet
    435 350 7%-8% tablet
    436 350 8%-9% tablet
    437 350  9%-10% tablet
    438 350 10%-15% tablet
    439 350 10%-11% tablet
    440 350 11%-12% tablet
    441 350 12%-13% tablet
    442 350 13%-14% tablet
    443 350 14%-15% tablet
    444 350 15%-20% tablet
    445 350 20%-25% tablet
    446 350 25%-30% tablet
    447 350 1%-5% capsule
    448 350 1%-2% capsule
    449 350 2%-3% capsule
    450 350 3%-4% capsule
    451 350 4%-5% capsule
    452 350  5%-10% capsule
    453 350 5%-6% capsule
    454 350 6%-7% capsule
    455 350 7%-8% capsule
    456 350 8%-9% capsule
    457 350  9%-10% capsule
    458 350 10%-15% capsule
    459 350 10%-11% capsule
    460 350 11%-12% capsule
    461 350 12%-13% capsule
    462 350 13%-14% capsule
    463 350 14%-15% capsule
    464 350 15%-20% capsule
    465 350 20%-25% capsule
    466 350 25%-30% capsule
    467 350 1%-5% micropellets (capsule)
    468 350 1%-2% micropellets (capsule)
    469 350 2%-3% micropellets (capsule)
    470 350 3%-4% micropellets (capsule)
    471 350 4%-5% micropellets (capsule)
    472 350  5%-10% micropellets (capsule)
    473 350 5%-6% micropellets (capsule)
    474 350 6%-7% micropellets (capsule)
    475 350 7%-8% micropellets (capsule)
    476 350 8%-9% micropellets (capsule)
    477 350  9%-10% micropellets (capsule)
    478 350 10%-15% micropellets (capsule)
    479 350 10%-11% micropellets (capsule)
    480 350 11%-12% micropellets (capsule)
    481 350 12%-13% micropellets (capsule)
    482 350 13%-14% micropellets (capsule)
    483 350 14%-15% micropellets (capsule)
    484 350 15%-20% micropellets (capsule)
    485 350 20%-25% micropellets (capsule)
    486 350 25%-30% micropellets (capsule)
    487 350 1%-5% spheroids (capsule)
    488 350 1%-2% spheroids (capsule)
    489 350 2%-3% spheroids (capsule)
    490 350 3%-4% spheroids (capsule)
    491 350 4%-5% spheroids (capsule)
    492 350  5%-10% spheroids (capsule)
    493 350 5%-6% spheroids (capsule)
    494 350 6%-7% spheroids (capsule)
    495 350 7%-8% spheroids (capsule)
    496 350 8%-9% spheroids (capsule)
    497 350  9%-10% spheroids (capsule)
    498 350 10%-15% spheroids (capsule)
    499 350 10%-11% spheroids (capsule)
    500 350 11%-12% spheroids (capsule)
    501 350 12%-13% spheroids (capsule)
    502 350 13%-14% spheroids (capsule)
    503 350 14%-15% spheroids (capsule)
    504 350 15%-20% spheroids (capsule)
    505 350 20%-25% spheroids (capsule)
    506 350 25%-30% spheroids (capsule)
  • Further analogous examples for release in the colon may be made by substituting ethyl acrylate/methyl methacrylate/methacrylic acid copolymer as the release-delaying agent in the enteric coat instead of a methacrylic acid/ethyl acrylate or methacrylic acid/methyl methacrylate copolymer. The ethyl acrylate/methyl methacrylate/methacrylic acid copolymer may be any such suitable copolymer, for example, Eudragit® S 100, Eudragit® S 12.5 or Eudragit® FS 30-D. As formulated, the MGBG core of the tablet, micropellets, or spheroids may optionally be combined with one or more excipients as disclosed herein or known in the art. It is expected that the formulations below will bypass the stomach and release MGBG primarily in the colon. Standard USP or in vitro assays, as well as in vivo models, which are known in the art, may be used to confirm this effect. When using USP or in vitro models, it is expected that successful delayed-release dosage forms will dissolve above about pH 7. When using in vivo models, it is expected that exceptionally successful delayed-release dosage forms will yield reduced gastrointestinal side effects, such as nausea, emesis, gastric irritation, ulceration, and/or bleeding, and loose stool and/or diarrhea in subjects. It is also expected that the Tmax will be right-shifted (on a concentration-versus-time graph having a concentration on the vertical axis and time on the horizontal axis, i.e., delayed) by at least three hours; in certain embodiments, the Tmax will be right-shifted by three to twenty-four hours.
    • EXAMPLE 507 Enterically Coated Capsules for Delayed-Release
  • MGBG was encapsulated neat (undiluted) using Torpac gelatin capsules. Methylglyoxal bis (guanylhydrazone) dihydrochloride hydrate (MGBG) was used; a correction factor of 1.49 (to account for the dihydrochloride salt/monohydrate) was used when calculating the required amount of test article. The amount in each capsule was 10, 30, or 100 mg/kg, calculated based on subject body weight. Capsules were enterically coated with Eudragit® L100-55, as required, using a Torpac Pro-Coater® according to the standard dip procedure provided by the manufacturer (see www.torpac.com, go to “Reference/ProCoater Manual.pdf” or contact Torpac, Inc. for detailed instructions).
    • Comparative Examples: Immediate-Release Dosage Forms
  • Solid MGBG or a salt thereof may be passed through one or more sieve screens to produce a consistent particle size. Excipients, too, may be passed through a sieve. Appropriate weights of compounds, sufficient to achieve the target dosage per capsule, may be measured and added to a mixing container or apparatus, and the blend is then mixed until uniform. Blend uniformity testing may be done by, for example, sampling 3 points within the container (top, middle, and bottom) and testing each sample for potency. A test result of 95-105% of target, with an RSD of 5%, would be considered ideal; optionally, additional blend time may be allowed to achieve a uniform blend. Upon acceptable blend uniformity results, a measured aliquot of this stock formulation may be separated to manufacture the lower strengths. Magnesium stearate may be passed through a sieve, collected, weighed, added to the blender as a lubricant, and mixed until dispersed. The final blend is weighed and reconciled. Capsules may then be opened, and blended materials flood fed into the body of the capsules using a spatula. Capsules in trays may be tamped to settle the blend in each capsule to assure uniform target fill weight, then sealed by combining the filled bodies with the caps.
    • Comparative Example C1
  • 300 mg Capsule: Total fill weight of capsule is 500 mg, not including capsule weight. The target compound dosage is 300 mg per capsule but may be adjusted to account for the weight of counterions and/or solvates if given as a salt or solvated polymorph thereof. In such a case, the weight of the other excipients, typically the filler, is reduced.
  • Quantity
    per Capsule,
    Ingredient mg
    MGBG 300.00
    Lactose monohydrate 179.00
    Silicon dioxide 3.00
    Crospovidone 15.00
    Magnesium stearate 3.00
    (vegetable grade)
    • Comparative Example C2
  • 150 mg Capsule: Total fill weight of capsule is 300 mg, not including capsule weight. The target compound dosage is 150 mg per capsule but may be adjusted to account for the weight of counterions and/or solvates if given as a salt or solvated polymorph thereof. In such a case, the weight of the other excipients, typically the filler, is reduced.
  • Quantity
    per Capsule,
    Ingredient mg
    MGBG 150
    Microcrystalline 147
    cellulose (MCC)
    Magnesium stearate 3
    (vegetable grade)
  • It is expected that when tested in humans or animals, the comparative immediate-release examples above will exhibit several of the following characteristics when compared to a controlled-release dosage form: shorter half-life, higher Cmax, shorter Tmax, and higher frequency and/or severity of side effects including gastrointestinal side effects.
    • In Vivo Evaluation of Enterically Coated Capsules
  • A comparative study of single, escalating doses of enterically coated MGBG capsules was undertaken to ascertain the feasibility and pharmacologic effect of delaying the release of MGBG until the capsule has passed the stomach. The dog was selected as the test species, both because it is typically the most gastrointestinally sensitive species and because it has consistently demonstrated dose-limiting emesis upon oral administration of standard capsules containing MGBG. Six male beagle dogs aged approximately 4 years 8 months to 5 years 6 months and weighing 10.95 to 12.85 kg (Covance Research Products) were weighed, acclimatized, and randomly assigned to treatment groups as shown below in Table 5.
  • TABLE 5
    No. of Animals
    Enterically-
    Group Dose, Standard Coated
    No. mpk Capsule Capsule
    1 10 3 —
    2 10 — 3
    3 30 3 —
    4 30 — 3
    5 100 3 —
    6 100 — 3
  • The test article was administered once at each dose level during the study orally via capsule. Duplicate sets of enteric-coated capsules were prepared for each animal at each dose and evaluated for dissolution. The duplicate sample was placed in a 0.1 N HCl solution and stirred using a magnetic stir bar and stir plate for at least two hours. Triplicate samples of the acidic dissolution media were collected for analysis of MGBG content. The capsule was transferred to a phosphate buffer solution (pH 6.8) and stirred using a magnetic stir bar and stir plate for approximately one hour. The capsule was visually inspected for signs of deformation. If dissolution criteria were not met—≤10% the concentration of the capsule in solution; visual inspection showing deformation of the capsule and release of the product—the enteric-coated capsule preparation was repeated in duplicate until the results of the duplicate test met the study requirements. Non-enterically coated (immediate-release) reference capsules were also prepared.
  • Dose levels were selected based on previous studies in dogs, which exhibited dose-limiting emesis when administered single doses of MGBG in standard capsules ≥10 mg/kg. The dose levels for the treated groups were 10, 30, and 100 mg/kg administered on Days 1, 8, and 33, respectively, in standard or enteric-coated gelatin capsules. Individual doses were based on the most recent body weights. The animals were administered the next escalating dose of the test article after completing a 7-day (between doses 1 and 2) or 25-day (between doses 2 and 3) wash-out period.
  • Observations for morbidity, mortality, injury, and the availability of food and water were conducted twice daily for all animals. Observations for clinical signs were conducted predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 4, 8, and 24 hours postdose on Days 1, 8, and 33, and daily on non-dosing days. On occasion, clinical observations were recorded at unscheduled intervals. Body weights were measured and recorded on Days 1-4, 5, 12, and 32.
  • Sample collection and handling. Blood samples (approximately 1 mL) were collected from all animals for determination of the plasma concentrations of the test article. Samples were collected predose and at 0.5, 1, 2, 4, 8, and 24 hours postdose on Day 1, and predose and at 0.5, 1, 2, 4, 8, 12, 18, and 24 hours postdose on Days 8 and 33. The animals were not fasted before blood collection. Samples were placed in tubes containing lithium heparin as an anticoagulant. The blood samples were collected on wet ice and centrifuged for 10 minutes at 3000 g RCF under refrigeration at 4° C. At study termination, all animals were euthanized.
  • Analysis. Plasma samples were separated into two aliquots (approximately 200 μL per aliquot) following centrifugation and placed in tightly capped, pre-labeled, plastic vials and were stored frozen at −50 to −90° C. until analyzed. The vial label included the study number, relative study day, animal number, and the date and time interval of collection.
  • Pharmacodynamic results. One objective of this study was to compare tolerability and systemic exposure when the test article was administered by standard versus enteric-coated gelatin capsules. All dose levels were tolerated, with all animals surviving to study termination. MGBG-related clinical observations, with the highest incidence for salivation and emesis/vomitus, were primarily noted in the dogs administered standard capsules and most notably at 100 mg/kg/day. Enteric coating of MGBG capsules, therefore, appeared to be effective in preventing gastrointestinal adverse effects. See Table 6 below.
  • TABLE 6
    Incidence Incidence of
    of Emesis Emesis from
    Dose from Enteric-
    Level Standard Coated
    (mpk) Capsules (%) Capsules (%)
    10 0 (0) 0 (0)
    30 2 (67) 1 (33)
    100 3 (100) 0 (0)
  • Pharmacokinetic Results. Mean time-versus-concentration curves for standard and enterically coated capsules are presented in FIG. 2 (10 mg/kg), FIG. 3 (30 mg/kg) and FIG. 4 (100 mg/kg) and FIG. 5 (all doses on same axes). Plasma concentrations with the standard capsules generally declined rapidly during the first 4 hours and then gradually from 4 to 24 hours, while plasma concentrations with the enteric-coated capsules increased slowly from 0 to 8 (or 12) hours and then declined gradually. Measurable concentrations were observed after 24-hours in all groups and both capsule types. Tmax ranged from 2.33 to 3.5 hours for standard capsules and from 8 to 13.3 hours for enteric-coated capsules. Mean Cmax and mean AUC0-t exposure to MGBG increased with an increasing dose for both capsule types. Cmax was sometimes greater than dose-proportional with the standard capsule and dose-proportional with the enteric-coated capsules. AUC0-t was dose-proportional for both capsule types. The dogs dosed with the standard capsules had higher mean exposures at all dose levels, compared to dogs dosed with the enteric-coated capsules, even at 100 mg/kg/day with the incidence of emesis/vomitus. Cmax for the standard capsule ranged from 510 to 22,090 ng/mL, and 128 to 1,580 ng/mL for the enteric-coated capsules. AUC0-t for the standard capsule ranged from 3,370 to 33,000 ng·hr/mL, and 2,010 to 23,700 ng·hr/mL for the enteric-coated capsules. Mean data and standard deviations are given below in Table 7; see also FIG. 6, where Tmax and Cmax are compared across doses.
  • TABLE 7
    Dose Tmax Cmax AUC0-t
    (mg/kg) (h) (ng/mL) (ng*hr/mL)
    10 mg/kg 3.50 ± 3.97  510 ± 492 3370 ± 1210
    Standard
    10 mg/kg 8 128 ± 65 2010 ± 1240
    Enteric
    30 mg/kg 2.33 ± 1.53 1200 ± 456 9500 ± 1780
    Standard
    30 mg/kg 13.3 ± 10.1  403 ± 150 5040 ± 1640
    Enteric
    100 mg/kg 3.00 ± 4.33  22090 ± 18392 33000 ± 12922
    Standard
    100 mg/kg 10.7 ± 2.31 1580 ± 413 23700 ± 4100 
    Enteric
  • Comparison of mean AUC0-t between the enteric-coated capsules and standard capsules within dose groups resulted in relative bioavailability estimates that ranged from 53.1% to 71.8%. Dose proportionality was also analyzed. The ratio of high to low mean Cmax/Dose values was found to be 5.3 across the standard capsule dosages and 1.2 across the same dosages in enterically-coated capsules. In contrast, the ratio of high to low mean AUC0-t/Dose (relative bioavailability) values was found to be 1.1 across the standard capsule dosages and 1.4 across the same dosages in enterically-coated capsules. This indicates that MGBG exhibited greater than dose-proportional changes in Cmax after administration of the standard capsule and dose-proportional increases in Cmax with a dose for the enteric-coated capsule.
  • All references cited herein are incorporated by reference as if written herein in their entireties. U.S. Pat. Nos. 4,587,118, 6,274,171, 4,966,768, 6,874,207, and 5,508,042, as well as Remington: the Science and Practice of Pharmacy, 21st Ed., Am J Pharm Educ. 2006 Jun. 15; 70(3): 71, are explicitly incorporated by reference as if written herein.
  • From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims (30)

1. A controlled-release oral pharmaceutical dosage form comprising MGBG.
2. The oral pharmaceutical dosage form as recited in claim 1, wherein the dosage form is chosen from extended-release, sustained-release, delayed-release, and pulsed-release.
3. The oral pharmaceutical dosage form as recited in claim 2, wherein the dosage form is a delayed-release tablet or a delayed-release capsule.
4. The oral pharmaceutical dosage form as recited in claim 3, wherein the dosage form is a delayed-release capsule comprising an enteric coating.
5. The oral pharmaceutical dosage form as recited in claim 4, comprising about 25 to about 350 mg MGBG.
6. The oral pharmaceutical dosage form as recited in claim 4, wherein the enteric coating begins to substantially dissolve, and drug release commences, in the duodenum.
7. The oral pharmaceutical dosage form as recited in claim 4, wherein the enteric coating begins to substantially dissolve and drug release commences at about or more hours after ingestion.
8. The oral pharmaceutical dosage form as recited in claim 4, wherein the enteric coating begins to substantially dissolve and drug release commences at about 1 or more hours after ingestion.
9. The oral pharmaceutical composition as recited in claim 4, which has reduced side effects in patients compared to a non-enterically-coated capsule.
10. The oral pharmaceutical composition as recited in claim 4, which has reduced dose-limiting side effects as compared to a non-enterically-coated capsule.
11. The oral pharmaceutical dosage form as recited in claim 9, wherein said side effects are gastrointestinal.
12. The oral pharmaceutical composition as recited in claim 11, which is orally bioavailable.
13. The oral pharmaceutical dosage form as recited in claim 11, wherein said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.
14. The oral pharmaceutical composition as recited in claim 4, wherein emesis is reduced by at least 50% compared to a reference standard that is not enterically coated.
15. The oral pharmaceutical composition as recited in claim 4, wherein emesis is reduced by at least 70% compared to a reference standard that is not enterically coated.
16. The oral pharmaceutical composition as recited in claim 4, wherein emesis is reduced by at least 80% compared to a reference standard that is not enterically coated.
17. The oral pharmaceutical dosage form as recited in claim 11, wherein said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and inhibition of differentiation of stem or progenitor cells into epithelial lumen cells.
18. The oral pharmaceutical dosage form as recited in claim 4, which exhibits dose-proportional increases in Cmax and AUC.
19. The oral pharmaceutical dosage form as recited in claim 4, which exhibits a half life comparable to a reference standard that is not enterically coated.
20. A delayed-release oral pharmaceutical dosage form comprising MGBG dihydrochloride hydrate in capsule enterically-coated for duodenal release.
21. The delayed-release oral pharmaceutical dosage form as recited in claim 20, wherein the enteric coating comprises a methacrylic acid/ethyl acrylate copolymer.
22. The delayed-release oral pharmaceutical dosage form as recited in claim 21, wherein the methacrylic acid/ethyl acrylate copolymer is Eudragit® L100-55.
23. The delayed-release oral pharmaceutical dosage form as recited in claim 21, wherein the capsule comprises 25-350 mg MGBG.
24. The delayed-release oral pharmaceutical dosage form as recited in claim 23, reduced gastrointestinal side effects in patients compared to a non-enterically-coated capsule.
25. A method of treating pain comprising the administration, to a patient in need thereof, a delayed-release oral pharmaceutical dosage form comprising MGBG.
26. The method as recited in claim 25, wherein said delayed-release oral pharmaceutical dosage form is an enterically-coated capsule comprising MGBG.
27. The method as recited in claim 26, wherein the administration of the enterically-coated capsule comprising MGBG results in a reduction of gastrointestinal side effects when compared to a reference standard that is not enterically coated.
28. The method as recited in claim 27, wherein said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.
29. The method as recited in claim 28, wherein said gastrointestinal side effect is emesis.
30. The method as recited in claim 27, wherein MGBG is administered at a dosage level which would result in dose-limiting side effects if administered as a non-enteric coated dosage form.
US17/111,895 2011-01-19 2020-12-04 Controlled release oral pharmaceutical dosage forms comprising mgbg Abandoned US20210085625A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/111,895 US20210085625A1 (en) 2011-01-19 2020-12-04 Controlled release oral pharmaceutical dosage forms comprising mgbg

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161434269P 2011-01-19 2011-01-19
US13/354,076 US8858991B2 (en) 2011-01-19 2012-01-19 Delayed release oral pharmaceutical dosage forms comprising MGBG
US14/480,847 US9668988B2 (en) 2011-01-19 2014-09-09 Controlled release oral pharmaceutical dosage forms comprising MGBG
US15/583,697 US10881626B2 (en) 2011-01-19 2017-05-01 Controlled release oral pharmaceutical dosage forms comprising MGBG
US17/111,895 US20210085625A1 (en) 2011-01-19 2020-12-04 Controlled release oral pharmaceutical dosage forms comprising mgbg

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/583,697 Continuation US10881626B2 (en) 2011-01-19 2017-05-01 Controlled release oral pharmaceutical dosage forms comprising MGBG

Publications (1)

Publication Number Publication Date
US20210085625A1 true US20210085625A1 (en) 2021-03-25

Family

ID=46516367

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/354,076 Active US8858991B2 (en) 2011-01-19 2012-01-19 Delayed release oral pharmaceutical dosage forms comprising MGBG
US14/480,847 Active US9668988B2 (en) 2011-01-19 2014-09-09 Controlled release oral pharmaceutical dosage forms comprising MGBG
US15/583,697 Active US10881626B2 (en) 2011-01-19 2017-05-01 Controlled release oral pharmaceutical dosage forms comprising MGBG
US17/111,895 Abandoned US20210085625A1 (en) 2011-01-19 2020-12-04 Controlled release oral pharmaceutical dosage forms comprising mgbg

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US13/354,076 Active US8858991B2 (en) 2011-01-19 2012-01-19 Delayed release oral pharmaceutical dosage forms comprising MGBG
US14/480,847 Active US9668988B2 (en) 2011-01-19 2014-09-09 Controlled release oral pharmaceutical dosage forms comprising MGBG
US15/583,697 Active US10881626B2 (en) 2011-01-19 2017-05-01 Controlled release oral pharmaceutical dosage forms comprising MGBG

Country Status (10)

Country Link
US (4) US8858991B2 (en)
EP (1) EP2665471B1 (en)
CA (1) CA2825014C (en)
DK (1) DK2665471T3 (en)
ES (1) ES2662373T3 (en)
HU (1) HUE038543T2 (en)
NO (1) NO2665471T3 (en)
PL (1) PL2665471T3 (en)
PT (1) PT2665471T (en)
WO (1) WO2012100043A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112659A2 (en) 2007-03-09 2008-09-18 Pathologica Llc Regulation of osteopontin
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
CN102686222B (en) 2009-07-16 2015-06-24 帕萨罗杰卡有限公司 Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
ES2662373T3 (en) 2011-01-19 2018-04-06 Pathologica, Llc. Oral dosage controlled pharmaceutical dosage forms comprising MGBG
JP6370804B2 (en) 2013-01-08 2018-08-08 パソロジカ エルエルシー Methods and compositions for the treatment of demyelinating diseases
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
WO2019217973A1 (en) 2018-05-11 2019-11-14 Rhode Island Hospital Compositions and methods for treating articulating joint disorders with nucleoside reverse transcriptase inhibitors
KR20210137434A (en) 2019-01-25 2021-11-17 브라운 유니버시티 Compositions and methods for treating, preventing or reversing age-related inflammation and disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022242A1 (en) * 2001-06-23 2003-01-30 David Anderson Particles with improved solubilization capacity
US20060177506A1 (en) * 2003-03-17 2006-08-10 Shigeo Yanai Release control compositions
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US8258186B2 (en) * 2009-07-16 2012-09-04 Pathologica, Llc Pharmaceutical for oral delivery comprising MGBG
US8858991B2 (en) * 2011-01-19 2014-10-14 Pathologica Llc Delayed release oral pharmaceutical dosage forms comprising MGBG
US9675566B2 (en) * 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4520031A (en) * 1981-06-01 1985-05-28 The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone
CA1338366C (en) 1984-12-26 1996-06-04 Algis Anilionis Efficient prokaryotic expression system
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US6169115B1 (en) 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
JP2003522799A (en) 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス Oral, Nasal and Pulmonary Formulations of Copolymer 1
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical Sustained-release medicines
EP1425380A4 (en) 2001-08-15 2004-12-22 Univ California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1389480A1 (en) 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
WO2004069174A2 (en) 2003-01-31 2004-08-19 Slil Biomedical Corporation Monitoring and treatment of amyotrophic lateral sclerosis
PL1613288T3 (en) 2003-04-08 2009-07-31 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
RU2375048C2 (en) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Pharmacological composition with swelling coating
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20050113455A1 (en) 2003-10-22 2005-05-26 Bergeron Raymond J.Jr. Method and composition for amelioration of pain
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
WO2006081431A2 (en) 2005-01-28 2006-08-03 Xanthus Pharmaceuticals, Inc. Compounds for treating inflammatory and demyelinating diseases
WO2007016338A2 (en) 2005-07-29 2007-02-08 Goverment Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
PL1916995T5 (en) * 2005-07-29 2022-10-31 Stichting Groningen Centre For Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof
AU2006292063B2 (en) * 2005-09-23 2012-12-06 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
EP2164698A1 (en) 2007-03-09 2010-03-24 Sustainable Solutions, Inc. Regenerated cotton board material and method of manufacture
WO2009018368A1 (en) 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
JP2012505257A (en) 2008-10-13 2012-03-01 バイオヴィスタ，インコーポレイテッド Compositions and methods for the treatment of multiple sclerosis
US9498431B2 (en) * 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2283830A1 (en) * 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
EP2343075A1 (en) 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease
TWI590821B (en) * 2011-01-18 2017-07-11 輝瑞有限公司 Solid molecular dispersion
JP6370804B2 (en) 2013-01-08 2018-08-08 パソロジカ エルエルシー Methods and compositions for the treatment of demyelinating diseases

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US20030022242A1 (en) * 2001-06-23 2003-01-30 David Anderson Particles with improved solubilization capacity
US20060177506A1 (en) * 2003-03-17 2006-08-10 Shigeo Yanai Release control compositions
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8258186B2 (en) * 2009-07-16 2012-09-04 Pathologica, Llc Pharmaceutical for oral delivery comprising MGBG
US9616035B2 (en) * 2009-07-16 2017-04-11 Pathologica, Llc Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
US9675566B2 (en) * 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US20170290788A1 (en) * 2009-07-16 2017-10-12 Pathological LLC Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US10292950B2 (en) * 2009-07-16 2019-05-21 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8858991B2 (en) * 2011-01-19 2014-10-14 Pathologica Llc Delayed release oral pharmaceutical dosage forms comprising MGBG
US9668988B2 (en) * 2011-01-19 2017-06-06 Pathologica Llc Controlled release oral pharmaceutical dosage forms comprising MGBG
US10881626B2 (en) * 2011-01-19 2021-01-05 Pathologica Llc Controlled release oral pharmaceutical dosage forms comprising MGBG

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Allen et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th Edition, 1995, Williams and Wilkens, Media, PA , pages 260, 262 and 268-271. (Year: 1995) *
Hoffman, Inherited Metabolic Diorders, obtained online at: https://www.webmd.com/a-to-z-guides/inherited-metabolic-disorder-types-and-treatments, downloaded on September 14 2022. (Year: 2020) *
Hotamisligil, G. Inflammation and metabolic disorders. Nature 444, 860–867 (2006). (Year: 2006) *
Montana DPHHS, Neurological Disorders, obtained online at: https://dphhs.mt.gov/schoolhealth/chronichealth/neurologicaldisorders#:~:text=Neurological%20disabilities%20include%20a%20wide,are%20congenital%2C%20emerging%20before%20birth, downloaded on September 14 2022. (Year: 2022) *
TopDoctors, Neurological disorders, obtained online at: https://www.topdoctors.co.uk/medical-dictionary/neurological-disorders, downloaded on September 14 2022. (Year: 2022) *
UTSouthwestern Medical Center, Respiratory Disorders, obtained online at: https://utswmed.org/conditions-treatments/respiratory-disorders/#:~:text=Respiratory%20disorders%2C%20or%20lung%20diseases,%2C%20and%20life%2Dthreatening%20conditions, downloaded on September 14 2022. (Year: 2022) *

Also Published As

Publication number Publication date
EP2665471A2 (en) 2013-11-27
WO2012100043A2 (en) 2012-07-26
US20120269891A1 (en) 2012-10-25
US8858991B2 (en) 2014-10-14
ES2662373T3 (en) 2018-04-06
WO2012100043A3 (en) 2012-10-18
CA2825014A1 (en) 2012-07-26
US10881626B2 (en) 2021-01-05
DK2665471T3 (en) 2018-03-19
US9668988B2 (en) 2017-06-06
PL2665471T3 (en) 2018-06-29
NO2665471T3 (en) 2018-05-26
US20140377345A1 (en) 2014-12-25
HUE038543T2 (en) 2018-10-29
PT2665471T (en) 2018-03-21
US20180050000A1 (en) 2018-02-22
CA2825014C (en) 2019-01-08
EP2665471A4 (en) 2014-07-23
EP2665471B1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
US20210085625A1 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
US9616035B2 (en) Pharmaceutical for oral delivery comprising MGBG and methods of treating disease
US10350178B2 (en) Methods and compositions for treatment of demyelinating diseases
US20100151012A1 (en) Stabilised pharmaceutical composition containing pregabaline
HU231114B1 (en) Pharmaceutical preparations containing mycophenolic acid or mycophenolate
WO2019142207A1 (en) Pharmaceutical compositions comprising ibrutinib
AU2017203694B2 (en) Controlled release oral pharmaceutical dosage forms comprising MGBG
AU2012207334A1 (en) Controlled release oral pharmaceutical dosage forms comprising MGBG
US20110244049A1 (en) Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same
WO2007102169A1 (en) Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same
KR20170113463A (en) Capsule composite formulation containing tadalafil and tamsulosin with improved stability and dissolution
WO2023195022A1 (en) Stable pharmaceutical compositions comprising erdafitinib
US8865210B2 (en) Stable dosage formulations of imidazolylalkyl-pyridines
TW202425985A (en) Controlled release pharmaceutical composition

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: PATHOLOGICA LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCKEARN, JOHN;BLITZER, JEREMY;SIGNING DATES FROM 20130717 TO 20130723;REEL/FRAME:056298/0658

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION